Full Report

Government-Sponsored Managed Care: How the Arena Works

Molina Healthcare does not compete in commercial health insurance — the world of employer plans, networks, and PPOs that most investors think of when they hear "health insurer." It competes in a separate, regulated arena that exists almost entirely because governments wanted private operators to manage the health risk of populations the federal and state budgets would otherwise have to manage themselves: low-income families and people with disabilities (Medicaid), seniors and dual-eligibles (Medicare Advantage), and lower-income individuals buying subsidized coverage on the exchanges (ACA Marketplace). Molina is what management calls a "pure-play government-sponsored healthcare business" [1] — and the entire investment case rests on understanding the economics, the cycle, and the politics of that arena.

1. The Arena — A Trillion-Dollar Public Backstop Operated by Private Companies

The product these companies sell is risk transfer to the government. A state Medicaid agency or CMS sets a per-member-per-month price, hands the company a population, and tells it to deliver a defined set of benefits within that price. The company pockets the spread if it manages cost; it eats the loss if it does not. Closer to a regulated utility plus a primary-insurance underwriter than a traditional insurance broker.

How big is the market?

Three programs, each with its own funding architecture, set the scale:

Medicaid is the largest publicly funded program in the United States [2]. It was established in 1965 under the Social Security Act to provide healthcare and long-term services and support to low-income Americans, and is jointly funded by federal and state governments [3]. CMS estimates Medicaid spending will grow at an average annual rate of roughly 7% to \$1.5 trillion by 2031 [4].
Medicare is the federal program for people 65 and over and certain disabled persons [5]. Inside Medicare, over 12 million low-income elderly and disabled people qualify for both Medicare and Medicaid [5] — the "dual-eligible" population, the most complex, highest-acuity segment in U.S. healthcare, and the slice Molina has decided to anchor on after exiting the broader Medicare Advantage-Part D ("MAPD") market.
ACA Marketplace was created by the Affordable Care Act in 2014 to let individuals and small groups buy federally subsidized health insurance via state and federal exchanges [6]. Plans must cover essential health benefits, and most members qualify for premium tax credits ("PTCs") based on annual household income [6].

The Medicaid figure is CMS's estimate cited by Centene [4]; the Medicare and Marketplace bars are illustrative scale anchors based on combined industry reporting and are shown for orientation, not precision.

Who plays at scale

The industry has a long tail of state-level plans, but premium revenue is concentrated in seven national platforms. To put Molina in context, here is where the largest U.S. managed care players sat at the end of FY2025:

UnitedHealth at \$447.6 billion is roughly ten times Molina's \$45.4 billion of total revenue [7]. But the headline revenue comparisons are misleading, because UNH, CVS, CI, ELV, and HUM are diversified across employer-sponsored commercial insurance, pharmacy benefits management (PBM), care delivery, and PDPs. Optum Health alone serves 95 million consumers [8]. The companies that look most like Molina in business model are Centene (Medicaid, Marketplace, Medicare; "the nation's largest managed care company focused on underserved populations" [9] — 27.6 million members and the largest Medicaid and Marketplace insurer in the country [9]) and, in pieces, Elevance's government business and UnitedHealthcare Community \& State, the Medicaid arm of UNH [8]. The rest of the field is best viewed as adjacent, not analogous.

2. Unit Economics — A PMPM Business Where 90 Cents of Every Premium Dollar Is Medical Cost

The financial model is unusually simple to describe and unusually hard to manage well.

A state or CMS pays the MCO a fixed monthly capitation rate — "per-member-per-month" or PMPM — for each enrolled member, in exchange for the company providing the contractually mandated set of benefits and absorbing all medical and administrative cost risk [10]. Rates are typically reset on an annual cycle and must, by federal rule, be "actuarially sound" [10]. The arithmetic that follows runs the whole business:

No Results

Two numbers in that ladder do almost all the work and deserve professional fluency:

Medical Care Ratio (MCR) — medical care costs divided by premium revenue. For Molina, FY2025 consolidated MCR was 91.7%, up from 89.1% in FY2024 — a 260-basis-point jump [11], pushed there by higher utilization of behavioral health services, high-cost drugs, long-term services and supports ("LTSS"), and broader inpatient and outpatient pressure [12]. Management's long-term target range is roughly 88-89%; 91.7% sits well above it [13].
G\&A ratio — administrative expense divided by total revenue. Molina ran 6.6% in FY2025 [11], reflecting operating leverage on the bigger revenue base. The "low-cost operator" claim in Molina's vision statement [14] is essentially a claim about this number versus peers.

Pre-tax margin in this business is normally 2-5%. There is no fat in the cost structure to absorb a bad medical trend year — a single point of MCR overshoot wipes out a meaningful fraction of operating income, which is exactly what happened in FY2025: operating income fell from \$1,707 million to \$781 million [11]. That is the central economic fact of the industry: rates are annual, trend is continuous, and the gap between them is the cycle.

What keeps the model honest

Three regulatory mechanisms keep MCOs from chronically over-earning at the government's expense:

Minimum medical loss ratio (MLR) floors. The ACA imposed minimum MLRs on Medicare and Marketplace plans, and states may impose their own — often more stringent than federal [15]. If a plan spends less than the MLR floor on medical care, it rebates the excess.
Risk corridors. Many state Medicaid contracts include corridors that share gains and losses between the plan and the state inside a band of MCR outcomes. They blunt both upside and downside.
Rate-setting authority. States set Medicaid PMPM rates annually through their appropriation process; CMS sets MAPD rates each year via the bid process. The state and federal customers, not the MCOs, ultimately decide unit pricing.

These mechanisms protect taxpayers, but they also mean the MCO is structurally short pricing power — it advocates for actuarial rate increases but does not set them.

3. The Three Programs — Different Members, Different Margins, Different Politics

Molina has four segments — Medicaid, Medicare, Marketplace, and a tiny "Other" — but the first three are the entire story [16]. They are different businesses sharing a corporate parent and an actuarial mindset, with very different demand drivers and cycle behaviors.

No Results

Membership counts and premium revenues are FY2025 disclosures from Molina's 10-K [17]; segment-level MCRs and medical margins are from MD\&A [12].

Medicaid alone accounts for 75% of consolidated premium revenue [18]. Investors who model Molina without understanding Medicaid's mechanics will model the wrong company.

Medicaid — the core, and the cycle

Medicaid is jointly funded by the federal and state governments; the federal share is set by each state's federal medical assistance percentage ("FMAP"), which averages roughly 60% across all jurisdictions and varies inversely with state personal income [19]. Most states contract with managed care plans to deliver Medicaid services rather than running fee-for-service themselves, because managed care gives states budget predictability and constrained spending [19].

How Molina actually gets members:

Bid wins. State Medicaid contracts typically have three- to five-year terms with renewal options and a state's right to terminate with or without cause [20]. States issue RFPs to rebid contracts to other health plans; losing a competitive rebid is an existential event for that contract.
Auto-assignment. When eligible Medicaid members do not choose a plan but are required to enroll in managed care, states algorithmically assign them. Criteria include previous enrollment, family enrollment, plan quality scores, network and enrollment size, lowest bid in a county/region, and equal assignment [21]. This is why the "low-cost, high-quality" positioning [14] is not corporate boilerplate — it directly drives membership flow.

Molina's Medicaid book is state-concentrated: California, New York, Texas, and Washington each contribute ≥10% of consolidated Medicaid premium [22]. A single state procurement loss can move 10-13% of segment revenue.

Medicare — pivoting to dual-eligibles

Medicare Advantage is the slice of Medicare where private plans contract with CMS to provide Medicare benefits in exchange for a fixed PMPM that varies by member demographics and Star Rating [23]. Star Ratings are CMS's quality scorecard; plans rated 4.0 or higher are eligible for quality-bonus payments and can offer enhanced benefits and market for longer windows [23].

For 2025, Molina disclosed a strategic shift: MAPD (the broader Medicare Advantage-Part D product) "does not align with our strategic shift to focus exclusively on dual eligible members" and the company intends to exit MAPD for 2027 [24]. The dual-eligible business — D-SNP, FIDE, HIDE — is structurally a stickier book because the same member is often a Medicaid member already, which gives Molina a member-acquisition cost advantage versus pure Medicare Advantage players (CVS/Aetna, Humana, UNH). The Medicare segment also includes the recently transitioned MMP-to-integrated-D-SNP contracts in Illinois, Michigan, Ohio, South Carolina, and Texas, totaling \$1.9 billion in revenue that crossed over on January 1, 2026 [24].

Marketplace — the most volatile slice

ACA Marketplace plans are one-year contracts; rates are filed in spring for the following calendar year based on estimated utilization, member risk acuity, federal risk adjustment transfers, and non-benefit expenses [25]. The book reprices annually but with no claim experience of the new mix — which is why Marketplace MCR can swing 1,500 basis points in a single year, as Molina's did in FY2025 (90.6% versus 75.4% in FY2024) [26].

Molina's Marketplace strategy is deliberately Medicaid-adjacent: plans are offered in many of the same states where it operates Medicaid plans, allowing Medicaid members to stay with their providers as they transition between Medicaid and the Marketplace [6]. When Medicaid redetermination disenrolls a member, Molina captures some of them in Marketplace — the company added 252,000 net Marketplace members in 2025 [26].

The complicating factor: enhanced ACA subsidies (the enhanced PTCs from the American Rescue Plan, extended by the Inflation Reduction Act) expired at the end of 2025 [27]. Centene, the largest Marketplace carrier in the country at 5.5 million members, has acknowledged the same expiration in its own 10-K [28]. This is the single largest live political question for Marketplace economics in 2026-27.

4. Where the Industry Sits in Its Cycle — Rates Are Annual, Trend Is Continuous

The defining feature of this industry — and the single thing an investor must internalize before reading any other tab — is that medical cost trend is a continuous process and pricing is an annual reset. When trend is benign, the cycle runs hot (low MCR, fat margins). When trend inflects and rates have not caught up, the cycle bites hard. The 2020-25 record shows one complete loop.

The premium revenue numbers and MCRs for FY2025 [11], FY2024 [29], FY2023, FY2022 [30], and FY2021 [31] come straight from the front pages of each year's 10-K.

Reading the cycle, oldest to newest

2020-22 — The PHE bonanza. COVID's Public Health Emergency triggered continuous-coverage requirements on Medicaid: enrollment was effectively frozen, utilization collapsed because patients deferred non-emergent care, and Molina's MCR sat around 86.5-88.3% [31] [32]. Premium revenue went from \$18.3 billion in 2020 to \$30.9 billion in 2022 [30]. This is the high-water mark for the industry's recent history.
2023 — Redetermination begins. The Consolidated Appropriations Act of 2023 ended the PHE FMAP increases and let states resume Medicaid eligibility renewals starting April 2023 [27]. Molina alone lost approximately 675,000 members to eligibility redeterminations following the PHE [33].
2024 — Cycle turns. Industry-wide medical cost trend accelerated; behavioral health, LTSS, and high-cost pharmacy drugs surprised plans to the upside. Q4 FY2024 trend ran at 1.2% versus a 50-basis-point forecast [34]. Management called it "industry-wide headwinds" [34] and guided FY2025 on the assumption of a 4.5% rate increase against a 4.5% medical trend [35].
2025 — Cycle peak. Trend overshot pricing across every segment. Medicaid MCR rose 150 basis points to 91.8% [12]; Medicare MCR rose 330 basis points to 92.4% as high-acuity duals utilization (LTSS, high-cost pharmacy) overshot what was priced [26]; Marketplace MCR rose 1,520 basis points to 90.6% as the new-member mix turned out higher-acuity than priced and CMS program integrity initiatives disenrolled members whose medical claims Molina still had to cover [26]. Net income fell from \$1,179 million to \$472 million in a single year [11].
2026 — Early stabilization signals. In Q1 FY2026, management noted the 2.5-percentage-point "acuity shift" component of 2025 trend did not recur, and the annualized first-quarter trend would put the year at better than 5% [36]. The percentage of "low and no utilizers" in the membership is 7.5 percentage points lower than the pandemic peak and below pre-pandemic levels — meaning the post-redetermination acuity shift may be largely behind the industry [37].

The cycle is correcting via rate negotiation — Molina's CEO has framed FY2025 as "maybe a rate action or two, not a rate cycle, away from being at the top end of our long-term range" of 89% Medicaid MCR [35]. But the correction is geographically uneven — Molina is in 21 states [7], and trend pressure does not show up in the same states as the corridor protections, which limited the cushion in 2025 [35].

5. Regulatory Architecture — The Rules That Set the Margins

This is a heavily regulated industry where the rule-makers and the customers are the same entities. Five regulatory anchors shape the economics:

Federal: ACA, OBBBA, CMS Star Ratings, Marketplace integrity

The Affordable Care Act mandated minimum MLRs for Medicare and Marketplace plans, created the federally-facilitated and state-based exchanges, and authorized states to adopt more stringent MLR thresholds than the federal floor [15].
The One Big Beautiful Bill Act ("OBBBA"), signed in July 2025, is the most consequential Medicaid regulation since the ACA. It requires states to establish work requirements, more frequent redeterminations, and cost sharing for the Expansion program between 2027 and 2029 [38]. Molina estimates the changes will reduce enrollment 15% to 20% by 2029 on its 1.2 million Medicaid Expansion members [38]. OBBBA also reduces the provider taxes states use to finance their share of Medicaid, and caps payments to Medicaid providers at 100-110% of the Medicare rate [38]. The downstream economic impact will play out over 5-15 years and is genuinely uncertain — the magnitude depends on how states adapt their funding policies in response.
The Marketplace Program Integrity and Affordability Rule, finalized June 2025, shortens the open enrollment period starting in 2027, eliminates the special enrollment period for individuals at or below 150% of the federal poverty level, and tightens eligibility verification [27].
CMS Medicare Star Ratings are the bonus-payment lever for Medicare Advantage. Plans rated 4.0+ stars are eligible for quality bonus payments [23]; a 0.5-Star drop on a major plan can move tens of millions of dollars of next-year revenue. Molina's 2026 Star Ratings (for 2024 plan year data) had six plans maintain, three increase by 0.5 stars, and two decrease by 0.5 stars [39].
RADV audits (risk adjustment data validation) let CMS retroactively claw back Medicare Advantage payments. A 2023 CMS rule that would have removed the "fee-for-service adjuster" was vacated by court ruling [23]; CMS must decide whether to appeal or re-issue a new rule.

State: Procurement, licensing, dividend approval

State insurance departments license each health plan subsidiary and impose minimum statutory capital requirements [40]. Crucially, state regulators must approve dividends from subsidiary plans up to the parent, which is how the parent funds buybacks, M\&A, and debt service [40]. In Molina's Q1 FY2026 commentary, the company noted parent cash will rise from about \$200 million in Q1 to more than \$600 million by year-end via subsidiary dividends, with company-wide RBC ratio holding around 305% versus a 300% target [41].

Fraud and abuse — the cost of operating

Because revenue flows from federal and state government agencies, every MCO is subject to federal and state anti-kickback statutes, prohibited-referral rules, and the federal False Claims Act, which authorizes treble damages plus civil and criminal penalties [42]. HIPAA / HITECH layer on data-privacy and breach-notification regimes [42]. Qui tam ("whistleblower") suits — where a private relator brings a False Claims Act case and can recover 15-30% of damages — are an active risk vector for the industry.

No Results

6. Competitive Structure — A Few Nationals, Many State-Level Contests

Management's own framing of the industry: "highly competitive on a national, regional, and local level," competing for state contracts, members, provider networks, agents, and brokers [43]. The structure varies dramatically by program.

Medicaid — a state-by-state contest

For state government Medicaid contracts, Molina competes with national multi-product MCOs, Medicaid-focused MCOs, and sometimes provider-formed entities [43]. The criteria states use to award contracts: provider network, quality of service, care management capabilities, member satisfaction, reputation, financial resources, and other factors [43]. Crucially, "incumbency status may not necessarily guarantee our ability to retain contracts when they are up for rebidding" [43] — a single procurement loss can erase a multi-hundred-million-dollar revenue stream, as Molina's Virginia experience in 2024 showed when it lost the CCMC 2.0 procurement [44].

Medicare — three national giants and Molina

In Medicare, the market is dominated by large national platforms — Molina names them: CVS Health Corporation, Humana, Inc., and UnitedHealth Group Inc. [45]. Molina is a niche player in the broader MAPD market — which is precisely why management chose to exit MAPD and concentrate on the dual-eligible niche where Medicare overlaps with its Medicaid book.

Marketplace — essentially a duopoly at the bottom of the income stack

For low-income, subsidy-driven Marketplace membership — Molina's slice — "our primary competitor for low-income Marketplace membership is Centene Corporation" [45]. Centene's 5.5 million Marketplace members (Ambetter) make it the largest carrier nationally [28]. Outside the low-income subsidy slice, larger Blue/UNH/Aetna footprints dominate, but they tend not to fish in the income range Molina targets.

A note on the indexed peer set

The auto-indexed peer set in this run — UNH, CVS, CI, ELV, CNC, HUM — is mixed in business-model relevance. Centene is the only close model match (Medicaid-led pure-play government managed care). Elevance has a sizable Medicaid book inside its much larger commercial business. UnitedHealth Community \& State is the Medicaid arm of UNH but is buried inside a diversified platform whose economics are dominated by Optum [8]. CVS/Aetna, Humana, and Cigna are mostly commercial, Medicare Advantage, and PBM businesses; they overlap with Molina on Medicare (where Molina is sub-scale) but not on Medicaid. The MOH-vs-CNC scatter below is the only peer comparison that compares like to like; everything else needs heavy framing.

7. Peer Economics — Revenue Scale, Margin Profile, and the FY2025 Margin Reset

No Results

Two read-outs from the peer table:

FY2025 was a margin-reset year for the whole industry, not just Molina. Centene swung to a \$6.7 billion net loss, driven primarily by a \$6.7 billion goodwill impairment and other write-downs; on an adjusted basis Centene still earned \$1.0 billion versus \$3.8 billion the prior year, with adjusted EPS falling from \$7.17 to \$2.08 [46]. Humana's net income fell to \$1.2 billion from \$1.2 billion the prior year (essentially flat) on rising MCR. UnitedHealth's operating income fell from \$32.3 billion to \$19.0 billion. The trend pressure was industry-wide.
Scale doesn't directly translate to managed-care margin. UNH at ~4% op margin earns disproportionately in Optum (care delivery, data, PBM), not in UnitedHealthcare insurance. The pure-insurance underwriting margin is structurally 2-4% across the board.

8. The Industry Watchlist — Six Signals That Move the View

If only six dials existed for tracking this industry, an investor would track these. Each is grounded in a mechanism specifically described in the primary record:

No Results

The industry is at a clear inflection — exiting a multi-year margin reset (FY2024-25) into either (a) a multi-year rate-catch-up and re-rate higher, or (b) a structural reset lower if OBBBA Medicaid cuts and Marketplace subsidy expirations bite harder than priced. The 2026 outcome is decided segment by segment, by rate cycle and political calendar. The Q1 FY2026 commentary — acuity shift declining, trend annualizing closer to 5%, parent cash refilling [36] [41] — is the first set of positive data points, but it is one quarter.

References

Know the Business — Molina (MOH)

What kind of business is Molina, what should it trade like, and what has to be true for FY2026 numbers to compound back to where the franchise can earn?

Molina is a disciplined, low-cost, low-margin, state-contract Medicaid operator with bolt-on duals and Marketplace optionality. Its quality is operational, not structural — the moat is RFP win rate, member-acquisition cost on dual-eligibles, and a parent/subsidiary capital architecture that lets a small balance sheet finance a much larger book — not pricing power, brand, or scale. So it should be valued through the cycle, not at one snapshot — and FY2025 was the most violent snapshot in the data.

1. The Verdict in One Page

FY2025 Revenue (USD B)

$45.4

FY2025 Net Income (USD M)

$472

FY2025 Consolidated MCR (%)

91.7%

FY2025 Diluted EPS (USD)

$8.92

FY2025 ROE

11.6%

FY2025 ROCE

9.5%

Members (thousands)

5,491

States in footprint

The KPI strip is the headline of a cycle bottom, not the franchise. FY2025 revenue hit \$45.4 billion at a 91.7% consolidated MCR; net income fell to \$472 million from \$1,179 million the year prior, and diluted EPS dropped to \$8.92 from \$20.42 [1]. Returns on equity collapsed from a steady 25-32% in FY2020-24 to 11.6% in FY2025 — not because the business broke, but because medical cost trend ran roughly 7.5% against actuarial rates priced for ~4.5% [2] [3]. Reading the FY2025 P\&L as the run rate gets the company wrong in both directions.

Business quality verdict. A high-quality operator in a structurally low-margin, regulated industry — not a high-quality business in the Buffett sense. Returns are manufactured by procurement-cycle wins and parent-level capital efficiency, not by pricing power or customer captivity. The right comp set is not pharma, software, or even commercial insurance — it is a regulated utility with a 2-4% statutory operating margin and a contract life that gets re-bid every three to five years.

2. The Economic Engine — A PMPM Spread Business Running on \$0.92 of Every Premium Dollar

Strip away the segments and the engine is one equation. A state Medicaid agency or CMS pays Molina a per-member-per-month ("PMPM") rate; Molina absorbs medical and administrative cost risk for that population in exchange [4]. The contract is fixed in price, variable in cost, and the gap is the company's earnings.

No Results

The unit economics: about \$0.92 of every dollar of premium revenue is medical care cost [5]; after another \$0.065 of G\&A and a couple of pennies of D\&A, interest, and tax [5], the company keeps about a penny of net income on a dollar of revenue. Said differently: a single point of MCR overshoot wipes out a meaningful fraction of operating income. Molina spells this sensitivity out in its own 10-K: had FY2025 MCR been 92.7% rather than 91.7%, diluted EPS would have been roughly \$2.72 instead of \$8.92 — a \$6.20 difference from 100 basis points [6].

That sensitivity is the central economic fact about Molina. Everything else — the segments, the moat conversation, the buyback program, even the multi-year multi-billion-dollar M\&A pipeline — is downstream of how well management can keep that 92¢ line steady against a continuously-trending medical cost base while states reset price once a year.

How the engine scales

The other side of the operating leverage equation is G\&A — what Molina calls its "low-cost operator" claim [7]. The G\&A ratio is the cleanest visible evidence of operating discipline:

G\&A has compressed from 7.6% in FY2020 to 6.5% in FY2025 — 110 basis points of leverage over five years on a revenue base that nearly tripled from \$19.4 billion to \$45.4 billion. That is real evidence that the back office scales. The flipside: G\&A leverage is small comfort when 92 cents of every dollar is medical cost and rates lag trend.

3. The Three Programs — Three Different Businesses Inside One Ticker

Molina reports four segments — Medicaid, Medicare, Marketplace, Other — but the first three do all the work [8]. Each is structurally different: different customers, different price-setting cadence, different competitive set, different acuity profile. Treating them as one model is the most common modelling mistake new investors make.

No Results

Segment shapes for FY2025: Medicaid is roughly 75% of premium revenue at 4.57 million members [9] [8]; Medicare ~14% on 262 thousand higher-acuity members [10]; Marketplace ~10% on 655 thousand members after a +252,000 net add year [10]; "Other" is rounding (the ConnectiCare commercial book plus LTSS consulting in Wisconsin [8]).

Medicaid is the company

Medicaid MCR ran 87-89% from FY2020 through FY2023 — the 88-89% long-term target range management still anchors guidance against [3] — then climbed 150 basis points in FY2024 and another 150 basis points in FY2025 to 91.8% [11]. The medical margin in absolute dollars actually fell from \$2,979 million in FY2024 to \$2,652 million in FY2025 even as premium revenue grew 5% — a clean statement that 2025 was a rate-versus-trend year, not a volume problem. Management's full-year FY2026 Medicaid MCR guide is 92.9%, built on a 4% rate increase against an expected 5% medical cost trend, with the optionality of off-cycle and retrospective rate updates from states later in the year [2].

Medicaid is also where the structural growth case lives. Management has set a long-term 11-13% premium revenue growth target and expects to surpass \$50 billion of premium revenue in 2027 [7]. The fuel is a mix of RFP wins, footprint expansion (Idaho, Florida Kids, Mississippi, Nevada, Massachusetts), and bolt-on M\&A — the same engine that delivered the prior decade of growth.

Medicare is being reshaped — exit MAPD, double down on duals

The Medicare story for FY2025 is a deliberate strategic narrowing. In February 2026, Molina announced it will exit Medicare Advantage-Part D ("MAPD") for plan year 2027 because it "does not align with our strategic shift to focus exclusively on dual eligible members" — MAPD represented approximately 117,000 members and \$1,566 million, or 25% of FY2025 Medicare segment premium revenue [12]. The replacement is a fast-growing dual-eligible book of D-SNP, HIDE, FIDE, and the converted MMP contracts that crossed over on January 1, 2026 in Illinois, Michigan, Ohio, South Carolina, and Texas, totaling \$1.9 billion of revenue [13].

Why concentrate on duals? Because duals are the one product where Molina's Medicaid book is a structural competitive advantage. A dual-eligible member is already a Molina Medicaid member — Molina knows the provider network, the social determinants, the care plan; member-acquisition cost is much lower than for a pure Medicare Advantage shopper that CVS/Aetna, Humana, or UnitedHealth would compete for. Q1 FY2026: the converted HIDE/FIDE members on \$2 billion of revenue "performed much better out of the gate than we had anticipated" [14], reinforcing the thesis.

Marketplace is volatile and is being deliberately shrunk

Marketplace MCR jumped from 75.4% in FY2024 to 90.6% in FY2025 — a 1,520-basis-point single-year reset [10]. The cause was a textbook adverse-selection event: Molina added 252,000 net members in 2025 [10], but the new mix was higher-acuity than priced, and CMS program-integrity initiatives disenrolled lower-acuity members whose accumulated claims Molina still owed. Q4 FY2025 Marketplace MCR ran at 99%.

Management's response is rare for the industry — explicitly shrink the segment to defend margin. FY2026 guidance puts year-end Marketplace membership at approximately 220-250 thousand, down from 655 thousand at end-2025, a roughly 50% premium revenue cut [12] [2]. The renewal rate of remaining members is now 70%, concentrated in the silver tier (50% of mix) [2], and Q1 FY2026 reported MCR of 84% — or 79.5% adjusted for prior-year risk adjustment and program integrity impacts [15]. This is a deliberate exit from competition for low-income, subsidy-driven members where Centene's Ambetter (5.5 million Marketplace members at end-2025 [16]) is the structural low-cost incumbent.

The honest reading of Marketplace: this is a rate-sensitive, programmatically volatile product where Molina has been opportunistic during periods of favorable economics (Marketplace MCR of 58.9% in FY2018 and 68.2% in FY2019 from the segment dataset) and is now retreating because trend, mix, and political risk all turned at once. Marketplace should be valued as a call option on a stable subsidy regime, not as a recurring earnings stream. The enhanced ACA premium tax credits that drove the 2021-25 enrollment surge expired at end-2025; whether they are renewed will define the segment's economics for the rest of the decade [17].

4. Returns on Capital — High at the Top of the Cycle, Crushed at the Bottom

This is a thin-margin, asset-light operator: total assets of \$15.6 billion at year-end FY2025 produce \$45.4 billion of revenue, an asset turnover near 2.9x — the highest in the peer set. Combined with operating margins that have ranged from 1.7% (FY2025 trough) to 6.0% (FY2019 peak), ROE swings violently with the cycle.

The seven-year average ROE through FY2025 is roughly 26%, ROCE roughly 21%. FY2025 cuts both in half. The honest framing: if FY2024 MCR-of-89.1% conditions repeat in FY2026-27 (management's central case in the Q1 transcript is for trend at 5% and rates at 4%, with off-cycle catch-up upside [2]), ROE returns to the 20-25% zone within two years. If trend remains 7-8% and rates remain at 4%, FY2026 looks much like FY2025. The reader's view on the rate-vs-trend gap is the dominant variable for ROE over the next two years.

5. Moat Analysis — A Scorecard Without Self-Congratulation

The right way to read Molina's competitive position is to drop the word "moat" and replace it with the four mechanical advantages that actually show up in the filings. Most of these are real, but they are operating-cost moats, not pricing moats.

No Results

A few of those rows need direct citation since they carry the moat verdict:

The procurement track record is management's own quantification: 90% re-procurement win rate on \$14 billion of retained revenue and an 80% new-contract win rate worth \$20 billion in premium since 2019, alongside acquisitions totaling more than \$10 billion of revenue over the same period [7]. FY2025 alone added "nearly \$9 billion of incremental annual premium revenue" from RFP wins and the ConnectiCare acquisition [18], and the FY2026 award stack includes the Florida CMS Kids contract (sole-selected, ~120,000 enrollees [19]; ~\$6 billion run-rate revenue per management [20]).
The auto-assignment mechanic is what converts low-cost into bid wins: state auto-assignment algorithms explicitly include "plans with the lowest bid in a county or region" among the criteria for assigning Medicaid members who do not choose a plan [4]. That is the literal economic mechanism connecting G\&A leverage to membership growth.
The dual-eligible angle: Molina explicitly named the exit of MAPD and the focus on duals as the strategic shift [12], and the early Q1 FY2026 read on the HIDE/FIDE conversion was that "they performed much better out of the gate than we had anticipated" [14].
The pricing-power constraint is structural: Medicaid PMPM rates are set annually by states subject to federal actuarial-soundness standards [4], and incumbency does not guarantee contract retention — "Incumbency status may not necessarily guarantee our ability to retain contracts when they are up for rebidding" [21]. Virginia, where Molina lost the Cardinal Care Managed Care 2.0 procurement in 2024 and saw its DMAS contracts terminate effective June 30, 2025, is the most recent reminder [19].

Moat in one line. The advantage is operational, not structural — a disciplined low-cost operator that wins on bids and converts G\&A leverage into auto-assignment volume, supplemented by a dual-eligible niche where its Medicaid book is a real edge. There is no pricing power, no brand captivity, and no national scale advantage. Investors should size positions accordingly.

6. State Concentration — The Anchor Four, the Procurement Risk

Each of California, New York, Texas, and Washington accounted for approximately 10% or more of consolidated Medicaid premium revenue in FY2025: Texas \$5,735 million (18%), California \$4,170 million (13%), Washington \$4,194 million (13%), and New York \$3,221 million (10%) [9] [22]. Together those four states are roughly 54% of Medicaid premium revenue and about 40% of total company revenue.

The procurement cadence shows what is at risk and when:

California Medi-Cal contracts effective January 1, 2024 cover four counties (Los Angeles, Riverside/San Bernardino, Sacramento, San Diego) [9] — a multi-year stable book.
Texas STAR+PLUS commenced September 1, 2024, with the STAR and CHIP contract still pending final terms [22]. Largest single concentration; biggest single procurement risk.
Washington Apple Health was renewed through 2026 and expected through 2027, with an RFP no earlier than Q4 2026 and an expected contract effective date of January 1, 2028 [22]. This is the next known procurement risk to watch.
New York is multi-county; about 10% of Medicaid premium [9].

The 10-K is explicit about what a procurement loss means: "A loss of any of our significant Medicaid contracts could have a material adverse effect on our business, financial condition, cash flows, or results of operations" [9]. Virginia in 2024 was the most recent worked example.

7. Capital Allocation — A Plumbing System, Not a Capital Allocator's Showcase

Molina does not raise outside equity. The capital-allocation playbook is a regulated plumbing system: medical margin earned at the health-plan subsidiary level → statutory capital cushion maintained at the subsidiary → excess upstreamed to the parent via state-regulator-approved dividends → at the parent, used for debt service, M\&A, and buybacks. The parent itself runs lean.

No Results

The flow, in plain English:

Subsidiary dividends to parent: regulated health plan subsidiaries paid \$985 million to the parent in 2025 (\$997 million in 2024) [23]. The parent contributed \$439 million back into subsidiaries (mainly Connecticut, California, Mississippi) to satisfy statutory capital requirements [23]. Net upstream of roughly \$546 million is what funded everything else.
Buybacks at the cycle: FY2025 buybacks totalled \$1 billion — Molina purchased ~1.68 million shares for \$500 million in Q1 2025 at an average cost of \$297.83 per share, and ~2.85 million shares for \$500 million in Q3 2025 at \$175.50 per share [19]. The Q3 program was authorized in April 2025 for up to \$1 billion through December 31, 2026 [24]. The 41% gap between the two average prices is what you'd want to see from a disciplined repurchaser through a cycle reset — buying more shares at a lower price.
Debt is cheap and laddered: In November 2025, Molina issued \$850 million of 6.500% Senior Notes due 2031, using the proceeds to retire \$740 million of existing term loan debt; the weighted-average cost of fixed debt sits at 5.0% [24] and the new revolving facility provides \$1.25 billion of capacity through November 2030, plus an additional \$800 million of incremental term-loan capacity available specifically to finance acquisitions [25].
M\&A discipline: In the Q1 FY2026 call, CEO Joe Zubretsky framed the M\&A pipeline as "full of actionable opportunities," with the historical pricing benchmark of "22 to 23 percent of revenue" now giving way to a book-value benchmark because so many distressed sellers are priced near regulatory-capital floors — "If you're only paying for regulatory capital, an M\&A deal can be as good as, if not better than, a new contract win" [26]. For a regulated business where every acquired plan brings statutory capital with it, this is the right frame; whether the discipline holds when sellers' capital is permanently impaired is the right question to test in the next twelve months.

The cyclical FCF illusion. FY2025 reported operating cash flow was negative \$535 million [27], creating a headline FCF of negative \$636 million. This is not a cash-burn business. As CFO Mark Keim explained in Q1 FY2026: "in a regulated business like Molina, what's more important than total company operating cash flow is cash flow at the parent" — the swings are timing of accruals for risk adjustment, MLR corridors, and government payment cycles; the cash either sits in subsidiary capital or upstreams to the parent. Parent cash was about \$213 million at end-Q1 FY2026 and is expected to exceed \$600 million by year-end via subsidiary dividends, with company-wide RBC holding near 305% versus a 300% target [28] [20]. The parent-cash trajectory is the right cash KPI for this business, not consolidated operating cash flow.

8. Track Record — Promises and Results, 2020-2025

The best test of management quality in a cyclical, contract-driven business is the consistency between what was promised and what was delivered. Molina's six-year record shows a high-quality operator who has over-delivered on the things it controls (G\&A, RFPs, M\&A integration) and under-delivered when forces it does not control (medical cost trend, redetermination acuity, Marketplace mix) collided with the annual rate-reset cycle.

No Results

The CEO's framing on the Q1 FY2026 call captures the management mindset: "We will again realize the intrinsic value of the franchise we have built over the past 8 years" [2] — a reminder that current CEO Joe Zubretsky was hired in 2017 as a turnaround CEO and that the FY2018 swing from a \$512 million net loss to a \$707 million net profit was the inflection. The investor should weight this management team's history of execution heavily against the apparent damage to FY2025 numbers — but should also keep in mind that the most powerful execution lever (procurement RFP wins) does not solve a within-contract medical-trend overshoot. The two skills are separable.

9. Embedded Earnings — The Mechanic of the FY2027 Bridge

Molina uses an unusual but useful disclosure called embedded earnings: the future incremental contribution of new contract wins and acquisitions that have not yet hit the run-rate P\&L. For FY2026, management quantifies \$2.50 per share of embedded earnings as the combination of (a) the MAPD product losses being eliminated in 2027 and (b) the Florida CMS Kids first-year implementation costs that ramp into a profitable run rate in 2027 [15]. Both are mechanical — one is a planned exit, one is an implementation lift.

Per CFO Mark Keim: "Both are certain to be positive impacts to our 2027 performance." [15] Per CEO Zubretsky on the MAPD drag: it produced roughly \$1 per share of FY2026 earnings drag that won't repeat [14].

The illustration above puts FY2027 baseline EPS at roughly \$7.50 — before any Medicaid rate catch-up. The math is mechanical from management's own disclosed components; the rate-vs-trend gap closing further is upside. The reader should verify the bridge with the Investor Day disclosure (scheduled May 8, 2026) [2], but the conceptual framework is the right one: FY2025 is the snapshot, FY2027 is the franchise.

10. Peer Set — Centene Is the Only Like-for-Like Comp

A reminder, because the auto-screened peer set in this run includes UnitedHealth, CVS, Cigna, Elevance, Humana, and Centene — only one of those is a true business-model match.

No Results

The Centene comparison matters because FY2025 was the industry margin reset year, and Centene's record clarifies that this was not a Molina-specific failure: Centene's adjusted diluted EPS fell from \$7.17 in FY2024 to \$2.08 in FY2025 [29], and Centene took a \$6.7 billion goodwill impairment that drove a GAAP net loss [29]. Centene serves 27.6 million members and is described in its own filing as the "nation's largest managed care company focused on underserved populations" [30]. Molina is a quarter of Centene's size and roughly the same business — and Molina took no impairment. That is a non-trivial relative data point on portfolio quality and acquisition discipline.

11. The Valuation Lens — How to Underwrite This Stock

Three observations frame how the right buy-side investor should approach Molina's valuation:

Don't use FY2025 P/E. EPS is at a cycle bottom. A 12x P/E off \$8.92 looks cheap by absolute standards but is being struck off depressed numerators. Off the management-guided FY2026 floor of "at least \$5," even modest multiples imply a premium. Neither single-year framing is the right one.
Do use through-cycle EPS or the FY2027 embedded-earnings bridge. Through-cycle ROE has averaged 24-25% on book value of about \$77 per share at end-FY2025 (\$4,069 million equity divided by roughly 52.9 million shares). That implies through-cycle EPS in the high teens. The FY2027 embedded bridge of roughly \$7.50 illustrated above is the starting point before rate catch-up, not the destination.
Watch parent-cash conversion and the buyback discipline. A 1-for-1 conversion of parent net retained cash into buybacks at the right prices (FY2025 cycle-trough buybacks at \$175.50 in Q3) is materially more accretive than maintaining the cash on balance sheet. Continued discipline at sub-cycle prices is a positive signal; chasing the price up to multi-hundred dollars again is a negative one.

Valuation lens recommended. Use P/B vs. through-cycle ROE as the primary lens (this is, mechanically, a regulated spread business). Pair with EV / embedded earnings for the FY2027 bridge and parent-cash deployment yield as the capital-allocation check. P/E on trailing or even forward 12-month earnings will mislead in either direction during a cycle reset. The right multi-year compounder math is: book value compounds at a high-teens ROE through cycle, buybacks at sub-cycle prices accelerate per-share growth, and the M\&A pipeline absorbs incremental capital at attractive prices when sellers are stressed.

12. What Has to Be True

Five things have to be true for the Molina franchise to compound back to its through-cycle earnings power over the next 24 months:

Medicaid rate-vs-trend gap closes. Management's FY2026 build is 4% rate against 5% trend; off-cycle catch-up rate filings are the swing factor [2]. The Q1 FY2026 result of 92% Medicaid MCR with "modestly favorable" trend [2] is the first positive data point. Two more quarters of confirmation, and consensus FY2027 EPS rerates.
OBBBA implementation comes in at the company's 15-20% expectation, not above. Molina has framed the membership impact as 15-20% reduction on 1.2 million Medicaid Expansion members by 2029 [18] [31]. State implementations are still being designed; the actual figure depends on how states design work-requirement and redetermination cadences.
Marketplace shrinkage stops bleeding into adjacent KPIs. Cutting the book in half is a margin-defense move; the test is whether it actually restores normalized 80% MCR for the residual book without dragging Medicare or Medicaid acuity mixes.
The procurement engine keeps producing. The "near \$9 billion of incremental annual premium revenue" delivered in 2025 [18] was an exceptional vintage. The base rate of RFP wins matters more than any single year — Texas STAR/CHIP and Washington Apple Health 2028 are the next material decisions.
M\&A discipline at book-value-anchored prices. With \$1.25 billion of revolver capacity plus \$800 million of acquisition-financing incremental term-loan capacity [25] and a willingness of distressed sellers to transact at book, this is an environment where the company can lay out the next decade of growth at attractive prices — or destroy that optionality with one bad deal.

The franchise is structurally what it has always been: a disciplined low-cost operator with a 21-state Medicaid book, a niche dual-eligibles strategy, an operationally consistent management team, and zero pricing power against a regulator-customer. The cycle says "wait"; the bridge says "the answer to whether this compounds depends on the next four quarters of trend-vs-rate." That is the investor's question to answer.

References

Long-Term Thesis - Molina Healthcare, Inc. (MOH)

The right long-horizon question is not "will FY2026 print above $5 of adjusted EPS?" — that is a single-cycle question. It is: does this franchise compound the public capital it has been entrusted with at an attractive through-cycle ROE — without diluting the procurement engine, without breaking the regulatory-capital architecture that lets a small balance sheet finance a much larger book, and without leaning so hard on Marketplace and MAPD optionality that another rate-vs-trend gap re-prices the whole equity to a lower base? The multi-year primary record says yes, modestly — provided the next two procurement vintages (Texas STAR/CHIP, Washington Apple Health 2028) hold and the duals niche translates into a margin premium by FY2027.

This page is the durable frame, not the catalyst calendar.

1. The Verdict in Four Dials

No Results

Top long-term driver: the Medicaid procurement engine compounding share in an expanding TAM at a sub-7% G&A ratio that lets MOH bid into auto-assignment counties no large-commercial player can match without subsidizing from another segment.

Top failure mode: a Texas or Washington procurement loss (each $4-6B of premium [1]) compounding with a structurally smaller post-OBBBA Medicaid Expansion base [2] — the franchise re-rates from "narrow moat compounder" to "regulated-utility yield substitute."

2. The Multi-Decade Arc - Where Molina Came From, Where the Math Goes

Molina was founded in 1980 by C. David Molina, M.D. as a Medicaid clinic network in California, became an HMO in 1994, and went public in 2003 with $644 million of revenue and approximately 511,000 members [3]. By FY2025 it served 5.49 million members across 21 states with $45.4 billion of total revenue. That is a 22-year compound revenue CAGR of roughly 21% and a 10x growth in member count — not from a single product launch but from a state-by-state procurement engine plus a multi-decade M&A roll-up that absorbed AgeWell New York (2022), Cigna's Texas Medicaid book (2022), Magellan Complete Care (2020), My Choice Wisconsin (2023), Bright HealthCare's California MA book (2024), Affinity Health Plan (2021), and ConnectiCare (2025).

What this arc tells a long-horizon investor: Molina is not a "high-quality business" in the Buffett sense (no pricing power, no consumer brand), but it is a high-quality vehicle for participating in a structural growth program that one of the company's own peers describes as the largest publicly funded program in the United States [4]. The reason to own a regulated low-margin operator is that the regulator is funding the growth, and over 22 years Molina has been one of the most disciplined recipients of that funding.

3. The Structural Growth Runway - 5 to 10 Years

The single most important multi-year fact for this thesis is that the demand-side TAM is growing whether the rate-vs-trend gap closes or not. Medicaid is jointly funded by federal and state governments [5] and Centene's FY2025 10-K cites the CMS projection that Medicaid spending will grow at roughly a 7% average annual rate to $1.5 trillion by 2031 [6]. Medicaid managed care is the structural delivery vehicle states have chosen because it provides budget predictability and constrained spending [7]. Over 12 million low-income elderly and disabled people qualify for both Medicare and Medicaid [8] — the dual-eligible pool that is MOH's strategic anchor.

No Results

Three things are durable in this framing:

The customer (the government) cannot stop spending. Medicaid is statutory; the only debate at any election is how to deliver the spend, not whether. OBBBA's 15-20% reduction on the 1.2 million Medicaid Expansion population [2] is the largest structural shrinkage in the 10-K and represents ~5% of total Molina membership — material but not existential.
The delivery vehicle (managed care) is the secular winner against fee-for-service. States migrate to managed care because it caps their fiscal exposure; the federal medical assistance percentage (FMAP) averages roughly 60% across jurisdictions [1], so every state has a structural incentive to push more populations into capitated arrangements.
MOH has explicitly committed to a multi-year top-line target. Management discloses a "long-term premium revenue growth target of 11-13%" and expects to surpass $50 billion in premium revenue in 2027 [9] — a target that requires execution but does not require the rate-vs-trend gap to close. It is a volume statement; the margin question is independent.

The multi-year volume runway is therefore not the variable to underwrite. The variable is whether MOH captures share inside an expanding pool at a margin that compounds book value, or whether the procurement engine ratchets revenue while the cost discipline that turns revenue into shareholder returns erodes.

4. The Procurement Engine - The One Mechanism a Long-Horizon Investor Has to Believe

The single most important sentence in the FY2025 10-K for a 5-to-10-year holder is buried in the strategic retrospective on page 9: "We have achieved a 90% re-procurement win rate for Medicaid requests for proposal ('RFP') representing $14 billion in retained revenue and an 80% new contract win rate worth $20 billion in premium, and we have completed acquisitions totaling more than $10 billion of revenue during this period" [9]. FY2025 alone added "nearly $9 billion of incremental annual premium revenue" from RFP wins and the ConnectiCare acquisition [10].

No Results

The economic mechanism that produces these win rates is the only mechanism in the moat scorecard that is mechanically explainable: state auto-assignment algorithms explicitly include "plans with the lowest bid in a county or region" among the criteria for assigning Medicaid members who do not choose a plan [11]. A 6.5% G&A ratio (down from 7.6% in FY2020 per upstream tabs) lets MOH bid at a price that triggers auto-assignment in counties where it competes against higher-cost MCOs; auto-assignment then converts into multi-year member-months because state contracts are 3-5 year terms. The 10-K is explicit, however, that the moat is bounded: "Incumbency status may not necessarily guarantee our ability to retain contracts when they are up for rebidding" [12], and Virginia in 2024 — the DMAS Cardinal Care Managed Care 2.0 procurement, terminating MOH's contracts effective June 30, 2025 — is the most recent example of a procurement loss that wiped out a multi-hundred-million-dollar revenue stream regardless of franchise health.

The honest read for a long-horizon investor. The procurement engine has produced for six straight years and survived three stress events (the 2017 control failure, the 2020-22 PHE windfall, the 2024-25 trend overshoot). It is the most reliable mechanism in this thesis. It is also a per-state, per-cycle moat: a 90% retention rate across many independent contracts is not the same thing as a 90% probability of retaining any single specific contract. The Texas STAR/CHIP rebid (still pending final terms per the FY2025 10-K [13]) and the Washington Apple Health 2028 procurement (RFP expected no earlier than Q4 2026, contract effective January 1, 2028 [13]) are the two largest binary outcomes inside the long-horizon window.

5. The Regulatory Capital Architecture - The Less-Discussed Half of the Moat

The procurement engine gets discussed; the regulatory-capital architecture rarely does. It is the protection that survives a cycle reset. The combined minimum statutory capital and surplus requirement across MOH's regulated health-plan subsidiaries was approximately $3.1 billion at December 31, 2025 (versus $2.6 billion a year earlier) [14], and net assets at the subsidiaries that "may not be transferable" to the parent without regulator approval were approximately $4.4 billion at year-end [15] — roughly the entire equity base of the company sits behind a state-by-state ring fence. All Molina health plans except California, Florida, and New York are subject to NAIC risk-based-capital ("RBC") rules; the three exempt states impose their own frameworks [15].

This stack is the actual barrier to entry. A well-capitalized tech entrant cannot simply "Uber" Medicaid management — every state license requires years of seasoning, statutory capital deposits, and contract relationships. The barrier protects every existing national platform equally, so it is a moat against new entrants, not a moat against UnitedHealth, Centene, CVS, or Elevance. But it is also the structural reason multi-billion-dollar M&A continues to be the fastest way to add states: every acquired plan brings its own statutory capital, license, and contract relationships. CEO Joe Zubretsky's framing on the Q1 FY2026 call was the clearest distillation: "If you're only paying for regulatory capital, an M&A deal can be as good as, if not better than, a new contract win" [16].

For a long-horizon investor, this architecture has two implications:

The franchise has a self-replicating funding mechanism. Subsidiaries earn medical margin → statutory capital is maintained at the subsidiary → excess upstreams to the parent via regulator-approved dividends → the parent funds debt service, M&A, and buybacks. In FY2025, subsidiary-to-parent dividends were $985 million (FY2024: $997 million) [17] — the plumbing did not break even in the worst earnings year of the post-2017 era. In a normalized year the upstream is materially larger.
The available distressed-M&A pool is denominated in regulatory capital, not revenue multiples. In a cycle where peers are stressed (Centene took a $6.7 billion goodwill impairment in FY2025 per upstream tabs), MOH can add states at book value rather than the historical "22 to 23% of revenue" benchmark management has cited [16]. The financing capacity exists: a $1.25 billion revolving credit facility through November 2030, plus an additional $800 million of incremental term-loan capacity available specifically to finance acquisitions [18].

6. The Multi-Year Track Record - Promises vs Delivery

The best test of a low-margin operator over a long horizon is whether what management said three, five, and seven years ago actually compounded. The composite record across the 2018-2024 Zubretsky era is strong; FY2025 is the rupture; FY2026 is the conservative reset. A long-horizon investor needs to be honest about both halves.

No Results

The 5-year cumulative shareholder return is the single most candid data point in the 10-K: a $100 investment in MOH common stock at year-end 2020 was worth $80 at year-end 2025, against $195 for the S&P 500 Index [19]. The earnings compounded; the multiple did not. That distinction is the heart of a long-horizon thesis question: if EPS recovers to FY2024's $20.42 by 2027-28 (the bull case), the de-rating fixes itself; if the rate-vs-trend gap proves multi-year (the bear case), the multiple stays low and the franchise compounds at a lower per-share rate than the underlying ROE would suggest.

The seven-year average ROE through FY2025 is roughly 26% per upstream tabs; FY2025 cuts it to 11.6%. For a 5-to-10-year holder, the single most powerful piece of evidence on whether the franchise compounds is whether the embedded-earnings pipeline (the difference between current run-rate EPS and the run-rate that contracts already won but not yet at target margin imply) is real. Management's disclosure is unusually quantified: embedded earnings "now greater than $11 per share" in cumulative not-yet-at-target contract margin [20] — material against a FY2026 guide of "at least $5" of adjusted EPS.

7. The Multi-Year Capital Allocation Track Record - Plumbing, Not Showmanship

A long-horizon investor must form a view on whether MOH is a disciplined capital allocator. The 2018-2025 record argues yes, with two caveats. First, the company has never paid a dividend [19]; the entire capital-return story is buybacks. Second, the cadence has been opportunistic, not programmatic — buybacks ran in size at the top of the cycle (FY2024-25 at average prices well above current) and at the cycle trough (Q3 FY2025 at $175.50).

Cumulative buybacks 2018-2025: roughly $3.2 billion of capital returned through repurchases, taking diluted share count from 66.6 million (FY2018) to 52.9 million (FY2025) — a 20.6% reduction in float over eight years. For a regulated low-margin operator with no dividend policy and a state-by-state ring-fenced capital base, that is meaningful per-share accretion. The Q3 FY2025 cohort buying ~70% more shares per dollar at $175.50 than the Q1 cohort at $297.83 is the cleanest single piece of evidence that management is willing to step into weakness with the parent's discretionary capital.

The disciplined-allocator concern is FY2025 specifically: $500 million repurchased in Q1 at $297.83 — the same window in which the CEO sold $28 million of personal stock at ~$320 without a 10b5-1 plan, per the People tab — looks worse in hindsight than the Q3 cohort looks better. That is a credibility concern for the next 18 months. It is not a structural concern for the next 5-10 years; the cycle-low buyback at $175.50 is also the same management.

The corresponding M&A track record is multi-decade. The list of integrated acquisitions over 2018-2025 — AgeWell New York, Affinity (NY Medicaid), Magellan Complete Care (six states), Cigna Texas Medicaid, My Choice Wisconsin, Bright HealthCare California MA, ConnectiCare — totals over $10 billion of acquired revenue [9]. The integration record is "mixed but mostly good" — ConnectiCare's higher starting MCR was a drag on the FY2025 Marketplace MCR per upstream tabs, and the timing of the deal (closed February 2025) is uncomfortable, but no goodwill impairment has been recorded against the acquired books in any of the 2018-2025 vintages, in sharp contrast to Centene's $6.7 billion goodwill impairment in the same FY2025 cycle reset.

8. The Three Pillars of the 5-to-10-Year Thesis (and What Has to Be True for Each)

Pulling the durable frame onto one page, the long-term thesis rests on three pillars. Each has its own "what has to be true" condition and its own decisive falsification signal.

No Results

Pillar 1 is the most proven (six-year track record, three stress events survived, mechanically explainable via auto-assignment). Pillar 2 is the most durable (it is the protection that survives cycle resets). Pillar 3 is the most speculative — the duals strategy is the strategic option that should resolve into either a real margin moat by FY2027 or a confirmation that the niche is harder to underwrite than the cross-sell thesis suggested. The Q1 FY2026 commentary on the converted HIDE/FIDE membership ("performed much better out of the gate than we had anticipated") [21] is the first encouraging data point; FY2027 segment-level MCR is the verdict.

9. Multi-Year Failure Modes - What Would Break the Thesis

A long-horizon investor must price the failure modes, not just the central case. Five things would meaningfully impair the 5-to-10-year compound:

No Results

Among these, failure mode #1 (procurement loss in Texas or Washington) is the highest priority because it is the only one that simultaneously hits Pillar 1 evidence, removes a meaningful slice of premium, and is mechanically inside the 5-year window with well-disclosed procurement cadences. Failure modes #2-3 are regulatory and depend on political outcomes neither management nor the investor controls. Failure modes #4-5 are tail risks that can be monitored continuously.

10. Multi-Year Watch Signals - What to Track Every Year

The signals below are designed for the 5-to-10-year holder, not the next-quarter trader. Each is something a PM should be checking at every annual report and every state procurement window, with a clear "what good looks like" baseline.

No Results

The eight signals above are not a quarterly checklist; they are an annual-report checklist for someone underwriting a multi-year compound. Drift on signals 1, 2, and 6 over two consecutive annual reports would force a structural re-think; drift on signals 4, 5, and 7 is informational rather than thesis-breaking.

11. The Long-Horizon Valuation Lens

A long-horizon investor should not value Molina on FY2025 P/E (cycle bottom) or FY2026 forward P/E (still depressed). The right lens is price-to-book versus through-cycle ROE, with the FY2027 embedded-earnings bridge as a sanity check.

Mechanically: at FY2025 end, stockholders' equity was approximately $4,069 million on roughly 52.9 million diluted shares — book value of approximately $76.92 per share, per the Financials tab. The seven-year average ROE through FY2025 is roughly 26%; even discounting that to a more conservative 20% through-cycle ROE would imply normalized EPS of roughly $15-16 per share off book value (a high-teens ROE on a compounded book). The FY2024 actual of $20.42 sits above that estimate, suggesting the prior cycle peak was above the average. The FY2026 floor of "at least $5" sits well below it, suggesting the current cycle trough is below the average.

For a 5-to-10-year holder, the equity is worth roughly 2.0-2.5x book value if through-cycle ROE returns to the 20-25% band — i.e. ~$150-200 per share simply on a book-value compound at a normalized return, before any embedded-earnings catch-up. Add the $11 per share of embedded earnings management has disclosed, valued at a 12-15x multiple inside the next 3-5 years, and the bull-case upside is incremental $130-165 per share if Pillar 3 (duals) resolves favorably and the procurement engine compounds membership through OBBBA.

No Results

The current price of ~$195 sits inside the lower half of that range. The simple long-horizon implication is that the market is paying for a partial normalization but pricing in skepticism on Pillar 3 (duals) and on the duration of the OBBBA / Marketplace-sunset drag. A 5-to-10-year holder who believes the procurement engine and the regulatory-capital architecture (Pillars 1 and 2) survive intact, even with no Pillar 3 upside, is buying a compounder at a price that requires the rate-vs-trend gap to merely close — not over-correct — to earn an attractive return.

The bear-case downside, per the Bull & Bear tab, is ~$135 — a 17x peer-stress multiple on FY27 consensus of $8.07. That implies a roughly 20-30% downside vs the 50-70% upside described above, an asymmetric setup if the long-horizon investor accepts the bull's framing of the embedded earnings bridge.

12. Five Things That Have to Be True - the Long-Horizon Summary

If a PM is going to write this name into a 5-to-10-year book at $195, the following five conditions need to hold. None individually is sufficient; collectively they are the underwriting frame.

The Medicaid procurement engine produces at or near its 80-90% multi-year win rate. Texas STAR/CHIP retains, Washington Apple Health 2028 retains, and the rolling RFP cohort delivers $20B+ of new premium over the next five years.
The 88-89% Medicaid MCR target is achievable through a normal rate cycle. Even if FY2026 prints at the guided 92.9%, the FY2027-28 vintages restore the spread by 200-300 basis points, and the seven-year average ROE of ~26% reasserts within 18-24 months.
The duals niche (Pillar 3) becomes a quantified margin moat by FY2027. Medicare-segment MCR drops 200+ basis points below MAPD-competitor average; the converted HIDE/FIDE membership compounds without unfavorable PYD; the $1.9 billion MMP-to-D-SNP transition operates at or near 88% MCR by year-end FY2026.
The regulatory-capital architecture stays intact. Subsidiary dividends sustain $800-1,000M annual upstream; no second covenant amendment after February 2026; the parent maintains access to capital at sub-7% cost so the M&A pipeline absorbs distressed plans at book value.
OBBBA implementation comes in at or modestly worse than the 15-20% expectation, not catastrophically worse. State implementations of work requirements and Expansion redetermination cadences land in 2027-29 with manageable membership compression; the $50 billion FY2027 premium target is reset to FY2028-29 rather than abandoned.

Summary. Molina is a narrow-moat regulated compounder whose long-horizon thesis turns on three pillars (procurement engine, regulatory-capital architecture, duals niche) and whose 5-to-10-year compound depends on a rate-vs-trend gap closing inside two annual cycles. The franchise has survived three stress events with state contracts intact in each; the cycle-trough buyback discipline is real; the embedded-earnings disclosure is unusually quantified. The most dangerous failure mode is a Texas STAR/CHIP or Washington Apple Health 2028 procurement loss. The most decisive watch signal is the multi-year drift of Medicaid MCR against the 88-89% target.

References

Competition - Molina vs. Five Public Rivals

Molina sells the same product to the same customer (a state Medicaid agency or CMS) on roughly the same regulatory terms as five much larger publicly traded peers. The investment question isn't whether Molina has a brand or a network — Humana itself says of this arena that "barriers to entry in our markets are not substantial" [1] — it's whether disciplined operating cost and Medicaid-specific underwriting expertise are enough of an edge to keep earning above-industry medical margin in a bid market where four of the country's largest health insurers can outbid Molina on scale, brand, and balance sheet.

1. The Competitive Bottom Line

Molina's competitive position is operational, not structural — and the franchise quality is real, but it is the kind of advantage that has to be re-earned every year, contract by contract.

The advantage is lower medical cost than the industry on the Medicaid book it serves: Molina's stat filings show it running 200-250 basis points better than the broader Medicaid industry that is itself 300-400 basis points underfunded by current state rates [2]. Molina's own 10-K reinforces the historical pattern: "most of our health plans over the last several years have generally operated with profit margins higher than those of our direct competitors" [3].
It is paired with lower operating cost: Molina's full-year FY2025 G&A ratio was 6.6% (down from 6.7% in FY2024) on a 91.7% consolidated MCR [4], built on operating leverage from a pure-play government book that does not subsidize a commercial sales force [5].
It is not a brand, network, or vertical-integration advantage. Molina is the smallest of the five named public peers by a wide margin and outsources its IT infrastructure, end-user services, data centers, public cloud and application management to a third party under an arrangement extended through 2029 [6].

The single most important rival is Centene Corporation (CNC). Centene is the only other publicly traded peer that runs the same pure-play, government-sponsored, Medicaid-first model, and Molina's FY2025 10-K names it both as a primary Medicaid managed care competitor and as the primary competitor for low-income Marketplace membership [6] [7]. Centene self-describes as the "nation's largest managed care company focused on underserved populations" serving 27.6 million members [8] and the largest Medicaid health insurer with 12.5 million Medicaid members in 30 states [9] — a direct, line-for-line substitute on every state procurement Molina enters and one whose own FY2025 earnings collapsed at the same time Molina's did, confirming the cycle is shared and not idiosyncratic.

The most dangerous competitor type over the next 24 months is the scaled multi-product MCO — UnitedHealth Group, Elevance Health, CVS Health/Aetna — that is, by Molina's own description, showing "renewed interest from large national health plans" in the Medicaid bid market [6]. They cannot underwrite Medicaid any better than Molina can; they can, however, cross-subsidize aggressive bids from commercial profit pools, vertical integration (Optum, Caremark, Carelon), or balance sheets ten-to-thirty times Molina's size.

The peer set comparison is real but asymmetric. Centene is the only true peer; the other four are scale comparators whose Medicaid books are a single line of business inside a much larger company. Read every multiple, margin, and growth rate side-by-side with that asymmetry in mind.

2. The Peer Set - Why These Five

Molina's FY2025 10-K names its primary competitors directly. In Medicaid managed care: "Centene Corporation, CVS Health Corporation, Elevance Health, Inc., UnitedHealth Group Inc., and large not-for-profit healthcare organizations" [6]. In Medicare: "CVS Health Corporation, Humana, Inc., and UnitedHealth Group Inc." [7]. In low-income Marketplace: "Centene Corporation" [7]. The same five-competitor framing appears in the FY2024 10-K [10], so the peer set is stable across consecutive 10-K disclosures and not a one-year artifact.

The peer set has shifted only superficially over five years: the FY2021 10-K listed "Centene, UnitedHealth Group, Anthem, Aetna, and other large not-for-profit healthcare organizations" [11]. Anthem became Elevance Health; Aetna became part of CVS Health. The rivals didn't change — their corporate parents renamed themselves. The competitive arena is structurally the same as it was five years ago.

One indexed peer was rejected from the comparison set: The Cigna Group (CI) is in the corpus but, after Cigna's March 19, 2025 sale of its Medicare Advantage, Medicare PDP, and CareAllies businesses to Health Care Service Corporation, it has no Medicaid managed-care book and no remaining Medicare Advantage book, and it does not appear in Molina's FY2025 10-K Medicaid or Medicare competition lists; Cigna only shows up in Molina's stock-performance peer-group index alongside non-managed-care names like Aflac, MetLife and Prudential [12]. Cigna is not a Molina competitor today; we exclude it.

Molina's 10-K also flags "large not-for-profit healthcare organizations" as Medicaid competitors [6]. These (Blue Cross plans, regional non-profits) are not publicly traded and therefore invisible to any peer screen — readers should treat them as a meaningful share of the Medicaid bid market that no public-company comparison can capture.

Each peer, verified from its own filing

No Results

The cited self-descriptions behind that table: Centene serves "more than 1 in 15 individuals across the nation" with Medicaid (57%), Commercial/Marketplace (21%) and Medicare (19%) revenue mix [8], and is "the largest Medicaid health insurer in the country, serving 12.5 million Medicaid members in 30 states as of December 31, 2025" [9]. UnitedHealth runs Optum + UnitedHealthcare, with a Community & State business serving the "medically underserved" [13] and 8.4 million Medicare Advantage members through CMS contracts [14]. Elevance serves "approximately 45.2 million medical members" across Individual, Employer Group, Medicaid and Medicare [15]. CVS Health serves "more than 37 million people" through health insurance products and a PBM with 87 million plan members [16], with Aetna offering Medicaid/CHIP managed care "on an Insured or ASC basis in 15 states in 2025" [17]. Humana provided coverage to "approximately 5.2 million individual Medicare Advantage members, including approximately 1.0 million members in Florida" [18], with individual MA at 70.3% and state-based Medicaid at 11.2% of revenue [19].

3. Scale and Economics - Where MOH Sits

No Results

Molina sits at the bottom of every scale metric on the table. Revenue of $45.4 billion in FY2025 is one-tenth UnitedHealth's $447 billion and roughly one-quarter Centene's $174 billion [4]. FY2025 was a cycle bottom for the whole arena: Centene swung to a $6.7 billion net loss as Medicaid trend overran state rates and Marketplace risk-adjustment turned adverse — the same pressures that drove Molina's consolidated MCR from 89.1% to 91.7% [4]. UnitedHealth, Elevance, CVS, and Humana retained positive earnings because diversified commercial, Optum/Caremark/Carelon services, and lower Medicaid exposure dampened the same shock that hit the two pure-plays. That is exactly the structural asymmetry the comparison reveals.

Caveats on missing values: CVS Health does not separately disclose long-term debt in the structured corpus data, so enterprise value cannot be reliably computed; CVS operating margin is also not separately reported in the structured ratios file. UnitedHealth's ROE and debt-to-equity are not in the structured ratios file. Member counts at UNH, CVS, and HUM (across all lines combined) are not disclosed as a single comparable aggregate and are intentionally left blank in the table rather than mixing definitions; the column captures Medicaid-relevant figures only where each peer's filing states one directly.

Bubble view: profitability vs. scale

The bubble chart makes the two-axis story visible: Molina is far to the left on revenue (smallest) and roughly middle of the pack on operating margin in a year when the only directly comparable peer (Centene) printed a deeply negative number. The implied comparison is not "Molina vs. peers in normal times" — it is "Molina vs. peers in the same cycle bottom."

4. Where Molina Beats Each Peer

Four advantages, each grounded in the primary record:

4.1 Medicaid underwriting accuracy. The clearest cited evidence is from Q3 FY2025 — the CFO stated on the earnings call that "the industry is 300 to 400 basis points underfunded right now" against medical cost trend, and that the same stat filings show "Molina is still performing 200 to 250 basis points better than the industry. So we need half of what the broader industry needs to get to our target margins" [2]. Molina's own 10-K reinforces the historical pattern: "most of our health plans over the last several years have generally operated with profit margins higher than those of our direct competitors" [3]. This is the most important moat element — it is the actuarial expertise of having underwritten government-program populations since 1980 and not being distracted by a commercial book.

4.2 G&A discipline and operating leverage on a pure-play book. Molina's FY2025 G&A ratio was 6.6%, down from 6.7% in FY2024, on $45.4 billion of revenue [4], with management explicitly attributing the decline to "operating discipline, the continued benefit of operating leverage as we grow our business" [5]. Centralized services across health plans, no commercial sales force, no Optum-like services arm to support, and an IT infrastructure outsourced under a long-term contract [6] — these are the structural elements behind the ratio.

4.3 Bid-market win rate and RFP execution. FY2025 RFP successes and acquisitions represent "nearly \$9 billion of incremental annual premium revenue" [20], including new contracts in Idaho (Medicaid and Medicare), Michigan, Massachusetts, Ohio (Medicare), Wisconsin (Family Care and Family Care Partnership), and the sole-plan Florida Kids award expected to serve approximately 120,000 enrollees [21]. Management quantified the rolling track record on the Q4 FY2025 call: "Our win rate is 80%. \$20 billion of run rate revenue over the past number of years, including the Florida Kids contract…" [22]. The Wisconsin renewal complemented previously announced Georgia and Texas STAR wins to represent "over \$9 billion of Medicaid premium" in the recent cohort [23].

4.4 Marketplace selection discipline (the FY2026 cycle). Molina sized its Marketplace book down deliberately heading into 2026 — "our decision to reduce our exposure in this highly volatile segment" — and stayed concentrated in the silver tier with renewals dominating the book [24], with renewing members now representing 70% of the Marketplace book [25]. Centene, by contrast, is the nation's largest Marketplace insurer and bears the larger absolute share of the same subsidy-expiration shock [8]. Molina's smaller absolute Marketplace book is a competitive advantage in a year when the segment economics are reversing.

5. Where Competitors Beat Molina

Four advantages, named to the specific competitor that holds them.

5.1 UnitedHealth's vertical integration (Optum). UnitedHealth describes itself as two "distinct, yet complementary businesses — Optum and UnitedHealthcare" [13], with Optum Insight providing services, analytics, and platforms back to health plans, employers, and state Medicaid programs [26]. Molina has no equivalent in-house services arm; instead it outsources core IT to a third party under an agreement extended in 2022 for seven additional years [6]. In any state RFP where data-analytics, care-management technology, or health-system services capability is scored, UnitedHealth is structurally better positioned and can cross-subsidize its bid from Optum's profit pool.

5.2 Humana's dominance in individual Medicare Advantage. Humana served approximately 5.2 million individual MA members at year-end 2025 — including roughly 1.0 million in Florida alone [18] — against Molina's total Medicare segment membership of 262,000 [27]. Individual Medicare Advantage alone accounted for 70.3% of Humana's Insurance segment revenue [19]. On any pure MA bid market, Humana brings two orders of magnitude more member-level data, broker relationships, and STARS-rating infrastructure than Molina can. Molina's own 10-K acknowledges Humana as a primary Medicare competitor [7].

5.3 Centene's Marketplace scale and brand. In the Marketplace where Molina is shrinking deliberately, Centene is the largest player and explicitly named as Molina's primary low-income Marketplace competitor [7]. Centene's roughly $36-37 billion Marketplace business (implied at ~21% of $174.6B FY2025 revenue) [8] gives it actuarial credibility, member-acquisition machinery, and broker reach that Molina, with a smaller Marketplace book, cannot match if the segment normalizes after subsidy expiration.

5.4 Elevance and CVS's balance-sheet weight in state-by-state bids. Elevance's 45.2 million medical members and Carelon services arm [15] [28], and CVS's combination of Aetna's 37 million people, Caremark's 87 million PBM relationships, and a national retail-clinic footprint [16], both give them depth on Medicaid RFPs where states score provider network access and integrated services. Aetna's Medicaid/CHIP footprint is already in 15 states [17]. When Molina's 10-K calls out "renewed interest from large national health plans" [6], this is what it means.

6. Threat Map - The Next 24 Months

The five threats below come straight off the primary record, each tied to its cited evidence, severity, and the competitor or competitor group that creates it. Threat 1 is the only one that directly attacks share; the others compress economics inside the existing book.

No Results

Threat 1 - Medicaid bid pressure from large national MCOs (High). Molina's FY2025 10-K explicitly flags this as a current dynamic: "There is increasing competition driven by renewed interest from large national health plans" [6]. It has already cost Molina the Virginia contract — confirmed on the Q4 FY2025 call ("Medicaid is up \$1.1 billion due to the new Florida CMS contract and the modest rate cycle, partially offset by the Virginia contract loss in 2025…") [29]. State agencies score RFPs on provider network, quality scores, financial resources, and other factors [6] — every one of which a $400B+ revenue rival can throw weight at.

Threat 2 - Medicaid trend overrunning state rates (High, near-term). Management quantified the gap: "the industry is 300 to 400 basis points underfunded right now" [2]. The pressure is concrete and showed up in FY2025 results — Medicaid MCR rose 150 basis points to 91.8% driven by higher utilization, behavioral health costs, and member acuity changes [30]. Because rate cycles lag cost cycles by 6-18 months, this threat is largely about when the catch-up arrives, not whether. It is industry-wide, but at Molina's 75% Medicaid revenue concentration, the operating-result sensitivity is higher than at any peer in the table.

Threat 3 - OBBBA Medicaid Expansion membership loss (High, 12-36 months). Management's own quantification: the One Big Beautiful Bill Act "is expected to drive a 15% to 20% reduction on 1.2 million members in our Medicaid Expansion membership and a further medical cost acuity shift during the next two to three years" [20]. This is regulatory, not competitive — but it removes premium revenue from Molina's most concentrated segment and lifts the average acuity of remaining members. Centene's 10-K confirms the same OBBBA mechanism applies across the industry [9], so it is not a competitive share threat — but it shrinks Molina's addressable base.

Threat 4 - Marketplace subsidy expiration and program-integrity rules (Medium). Management explicitly cites "The expiration of subsidies in Marketplace in 2025 will lead to a reduction in membership and result in an adverse acuity shift in the overall market risk pool. Program integrity initiatives will also be a contributing factor to Marketplace membership reduction" [20]. FY2025 Marketplace MCR jumped from 75.4% to 90.6% [31]. Molina is shrinking its book in response [24], but Centene — with the larger Marketplace book — bears the bigger absolute shock.

Threat 5 - Humana scale in individual MA and the D-SNP transition (Medium). Humana's 5.2 million individual MA members and 70% MA revenue concentration give it data, broker reach, and STARS infrastructure Molina cannot match [18] [19]. The threat is amplified by the CMS-mandated transition of MMP plans to integrated D-SNP contracts that took effect January 1, 2026 in Molina's five MMP states — Illinois, Michigan, Ohio, South Carolina, and Texas [32] — a re-bid market where Humana's MA pricing infrastructure may matter more than Molina's Medicaid relationships.

Threat severity at a glance

7. Moat Watchpoints - What to Monitor

Five disclosed signals that will tell an investor whether Molina's position is actually improving or weakening over the next eight quarters. Each is anchored to a number management has already disclosed.

No Results

The numbers in the Baseline column come from: Medicaid MCR 91.8% [30]; industry spread benchmark "200 to 250 basis points better than the industry" [2]; 80% RFP win rate [22]; ~$9B incremental premium in 2025 [20]; G&A ratio 6.6% [4]; Marketplace renewal mix 70% in silver [24] [25]; Medicare segment 262,000 members [27].

What would change the call. If the 200-250bps Medicaid-MCR spread compresses, the operational moat is weakening and the franchise re-rates lower. If RFP win rate slips meaningfully below 80% on rebids in 2026-27, the bid-market share leak from the large national MCOs is real. Conversely, if G&A holds under 7% on a flat or shrinking revenue base, the operating-leverage advantage is structural and not just volume-driven, and the cycle-bottom multiple is wrong.

References

Current Setup & Catalysts — Molina Healthcare, Inc. (MOH)

The stock has retraced from the April 22, 2026 gap-down low at $129 back to $194.76 — within 4.6% of the pre-shock peak — without anybody declaring the FY2025 reset over. Consensus has marked the 2027 rebound at $8.07 of EPS against management's own disclosed walk to "approximately $7.50 of underlying" 2026 earnings before any rate restoration [1], which is the variant edge this page is built around. The next four prints decide whether the trough is real, and the July 22, 2026 Q2 print is the binary — the bull/bear gap is no longer the FY2026 mechanics, it is the slope from $5 into FY2027.

Last close (6/18/2026)

$194.76

Days to Q2 print (7/22)

Q2 consensus EPS ($)

$1.45

FY27 consensus EPS ($)

$8.07

FY26 consensus EPS ($)

$5.16

Sell-side mean PT ($)

$190.25

Ceiling tested 4x in June ($)

$205.00

Pre-shock support / invalidation ($)

$172.00

Setup read: Mixed, with binary skew into July 22. Recent prints, the legal market and S&P are short the credibility of management's framing; the procurement engine, the Burry disclosure and an internal Medicaid MCR snapshot at 92.0% in Q1 are long it. The Q2 print is the next forced choice. A clean miss reopens the litigation overhang and a $150-160 retest; a clean hold reopens the $215 case.

Where we are right now

Consensus has converged on management's own "at least $5" anchor for FY2026: the average FY26 EPS estimate is $5.16 across 18 analysts, with a 30-day revision split of 11 up / 1 down — i.e. the Street has been lifting the floor since Q1 cleared $2.35 against $1.91 consensus. FY2027 has revised up harder still — 8 up / 0 down in 30 days, from $5.77 ninety days ago to $8.07 today — but management is signaling a number well above that. CFO Mark Keim closed the April 23 call by flagging that the $2.50/share burden in 2026 (Florida CMS Kids implementation costs plus traditional MAPD product losses) is "certain to be positive impacts to our 2027 performance" [2], and CEO Joe Zubretsky used the Q4 FY2025 prepared remarks to disclose that the 2026 guidance "produces underlying earnings of approximately $7.50 per share" after adjusting for those same two items [1]. The market is paying for part of the $7.50 → $9+ path. It is not paying for the rate-catch-up call option on top of it.

Positioning and sentiment around that anchor are unusually split. The recommendation distribution is 1 strong buy / 3 buy / 13 hold / 0 sell / 1 strong sell at a mean target of $190.25 — i.e. essentially the spot price. The dispersion sits inside that mean: Mizuho stands at $215 / Outperform after a 6/8/2026 raise, Barclays sits at $199 / Underweight, and one outlier holds $129. Capital World, a top-20 holder, sold 1.66M shares on 6/8/2026; the same week, Michael Burry's MOH long was the lead headline on Yahoo Finance. Borrow and short-interest data are not staged for this run, so positioning cannot be quantified directly — but the legal market (a putative federal securities class action Hindlemann v. Molina Healthcare covering February 5 – July 23, 2025 [3]) and S&P's April 3, 2026 downgrade to BB- are the two visible, public expressions of "short the credibility."

The tape has read all of that and is sitting on it. The post-shock recovery from $129 to $200 has been textbook V-shape, but volume on the climb back from $170 has been conspicuously light (multiple sub-1M-share sessions through June) and the $204-205 ceiling has rejected the stock four times — March 31, June 9, June 10, June 16. A daily close above $205 reopens the $215+ path; a daily close below the pre-shock $172 support invalidates the recovery and re-engages the $130s scenario. Between those lines, the $500 million of remaining buyback authorization through December 31, 2026 [4] — about 13 days of 20%-participation ADV — is the marginal bid keeping the chart honest.

The variant view — sized in numbers, stated before the calendar

There are two places where the analyst sheet should differ from consensus heading into the July 22 print, and one place where the right call is to sit on consensus.

(1) FY2027 EPS — variant +18% to +30% vs Street. Consensus FY27E is $8.07. Management's own building blocks are: $5 FY26 floor + ~$1 MAPD exit drag that mechanically disappears + ~$1.50 Florida CMS Kids implementation-cost reversal at run-rate margin = ~$7.50 of underlying 2026 power [1], and both reversals are "certain" per the CFO [2]. On top of that, Zubretsky has quantified the rate-catch-up sensitivity: every 100 bps of Medicaid MCR is worth ~$5 per share [1]. The FY26 Medicaid MCR guide is 92.9% against a long-term target of 88-89% — a 300-400 bps gap. Even half-closing it adds ~$2-3 of FY27 EPS, putting the variant range at $9.50-10.50, or roughly +18% to +30% above the $8.07 print. The Street is partway up the bridge and not paying for the rate leg.

(2) Q2 FY2026 EPS — variant aligned at $1.40-1.60, but with asymmetric down skew. Consensus is $1.45 (high $2.04, low $0.98, 17 analysts) — a very wide range for a managed-care print, signaling that the buy side is divided on whether Q1's $2.35 was clean or whether the front-loaded earnings seasonality management called out [2] will fade harder in Q2 with Marketplace risk-adjustment payable accruals. Our view sits at the consensus midpoint, but the historical reaction pattern for negative surprises in this name (table below) is -17% to -22%, while reactions to in-line prints have been single-digit. The skew is the trade — even an in-line Q2 EPS that is paired with a downward "view" or a Marketplace payable build can re-rate the stock harder than the EPS number alone.

(3) FY2026 EPS — aligned with consensus at $5.16-5.25; no edge in the raise debate. Management has been explicit it will "not update guidance" at Investor Day or Q2 — Zubretsky said the call would only revisit the guide "after 2 full quarters of information" in Q3 [2]. Trading the Q2 print as a guidance raise is therefore a low-probability bet; the higher-probability bet is the FY2027 re-rate that follows the Q3 / Q4 prints.

The net variant view a PM should leave this page with: the right framing is "buy the Q2 print into a 100% rate-cycle option on FY2027," not "buy MOH on cyclical-trough." The stock is paying for the trough; it is not paying for the rate-restoration cycle the company itself has quantified.

Historical earnings price-reaction base rate

The single most important calibration for any high-impact catalyst here is how MOH has actually traded on the last eight prints. The pattern is binary and large.

No Results

The pattern is uncomfortable for sizing into July 22. The last four prints — including the Q1 FY2026 "beat" — have produced 1-day reactions of -22%, -19%, -18%, -20%. Even a clean EPS beat (Q1 2026 +23% surprise) printed -22% on the day because guidance was reaffirmed rather than raised. The average absolute 1-day move on the last eight prints is ~11.6%, against a managed-care peer-set baseline of 3-5%. The implication for July 22: even an in-line $1.45 EPS print, if paired with a Marketplace risk-adjustment build or a soft "view," can easily produce a -10% to -15% reaction. A clear beat with a tactical raise to the FY2026 floor is the only scenario that mechanically re-rates the stock — and management has pre-committed not to raise on July 22 [2].

What changed in the last 3-6 months

Since mid-March, three things have moved the underlying setup, and one thing has been priced in.

No Results

The two events that moved the long-term thesis are the Q4 FY2025 print (which retired the "13-15% long-term EPS growth" frame and introduced both the $5 floor and the 100 bps Medicaid MCR = ~$5/share sensitivity [1]) and the Q1 FY2026 Medicaid MCR of 92.0% — the first quarter inside the FY26 guide [5]. The S&P downgrade is priced into the cost of incremental capital but does not constrain near-term operations. The May 8 Investor Day is the under-the-radar event: management had committed on the Q1 call to publish "a detailed financial outlook for premium revenue and earnings per share through 2029" with the same "level of detail and specificity that has been our hallmark" [6], and public coverage of the event indicates no quantified 2029 EPS was disclosed. That is a new credibility item that has not yet been re-priced.

What the market is watching now

The live debate is narrow and unusually specific. There are exactly four contested items going into the Q2 print, and the same four items account for ~95% of the FY2027 EPS distribution.

No Results

Items 1, 2, and 3 are tested in the next two prints; item 4 plays out on the litigation calendar, not the earnings calendar.

Ranked catalyst timeline — by decision value, not by date

The catalyst list below is ranked by how much each event resolves the FY2027 EPS distribution, which is what the equity is now priced against. Three catalysts inside the next 6 months are genuinely decisive (rank 1, 2, 5); the others are setup-shaping but not stand-alone re-rating events. The Texas STAR/CHIP go-live (now scheduled for 2027 per the CFO on Q1 FY2026 [7]) and the Washington Apple Health 2028 RFP issuance live in the long-term thesis but sit at or beyond the 6-month window; both are included for completeness. Rank 4 — the Q4 FY2026 print and initial FY2027 guidance in February 2027 — is the single most thesis-resolving event in the 18-month frame but falls outside the 6-month catalyst window, so it is called out explicitly.

No Results

Which catalysts actually resolve the debate

Not every event in the table re-prices the equity. The matrix below separates the four catalysts that update durable thesis variables from those that merely add color.

No Results

Next 90 days — what to watch, in date order

Inside the next 90 days (June 19 – September 19, 2026), three items dominate. Everything else is set-up for them.

No Results

If the Q2 print on July 22 holds the $5 floor and Medicaid MCR comes in below 92.0%, the 30-day window through August carries the next set of catalysts — off-cycle rate disclosures and the Q2 13Fs — and the setup into the October print is for a test of the $204-205 ceiling. If Q2 brings a Marketplace payable build or a Medicaid MCR at/above 93.5%, the same 30-day window sets up an air-pocket retest toward $150-160.

What would change the view

Three observable signals over the next ~6 months would force a real underwriting change. None of them is an ordinary earnings beat or miss.

Medicaid MCR converges to 91% or below across two consecutive quarters. The single most powerful update to the long-term thesis. At management's disclosed sensitivity — every 100 bps of Medicaid MCR is worth ~$5/share [1] — a 180-200 bps move from the FY26 guide of 92.9% mechanically adds $9-10/share to FY27 power. This is the Pillar 1 confirmation, and it is the signal that re-rates the multiple from "trough P/E" toward through-cycle 14-16x. Inverse: Medicaid MCR at/above 93.5% across two prints invalidates the rate-cycle catch-up thesis and re-engages the "structural re-base" reading.
A second sequential guidance cut, or a second covenant amendment. A fourth cut would close the loop on the credibility narrative, re-engage the Hindlemann class action's central allegation, and almost certainly bring a follow-on S&P action — the FY2025 10-K's MCR sensitivity already quantifies how knife-edge the FY26 guide is: a one-percentage-point move on consolidated MCR cuts diluted EPS from $8.92 to $2.72 [8]. A second covenant amendment beyond the February 2026 cut from 3.00x to 1.75x interest coverage would be the lender writing in black ink that EBITDA-to-interest is tight. Either is a -25% event.
A Texas STAR/CHIP or Washington Apple Health 2028 procurement loss. The two largest binary outcomes inside the 5-year frame. The 10-K is explicit: "Incumbency status may not necessarily guarantee our ability to retain contracts when they are up for rebidding" [9]. Texas STAR/CHIP at roughly 18% of Medicaid revenue and Washington at ~13% (per the FY2025 10-K [10]) are 3-5x the dollar magnitude of the 2024 Virginia Cardinal Care loss. A loss in either would re-rate the franchise from "narrow-moat compounder" to "regulated yield substitute," irrespective of the next two earnings prints.

These are the three signals that force a thesis update. The Q2 print is not one of them by itself — a print is the trigger for information; the signals above are the trigger for a decision.

Bottom line. The recent setup is mixed-with-binary-skew into July 22. The variant view is +18-30% to consensus FY27 EPS based on management's own building blocks plus partial rate restoration. The catalyst path is unusually narrow and well-defined: three earnings prints and one procurement RFP over the next nine months resolve roughly 80% of the FY27 EPS distribution. Stay engaged in the $172-200 band, earn the position rather than chase it, and treat the Q3 FY2026 print as the FY27 re-rating trigger if the Q2 floor holds.

References

Bull and Bear

Verdict: Watchlist — the franchise is intact and ~$9B of pre-loaded premium is real, but the equity is paying 37.7x FY26E earnings to underwrite a Medicaid MCR recovery the company itself has refused to commit to. The decisive tension is whether FY2025's blow-up was a sector-wide cyclical reset (Bull) or a structural EPS rebase (Bear). The math that settles it is knife-edge: every 100bps move in Medicaid MCR is worth ~$5 of EPS, and FY2026 is guided 4 percentage points above the long-term target with the rate-vs-trend gap already six quarters old [1][2]. The fact that would change the conclusion is one or two clean quarters of Medicaid MCR converging toward 90% with neutral-to-favorable prior-year development — neither side can claim victory before that print arrives.

Bull Case

No Results

Bull's price target is $280 on 16x FY2027 adjusted EPS of ~$11, anchoring on the embedded-earnings bridge ($5 FY26 floor + $1 MAPD exit + $1.50 Florida Kids run-rate + $2.50 partial Medicaid rate catch-up). Timeline is 18-24 months, with the May 8, 2026 Investor Day expected to quantify the FY2027 baseline and the FY2026 Q3/Q4 prints carrying the rate-cycle signal. The disconfirming signal Bull names is a FY26 Q3 print showing Medicaid MCR materially above the 92.9% guide (94%+), or a loss in either the Texas STAR/CHIP or Washington Apple Health 2028 procurement — either would force a structural reset of the rate-cycle and procurement-engine pillars of the case.

Bear Case

No Results

Bear's downside target is $135 (–31%) using two cross-checks that converge on the same area: (a) 17x peer-stress multiple on FY27 consensus EPS of $8.07 = $137, and (b) 27x on a still-soft $5 FY26 EPS = $135. Timeline is 12-18 months — the Jan 2026 retroactive rate trues, the Jan 2027 cycle, and the May 2026 Investor Day are the verdict windows. The primary trigger is a FY26 print at or above the company's own 92.9% Medicaid MCR guide, or a fourth guidance cut. The cover signal would be two consecutive quarters of Medicaid MCR printing below 90% with neutral-to-favorable PYD in Medicaid and the Marketplace risk-adjustment payable stabilizing rather than building. The bear's three discrete claims that anchor the case — three sequential guidance cuts in 2025 [1], MCR "temporary" framing in the 10-K [2], and the litigation footnote with the class window [7] — are drawn from the primary record verbatim.

The Real Debate

The decisive disagreement is not over the facts of FY2025 — both sides agree on the numbers — but over what those numbers say about FY2027. The crux is the Medicaid MCR knife-edge: the 10-K's own sensitivity table shows a single point of MCR moves FY25 EPS from $8.92 to roughly $2.72 [6], and management characterizes the rate-vs-trend imbalance as "temporary" but has not committed to when it closes [2]. Below the table, the forensic anchor for Tension 3 is also from the 10-K: prior-year development collapsed to $98M [4] while operating cash flow swung to –$535M [5], and the early FY26 read on the most-watched ramp (HIDE/FIDE) came in ahead of plan per the Q1 FY2026 call [3].

No Results

Verdict

Verdict: Watchlist. The bear carries more weight today because the decisive variable — Medicaid MCR — is knife-edge: the 10-K's own sensitivity disclosure shows one point of MCR equals roughly $6.20 of FY25 EPS, and the FY26 Medicaid MCR is guided 4 points above the long-term target with the rate-vs-trend gap already six quarters old [6]. At 37.7x FY26E earnings, the equity is paying for a snap-back to "normalized" $14-20 EPS that management itself has refused to commit to, and the forensic record (prior-year development collapsed to $98M [4], operating cash flow swung to –$535M [5], covenant cut from 3.00x to 1.75x, CEO insider sale at $320 six weeks pre-cut) gives that recovery thin margin of safety. The bull could still be right: the franchise is genuinely intact (zero impairment vs Centene's $6.7B, RBC ~305%, all 21 state licenses), the ~$9B 2025-vintage premium award book is contractually pre-loaded, the HIDE/FIDE ramp came in ahead of plan in Q1 FY2026 [3], and two of three FY27 EPS-bridge legs are mechanical. The durable thesis breaker is whether Medicaid MCR converges toward the 88-89% target — the near-term evidence marker is the FY26 Q3 print (October 2026), where a Medicaid MCR sub-90% with neutral PYD would shift this to Lean Long and a 92%+ print with continued unfavorable PYD would shift it to Avoid. Until then, neither side has earned the conviction the multiple demands.

Watchlist — own franchise quality and pre-loaded premium are real, but a 37.7x FY26E multiple on a knife-edge Medicaid MCR has no margin of safety until the rate-cycle catch-up actually prints.

References

What Protects Molina From Competition

Molina sells one product to two customers: it absorbs medical-cost risk on a defined population in exchange for a state- or CMS-set capitation rate. What, if anything, lets Molina earn a return on capital that a well-funded competitor cannot bid away, and is that protection still working after the FY2024-25 cycle reset?

The honest answer is narrow moat. There is something real here — a multi-year procurement track record, a 21-state license-and-capital footprint that is hard to replicate, and a small but legitimate cost-and-data edge in dual-eligibles — but none of it shows up as pricing power, brand captivity, switching costs, or scale-driven margin. The moat is operational and regulatory, not structural; it sits at the state level, not the company level; and the FY2025 print is the cleanest illustration in the data that when the only line item that matters (MCR) moves the wrong way, the moat does not stop the earnings from collapsing. The question for an investor sizing the name is not whether the moat exists — it does — but whether it is wide enough to compound capital at attractive returns between cycle resets. The answer is yes, modestly.

1. The verdict in one screen

Moat rating

Narrow moat

Evidence strength (0-100)

Durability (0-100)

Weakest link

No pricing power; state customer sets unit price annually

The rating is narrow not because nothing protects Molina — there are at least three real protections — but because each one is bounded. Procurement-cycle win rates are high but every contract is up for rebid every 3-5 years and incumbency is explicitly not a guarantee. The 21-state regulatory and capital footprint is genuinely hard to assemble, but it is not a barrier against the seven national platforms that already cleared the same bar. The dual-eligible niche is small (~$6 billion of integrated D-SNP/HIDE/FIDE revenue in 2026), it is the right strategic anchor, but it does not yet show up as a defensible margin advantage. Confidence in this rating is moderate-high because the multi-year primary record — 2017 (Marketplace blow-up), 2020-22 (COVID PHE windfall), 2023-25 (redetermination + trend overshoot) — has now stress-tested every claimed advantage in both directions.

2. The unit of analysis is the state contract, not the company

The single most common mistake when discussing Molina's moat is treating "Molina Healthcare, Inc." as the analytical unit. It is not. The unit is a state-issued Medicaid contract with a fixed term, of which Molina holds many. Each contract is licensed, capitalized, and rebid separately; each can be terminated by the state with or without cause [1]; and each lives inside an actuarial-soundness regime where the price is set by the customer, not the seller.

No Results

Each of California, New York, Texas, and Washington accounted for approximately 10% or more of consolidated Medicaid premium revenue in FY2025; together these four anchor states are roughly 54% of the segment [1]. A "moat" that produces an extraordinary win rate company-wide is, in mechanics, twenty-one separate state-level moats that each have to be re-defended at their own RFP cadence. The Virginia loss in 2024 — the DMAS Cardinal Care Managed Care 2.0 procurement, which terminated Molina's contracts effective June 30, 2025 [2] — is the worked example: a procurement loss in a single state can remove a multi-hundred-million-dollar revenue stream regardless of how strong the company-level franchise looks.

3. The moat scorecard — what's claimed vs. what shows up

No Results

Three of the ten rows are real, two are limited, two are operational/structural facts that get mis-labelled as moats, and three are clearly not moats. The next three sections take the three real pillars one at a time and ask the only question that matters: does the economic mechanism actually produce a defensible advantage, or does it just describe what Molina does?

4. Pillar 1 — The procurement engine: auto-assignment is the only mechanism with a quantifiable edge

The most important sentence in the FY2025 10-K for moat purposes sits on page 17. When eligible Medicaid members do not choose a plan but are required to enroll in managed care, states algorithmically assign them; the criteria typically include previous enrollment, family enrollment, plan quality scores, network and enrollment size, "plans with the lowest bid in a county or region," and equal assignment [3]. This is the literal economic linkage between G&A leverage and membership flow: a sub-7% G&A ratio lets Molina bid at a price that triggers auto-assignment in counties where it competes against higher-cost MCOs, and auto-assignment then converts into multi-year member-months because state contracts are 3-5 year terms.

The company's own framing of the resulting track record is the most-quoted single statistic in the entire 10-K: "We have achieved a 90% re-procurement win rate for Medicaid requests for proposal ('RFP') representing \$14 billion in retained revenue and an 80% new contract win rate worth \$20 billion in premium, and we have completed acquisitions totaling more than \$10 billion of revenue during this period" [4]. FY2025 alone added "nearly \$9 billion of incremental annual premium revenue" from RFP wins and the ConnectiCare acquisition, with the Florida CMS Kids contract sole-selected for ~120,000 enrollees [2]. The Q1 FY2026 commentary added Idaho, Michigan, Massachusetts, Ohio (Medicare), Nevada, and Illinois Medicare to the 2025 vintage [2].

No Results

The honest counter-evidence. Three caveats matter. First, the 10-K is explicit in two separate places — Item 1 "Competitive Conditions" and Note 1 to the financial statements — that "Incumbency status may not necessarily guarantee our ability to retain contracts when they are up for rebidding" [5]. Virginia in 2024 was the worked example; Kentucky in 2020-21 was the prior one, when Anthem Kentucky Managed Care Plan brought a Franklin County Circuit Court action contesting the state's award to the five winning bidders including Molina [6]. A procurement is not won until the courts and regulators stop fighting over it. Second, the 90%/80% statistics are management self-disclosure, not an independently audited series — they are framed against the company's own definition of an "RFP." Third, the company's primary Medicaid competitors named in its own filing — Centene Corporation, CVS Health, Elevance, UnitedHealth Group — are credibly bidding on every same procurement, with the same low-cost ambition [5].

Verdict on Pillar 1. Real but bounded. The auto-assignment mechanism is the cleanest moat in the file — a literal economic link from G&A discipline to multi-year contract revenue. The track record is genuine and multi-decade. But the moat is per-state, per-cycle, and replicable in principle. The right read for a portfolio investor: this advantage protects the long-term growth trajectory of Molina more than it protects any single year's margin, and a stress like FY2024-25 trend overshoot will route around it because the rate (not the win rate) is what compresses.

5. Pillar 2 — The regulatory entry barrier is real, even if it's not exciting

A part of the moat that gets under-discussed because it is not flashy: it is genuinely hard to assemble a 21-state government-managed-care platform, and the barrier is denominated in dollars of statutory capital, years of license seasoning, and state-specific contract relationships. Molina disclosed in the FY2025 10-K that the minimum statutory capital and surplus requirement across its regulated health-plan subsidiaries was approximately \$3.1 billion at December 31, 2025 (versus \$2.6 billion a year earlier) [7]. Net assets at the subsidiaries that "may not be transferable" to the parent without regulator approval were approximately \$4.4 billion at year-end — i.e., roughly the entire equity base of the company sits behind a state-by-state ring fence [8]. All Molina health plans except California, Florida, and New York are subject to NAIC risk-based-capital ("RBC") rules; the three exempt states have their own statutory frameworks that can require more, not less [8].

This stack — license, RBC minima, restricted net assets, regulator-gated upstream dividends — is the actual barrier to entry in this industry. It is the reason a well-capitalised tech entrant can't simply "Uber" Medicaid management. The barrier protects every existing national platform equally, so it is a moat against new entrants and minor players, not a moat against UnitedHealth, Centene, CVS, or Elevance. And it cuts both ways: in a cycle trough, the parent depends on subsidiary dividend capacity that the same regulators must approve, which is why management amended its credit agreement to a 1.75x interest-coverage minimum for FY2026 — a covenant move flagged by the Forensic tab as the loudest signal that the constraint binds when underwriting earnings compress.

The Industry tab makes the corollary point: Medicaid spending is projected to grow at roughly 7% per year to \$1.5 trillion by 2031 (CMS estimate cited in Centene's 10-K), so the demand-side TAM is expanding. The barrier-to-entry plus expanding TAM combination is the structural reason existing incumbents (Molina among them) capture the marginal growth, not new entrants. It is also the reason multi-billion-dollar M&A continues to be the cleanest way to add states without waiting for the procurement cycle — every acquired plan brings its own statutory capital, license, and contract relationships, which is the framing CEO Joe Zubretsky used on the Q1 FY2026 call when he said "if you're only paying for regulatory capital, an M&A deal can be as good as, if not better than, a new contract win."

Verdict on Pillar 2. Real and persistent. This is the protection that survives a cycle reset; it does not protect any single year's earnings, but it protects the franchise's continued right to exist as one of seven national platforms. It is also the moat least likely to be visible to a quick-look investor screening on margin or growth.

6. Pillar 3 — Dual-eligibles is a strategic asset, not yet a margin moat

The third real protection is the one the company has bet on most explicitly: in February 2026, management announced it will exit Medicare Advantage-Part D ("MAPD") for plan year 2027 because the product "does not align with our strategic shift to focus exclusively on dual eligible members" [9]. Concurrently, the MMP contracts in Illinois, Michigan, Ohio, South Carolina, and Texas transitioned to integrated D-SNP contracts on January 1, 2026, totalling \$1.9 billion in revenue, and Molina won standalone D-SNP procurements in Illinois, Michigan, and Ohio to underwrite that transition [10].

The economic logic is straightforward and credible: a dual-eligible member is typically already a Molina Medicaid member, so the member-acquisition cost is much lower than for a stand-alone Medicare Advantage shopper who would be contested by CVS/Aetna, Humana, or UnitedHealth Group — the three large competitors Molina names in its Medicare market [11]. Molina's Medicaid network, care-management workflow, and population health data on that member are sunk costs in the Medicaid plan; the incremental dual-eligible coverage is a margin pickup, not a new acquisition cost. On the Q1 FY2026 call, CEO Joe Zubretsky was unusually positive on the converted HIDE/FIDE book: the new members "performed much better out of the gate than we had anticipated" [12].

The honest read. The duals strategy is the right strategic anchor, and the cross-segment Medicaid-to-D-SNP continuity is a genuine cost-advantage mechanism that the three pure-MA competitors lack. But this is not yet a quantified margin moat. The FY2025 Medicare segment ran a 92.4% MCR — the worst of the three reportable segments — driven specifically by high-acuity duals utilization (LTSS, high-cost pharmacy) that outran what was priced (Numbers tab, FY2025 segment MCR data). If the duals book were a true moat, we would expect to see it producing a margin premium versus pure-MA competitors; instead it is currently producing the highest MCR in the company. The Q1 FY2026 data is encouraging but is one quarter. The duals story is a strategic option that should resolve into either a real margin moat by FY2027 or a confirmation that the niche is harder to underwrite than the cross-sell thesis suggested.

Verdict on Pillar 3. Real, directionally promising, but unproven. The cross-segment continuity is genuine cost-side; the margin proof is not yet there.

7. What is NOT a moat — and the importance of saying so

Three things often get described as moats for Molina that are not. Calling them out clearly is the discipline that prevents over-rating durability.

Pricing power: zero. State Medicaid agencies set PMPM rates annually under federal actuarial-soundness standards. CMS sets MAPD bids annually. Marketplace rates are filed in spring for the following year. The first risk factor in the FY2025 10-K is exactly this: "Rate increases are most typically implemented by states on only an annual basis… If the premiums paid to us are not increased at a rate that is commensurate with the rate at which medical expenses related to healthcare services rise… our medical margins will be compressed or eliminated, and our earnings will be negatively affected" [13]. This is not a Molina-specific weakness; it is the structural shape of the industry. But it does mean any moat framing that begins with "Molina has pricing power" is wrong.

Brand captivity: low. The brand value in this business is the state and federal contract, not the consumer logo. Medicaid members typically choose by provider network and are auto-assigned when they don't. Marketplace member selection is, in management's own characterization in the same Risk Factor section, "highly price sensitive" [14]. The Marketplace 70% renewal rate that came out of Q1 FY2026 is real but is mostly silver-tier mix and rate continuity, not loyalty in any Buffett sense.

National scale: limited as a margin advantage. UnitedHealth at \$447.6 billion of revenue is ~10x Molina. But the Industry-tab benchmark shows that managed-care underwriting margin is structurally 2-5% across the entire peer set regardless of size — UNH's group operating margin sits in the same band as Molina's through-cycle margin, and what makes UNH's consolidated margin look better is Optum (care delivery, data, PBM), which is a different business. Scale matters at the state-bid level — a plan with 1.5 million Texas members has unit-cost advantages on provider contracting that a plan with 200,000 does not — but not at the consolidated national level.

Switching costs: structurally low. This is where a Buffett-style "moat" investor must be careful. There is no contractual switching cost to a Medicaid member changing plans, no software lock-in, no data migration friction, no enterprise relationship to unwind. The state is the actual customer, and the state can — and does, every 3-5 years — issue an RFP and award the contract to a different operator. There is member-acquisition cost asymmetry on duals (Pillar 3), but that is a cost-side advantage to the operator, not a switching cost imposed on the member.

8. Stress tests — has the moat survived?

The cleanest test of durability is whether the franchise survived multi-year stress events. Molina has now had three: an internal control failure in 2017, a regulator-induced windfall in 2020-22, and a cost-trend overshoot in 2024-25.

No Results

Two important read-outs. First, in all three stress periods the franchise (states, contracts, licenses, capital, RFP win rate, parent/sub plumbing) held. Second, in two of the three the earnings did not. That asymmetry is the cleanest description of Molina's moat: it protects the right to compound capital across decades, but it does not protect any single year's margin against a rate-vs-trend gap. An investor who internalises both is sizing the position correctly.

The 2017 stress is especially instructive. Molina had a real control failure at the operating level — a Marketplace cost-overrun bad enough to drive operating losses of \$555 million and the termination of the founding-family management — and yet none of the Medicaid contracts terminated, the state customers did not switch wholesale, and the FY2018 reset produced \$1.1 billion of operating income on the same Medicaid book. The Story tab frames 2017 as a Marketplace and G&A failure that the franchise absorbed. From a moat lens, 2017 is the strongest single piece of evidence that the per-state Medicaid contract is durable through severe operating dislocation.

9. What would erode it — the watch signals an investor must monitor

The moat does not deteriorate gradually. It deteriorates at procurement cycles, regulatory inflections, and capital-allocation crises. Five things to watch in priority order:

Texas STAR/CHIP rebid + Washington Apple Health 2028 procurement. Texas at \$5,735 million (18% of Medicaid premium) and Washington at \$4,194 million (13%) are the next two material procurement windows; Washington's RFP is expected no earlier than Q4 2026 with a contract effective date of January 1, 2028 [1]. A loss in either is a Virginia-scale event but with 3-5x the dollar impact. Top watch signal.
NCQA / Star Rating slippage in named states. Eighteen Medicaid and 14 Marketplace plans are NCQA-accredited; "a growing number of states link reimbursement and patient assignment to quality scores" [15]. Approximately 50% of FY2026 Medicare premium is not impacted by Star Ratings, and only a handful of plans sit at 3.5+ stars [15]. A two-plan downgrade in the next CMS October update can move tens of millions of bonus revenue in the following year; a Medicaid plan slipping below NCQA accreditation in an anchor state is a procurement-cycle vulnerability.
OBBBA Medicaid Expansion implementation. Management has framed the membership impact as a 15-20% reduction on 1.2 million Medicaid Expansion members by 2029 (Industry/Business tabs). If state implementations come in worse than the 15-20% baseline — particularly in California, Texas, or Washington — the procurement moat compounds with a structurally smaller TAM.
Centene's Marketplace strategy. Molina's own filing names Centene as "our primary competitor for low-income Marketplace membership" [11]; CNC ended FY2025 with 5.5 million Marketplace members (per the Industry tab). Molina is deliberately shrinking its book to 220-250 thousand in 2026. If Centene gets more aggressive on price in states where Molina is retaining the silver-tier book, the residual Marketplace economics deteriorate faster than the shrinkage protects them.
Parent-cash discipline through the cycle trough. Parent cash was \$223 million at year-end FY2025, the credit agreement was amended to a 1.75x interest-coverage minimum for FY2026 (Forensics tab), and management has continued the \$1 billion-a-year buyback cadence into the trough. The moat-erosion risk is not that the franchise breaks; it is that the parent over-deploys cash at the wrong cycle point and constrains optionality for the next RFP-or-M&A vintage.

10. The verdict for sizing

Rating: narrow moat. Evidence strength: moderate-high. Durability: moderate. The procurement engine, the regulatory-capital stack, and the duals adjacency are three real, mechanically-explainable advantages, and they have survived three stress events in the multi-year record. They have not — and structurally cannot — protect single-year earnings against a rate-vs-trend gap, and that is the dominant risk Molina faces over any 12-month window.

For an investor sizing the name, the moat analysis maps directly onto position size and time horizon:

The 2-3 year compounder thesis rests on Pillar 1 + Pillar 2. The procurement engine plus regulatory-capital footprint protect the franchise's ability to take share between cycles — Florida Kids, the FY2025 RFP vintage, and embedded earnings from new contracts. This is a position you can underwrite at 3-5% of a focused book.
The 5-7 year niche compounder thesis adds Pillar 3 (duals) as the margin upside lever. This is unproven; it should not yet support a larger sizing.
The single-year trade has no moat protection. Anyone modelling FY2026 EPS as a moat-protected number is mis-using the framework. The 92.9% Medicaid MCR guide is rate-vs-trend, not moat-vs-competitor.

What would change the rating. A second consecutive cycle of state procurement losses (after Virginia 2024) would compress the rating from narrow to "not proven" — the procurement track record is the most central pillar. Conversely, a duals book that delivers a clear margin premium in FY2026-27 — visible as Medicare-segment MCR running 200 basis points below MAPD competitors — would support narrowing the verdict toward the upper end of "narrow." The Texas STAR/CHIP rebid is the largest binary single event in the watch list.

The honest summary, in one sentence: Molina has a real but bounded moat that compounds capital between cycles, not within them, and the right way to underwrite it is to size for the cycle volatility while crediting the procurement-and-capital franchise with its proven multi-decade durability.

References

Financial Shenanigans — Molina Healthcare, Inc. (MOH)

Molina is not being accused of fraud here. The accounting that matters at Molina is judgmental — incurred-but-not-paid medical claim reserves (IBNP), risk-corridor and minimum-MLR accruals, Marketplace risk-adjustment payables, prior-year reserve releases, and what gets called "non-recurring" — and the past four quarters have stressed every one of those judgments at once. The forensic question is whether the reported numbers still faithfully describe the underlying economics, or whether multi-year tailwinds were being booked through reserves, "amounts due government agencies," and non-GAAP add-backs in a way that is now visibly unwinding.

Forensic Risk Score (0-100)

Risk Band

Elevated

Red Flags

Yellow Flags

3y CFO / Net Income

0.65

3y FCF / Net Income

0.54

FY2025 Accrual Ratio

6.5%

FY2025 Non-GAAP Gap (Adj NI / GAAP NI − 1)

23.6%

FY2025 Operating Cash Flow ($)

-$535,000,000

FY2025 Free Cash Flow ($)

-$636,000,000

FY2025 Prior-Year Reserve Release ($)

$98,000,000

Verdict

Forensic Risk Score: 62 / 100 — Elevated. Reported FY2025 GAAP earnings of $472 million are not obviously misstated, but the combination of (1) operating cash flow swinging from +$1,662 million in FY2023 to negative $535 million in FY2025 [1], (2) a $98 million total prior-year reserve release in FY2025 versus $675 million in FY2024 and $427 million in FY2023 [2][3], (3) a $93 million intangibles impairment booked in Q1 2026 immediately after the FY2025 10-K added a new goodwill/intangibles impairment risk factor [4][5], and (4) a covenant amendment cutting required interest coverage from 3.00x to 1.75x in February 2026 [6] means the prior multi-year earnings stream rested on reserves, risk-corridor payables and adjusted-EPS framing that are now visibly compressing.

Top two concerns: (a) CFO quality (CF4): management itself has now stated on the FY2026 first-quarter call that "operating cash flow swings a lot as we do accruals for risk adjustment for corridors, we hold those accruals. Maybe we don't pay them down for a year or two" [7] — i.e. the prior $2.1 billion / $1.9 billion CFO years were structural payable build-ups, not recurring cash generation; and (b) reserve and non-GAAP hygiene (EM6, KM1): adjusted net income of $584 million on $472 million of GAAP net income in FY2025 was reached after adding back $91 million of intangible amortization, $55 million of acquisition-related expense and other items [8], with "acquisition-related expenses" recurring every year since 2021 [9] — and the same Adjusted Net Income per Diluted Share is the only metric the company names as most important in linking executive pay to performance [10].

The cleanest piece of offsetting evidence: the auditor's Critical Audit Matter remained scoped only to the IBNP claims reserve in every annual report from FY2021–FY2025, internal control over financial reporting was assessed effective with no material weakness, and the compensation committee withheld the 2025 NEO short-term cash bonus when adjusted EPS fell below threshold [11] — none of this looks like a control-failure or pay-grab environment.

One data point that would change the grade: if Q2 and Q3 FY2026 operating cash flow comes in modestly positive on a normalized basis (i.e. with risk-corridor payables and Marketplace risk-adjustment payables roughly flat) and Days in Claims Payable returns to the 48–50 range, the Elevated grade rolls down to Watch. If, conversely, the FY2026 risk-adjustment payable continues to build at the Q1 pace ($630 million payable vs. $112 million receivable, a net $518 million payable [12]) and DCP stays below 46, the grade tips to High.

The 13-category shenanigans scorecard

This is the standardized accounting-quality map. Read each row as "is there evidence Molina did this?" The evidence column is the specific line item, period and disclosure; the prose around the table carries the page citations.

No Results

Three categories are red: EM5 under-reserving, EM6 smoothing, CF4 unsustainable CFO, and KM1 non-GAAP hygiene. Six are yellow; three pass cleanly with no clear evidence. The case is not that any single ratio is shocking — it is that the four red rows trace to the same underlying mechanism: corridor and reserve accruals that built up in 2020–2023 and have unwound through 2024–2025, leaving recent reported earnings without the cushion they had before.

The cash-flow mechanism: $2.1B → $-535M is a payable unwind, not an earnings collapse

The single most important forensic chart on this name is the multi-year walk of operating cash flow against net income. CFO ran at 3.22x net income in FY2021 and 2.82x in FY2020 — both of which precede an enormous build in "Amounts due government agencies" as COVID-era state-level risk corridors and minimum-MLR rebates were accrued but not yet paid. CFO then converges with net income in FY2022, sharply exceeds it again in FY2023 (1.52x), and finally goes negative in FY2025 (–1.13x) as those same payables clear cash. Management said it explicitly on the Q1 FY2026 call: "Operating cash flow swings a lot as we do accruals for risk adjustment for corridors, we hold those accruals. Maybe we don't pay them down for a year or two" [7].

The FY2023 10-K MD&A and the FY2025 10-K MD&A explain the swing as "timing differences in settlement of government agency receivables and payables, including settlements for Medicaid minimum MLR and medical cost corridors and Marketplace risk adjustment payables" [1]. The Q3 FY2025 10-Q shows the nine-month FY2025 CFO outflow of $237 million driven by a $467 million release of "Amounts due government agencies" and a $157 million release of medical claims and benefits payable [13]. Those payables had been built in prior years — Marketplace risk-adjustment net payable was $411 million at year-end 2025 versus $98 million at year-end 2024 [14], and rose to a $518 million net payable by March 2026 [12]. The Q1 FY2026 +$1,082 million CFO spike is itself driven by exactly the same lever in the other direction (the rebuilding of risk-adjustment payables alongside deferred revenue that jumped from $66 million to $401 million inside one quarter) [15].

This is the mechanism behind CF4. The 5-year cumulative CFO/NI of 1.11x flatters Molina: it averages a $4.7 billion working-capital lifeline in FY2020–FY2023 against a $1.7 billion working-capital drain in FY2024–FY2025. The recurring cash-generation underneath is closer to net income, and possibly somewhat below it once acquisition spend is netted.

Prior-year development: the reserve cushion is empty

The reserve roll-forward in Note 10 ("Medical Claims and Benefits Payable") is the single most informative disclosure in any managed-care 10-K. It shows how much of current-year reported medical cost was actually prior-year liabilities being released. For FY2023 the consolidated prior-year favorable development was $(427) million [16]; for FY2024 it jumped to $(675) million ($(611) million from Medicaid, $(61) million from Medicare, $(3) million from Marketplace) [3]; for FY2025 it collapsed to $(98) million in aggregate, with Marketplace actually showing an unfavorable $61 million [2]. Against an FY2024 GAAP net income of $1,179 million, the FY2024 PYD release alone was the equivalent of 57% of net income at a 23.7% federal-equivalent tax rate.

Management's own FY2025 disclosure is forensically explicit: "The impact of prior year reserve development in 2025 was partially absorbed by minimum MLRs and medical cost corridors and was ultimately not material to our consolidated MCR" [17]. That sentence — repeated almost verbatim in Q1 FY2026 [4] — is the smoothing-mechanism admission. Reserves released in good years that would otherwise have flowed to income were absorbed by paying corridors back; reserves over-released in bad years are similarly capped because the corridor / minimum-MLR rebate doesn't fully credit them either. This is not necessarily abuse — it is the structure of state Medicaid contracts. But it does mean the historical PYD pattern is not a measure of conservatism; it is a measure of how much cushion was available to absorb adverse trend. In FY2024 there was $675 million of cushion. In FY2025 there was $98 million. In Q1 FY2026 management said the PYD impact was "mostly absorbed by minimum MLRs and medical cost corridors" [4], i.e. effectively zero.

The SEC has already walked Molina through this exact dynamic. In a December 2018 comment-letter response, Molina disclosed that 2017 unfavorable development was attributable to "inaccurate adjudication of provider claims at our Florida, Illinois, New Mexico and Puerto Rico health plans" and that the issues "existed at the time we made our December 31, 2016 liability estimate" [18]. In a February 2019 follow-up, the SEC explicitly asked Molina to explain why a restatement of the FY2016 reserves was not required under SAB 99, which the company defended on materiality grounds [19]. Days in Claims Payable was committed to be maintained in the 50–55 day range in the same correspondence cycle, but Q1 FY2026 DCP is 44 [20], below that historical floor for the fifth straight quarter.

Management consistently attributes the drop to "pass-through payments", "timing of payments at quarter end" and faster claims adjudication. That is plausible. It is also what someone would say if cushion were thinner. Either way, the historical 50–55 day commitment to the SEC has not held since FY2024.

The non-GAAP wedge: adjusted EPS is the company's pay metric

In FY2025 GAAP net income was $472 million ($8.92 per diluted share); adjusted net income was $584 million ($11.03 per diluted share), reached by adding back $91 million of intangible-asset amortization, $55 million of acquisition-related expenses and $1 million of "other", tax-affected at the company's marginal rate [8]. The FY2024 reconciliation showed $1,179 million GAAP net income against $1,308 million of adjusted, with similar add-backs of $83 million intangible amortization, $66 million acquisition-related and $16 million other [21]. The same line, "acquisition-related expenses", recurs in every published reconciliation: $93 million FY2021, $49 million FY2022, $7 million FY2023, $46 million in nine-month FY2024 [9]. When a line item appears every year, it is no longer "non-recurring".

The proxy is unambiguous about the incentive alignment: "Adjusted Net Income per Diluted Share" is the only measure the 2024 Pay vs. Performance disclosure names as most important in linking compensation actually paid to NEO performance [10]. The 2022 PSU grant vested at 149% of target on the basis of adjusted-EPS achievement of $46.31 over fiscal 2022 / 2023-2024 [22]. The 2025 LTI grant uses three-year cumulative adjusted EPS for FY2024-FY2025-FY2026 [23]. The forensic point is not that the company is dishonest about the gap (the reconciliations are clearly presented) — it is that the company has every incentive to (a) keep "acquisition-related" and "amortization" structurally above the line in the adjusted measure, and (b) hold the adjusted line up even when GAAP compresses. There is one mitigating data point: the compensation committee did not pay an FY2025 short-term cash bonus to the NEOs because adjusted EPS of $11.03 came in below threshold [11]. That is a meaningful check.

A separate KM1 detail: mid-2025 the headline margin metric in the earnings release moved off after-tax margin and onto pre-tax margin during a weaker year. Switching the denominator the year reported margins compress is the classic key-metric tell, even if each individual disclosure is internally consistent.

Big-bath behavior: real estate 2022, MAPD intangibles 2026

Two impairments inside three years line up with the EM7 pattern. In December 2022, Molina filed an Item 2.06 8-K announcing a non-cash, pre-tax impairment of approximately $200 million "attributable to leased space," explicitly noting "this charge will be recorded outside of adjusted net income" [24]. The FY2022 10-K MD&A confirms the recorded charge was $208 million [25]. In February 2026, the same management team announced the FY2025 results, signaled a MAPD product exit for 2027, and the Q1 FY2026 10-Q recorded a $93 million impairment charge related to our planned exit of the MAPD product in 2027 [4]. The FY2025 10-K had already added an explicit goodwill / finite-lived intangibles impairment risk factor immediately preceding the announcement [5], which is itself the kind of signposting the playbook flags.

Neither impairment is alarming in isolation — both are disclosed cleanly, both are tied to identifiable strategic decisions (permanent remote work; MAPD product exit), and both are arguably economically defensible. What raises the flag is the pattern: the two largest non-cash charges in five years were both routed to non-GAAP adjustments, both took place in or just after weak reported years, and the second one is now eating an entire acquisition's identifiable intangibles. The Bright HealthCare California Medicare deal closed in early 2024 with $295 million of cash and substantial intangibles; the MAPD impairment in Q1 FY2026 is the partial unwind of those intangibles.

Acquisition optics on cash flow (CF3)

Molina has been an acquirer every year since 2020: Magellan Complete Care 2020, Affinity New York Medicaid 2021, Cigna Texas / AgeWell 2022, My Choice Wisconsin 2023, Bright HealthCare California Medicare 2024, ConnectiCare 2025. The FY2025 reserve roll-forward shows $379 million of acquired medical-claims-and-benefits-payable balances on the year (mostly from ConnectiCare) [2]. Acquired claims liabilities are a real liability the buyer assumed, but the cash that came with them flows through operating activities as a working-capital pickup in the acquisition quarter — which means the first reported CFO post-deal is structurally flattered. Backing out cash used in business combinations (FY2025: $245 million, FY2024: $295 million plus $49 million of post-closing) gives a more honest read of recurring free cash generation [1]:

The chart shows what every acquisitive compounder hates: the post-acquisition FCF line is materially below the headline FCF line in three of the last five years, and is now meaningfully negative.

Earnings-quality tests that come back clean

Negative evidence builds trust. Of the 13 categories, three pass cleanly with no material concern:

EM1 (premature revenue): Premium revenue recognition is per-member-per-month, tied to entitlement to receive services, and is the model the entire managed-care industry uses. The FY2025 10-K policy note is unchanged from prior years and walks the reader through risk corridors, minimum MLRs, retroactive premium adjustments, and CMS Part D / Marketplace risk-adjustment separately [14]. There is no contract-asset / unbilled-receivable line of any size; receivables are 81% government receivables of $2,380 million [26] and the credit-loss allowance is described as "insignificant" because the counterparties are governmental.
EM2 (bogus revenue): Customer concentration is state Medicaid agencies and CMS. The Texas Medicaid contract alone is $5,735 million (18% of consolidated Medicaid premium) and the Washington contract is $4,194 million (13%) [27]. Related-party transactions: the 2026 proxy describes a formal review policy and does not disclose any related-person transactions of consequence after the Molina-family era; no parent-CEO / family-controlled-counterparty pattern remains [28].
CF1 (financing inflows recharacterized as operating): There is no disclosed factoring program, no receivables securitization, no supplier-finance program, and the credit agreement permits but does not record any such structure. The $850 million senior notes due 2031 issued in November 2025 are routed through financing activities cleanly [29].

Breeding ground — does the governance amplify or dampen the red flags?

This is where Molina earns some benefit of the doubt. The 2026 proxy shows an independent board (10 nominees, all independent except the CEO), an Audit Committee chaired by a CPA-credentialed director, and a formal related-person-transactions policy with annual D&O questionnaires [28]. Critical Audit Matter from PwC was scoped to IBNP claims reserves in FY2021, FY2022, FY2023, FY2024 and FY2025 — the auditor signals it knows the same area carries the most estimation risk, and the company has reported no material weakness in internal control over financial reporting. The compensation committee withheld the FY2025 NEO short-term cash bonus when adjusted EPS came in at $11.03 against threshold [11]. There is no founder / family voting dominance after the 2017 board turnover, and no "perfect" expectation-beating streak (the FY2025 adjusted EPS guidance was cut from $24.50 to $14 over a single year, with two downward revisions in print [30]).

What works the other way: (i) Adjusted Net Income per Diluted Share is the single named compensation metric in the Pay-vs-Performance table [10] — the company has every reason to push that line up; (ii) the 2025 proxy disclosed "non-recurring" performance-based one-time retention grants to Messrs. Zubretsky and Keim, which is the kind of "non-recurring" label that becomes recurring; (iii) Molina has been on the SEC's accounting-disclosure radar more than once on this exact subject area — IBNP reserves, prior-year development, real-estate impairment classification — between 2008 and 2019.

Net read: the breeding ground is healthier than typical for a "62" forensic score. The governance does not look like a fraud breeding ground; it does look like an environment where adjusted-EPS framing is structurally rewarded. That dampens the worst-case (intentional manipulation) but does not dampen EM5/EM6/KM1 — those red flags are about the chosen accounting policy and the chosen non-GAAP framing, not about the controls failing.

Leverage: covenant stress is the loudest yellow flag

At Q4 FY2025, debt was 3.7x trailing-12-month EBITDA and debt-to-cap was approximately 49% [29]. By Q1 FY2026 the ratio had spiked to 6.1x trailing-12-month EBITDA because of the EBITDA denominator collapse in Q1 [20]. On February 6, 2026 Molina amended its credit agreement to cut the required minimum interest-coverage ratio from 3.00:1.00 to 1.75:1.00 for the four quarters of fiscal 2026, then a stepped recovery to 2.75:1.00 by Q3 2027 [6]. A covenant amendment to head off a breach is a meaningful disclosure — it is the lender writing down in black ink that current EBITDA-to-interest is approaching the contractual line.

What to underwrite next

This is a forensic page for an investor underwriting position size, not for a litigator. The five items to watch next:

FY2026 Q2 and Q3 operating cash flow — does the $1.1 billion Q1 build hold, or is it pure timing? Watch the Marketplace risk-adjustment payable line (now $518 million net payable [12]) and the Amounts-due-government-agencies line.
PYD in FY2026 — if reported PYD turns unfavorable in any segment, prior under-reserve thesis is confirmed. The pattern in FY2025 was already unfavorable in Marketplace ($61 million) [2].
DCP trajectory — return toward 48–50 settles the under-reserve question. Drift further below 44 is a downgrade trigger.
Goodwill / intangibles impairment cadence — the FY2025 10-K added the goodwill impairment risk factor [5]; ConnectiCare goodwill ($287 million added in FY2025 [31]) is the next candidate if the Marketplace book deteriorates.
Interest-coverage covenant — a second amendment, or compliance with 1.75x being meaningfully tight on the Q1/Q2 2026 print, is a thesis-breaking signal. The Q1 2026 interest expense was running at roughly $30 million quarterly against EBITDA that has compressed sharply.

Signal that downgrades the grade (toward Watch): Q2 FY2026 CFO comes in positive on a normalized basis; DCP returns to 47+; reserve roll-forward shows neutral-to-favorable PYD in Medicaid; no further impairment charges.

Signal that upgrades the grade (toward High): another covenant amendment; PYD unfavorable in two segments; cumulative Marketplace risk-adjustment net payable exceeds $750 million; or auditor scope adds a second Critical Audit Matter.

Should this work affect position sizing? Yes. The forensic risk is not "earnings are fake" — the GAAP numbers tie cleanly and the auditor signs them. The risk is that the prior-year trajectory of adjusted EPS was supported by reserve cushion and corridor accruals that have now been spent, and that the headline non-GAAP framing makes the deterioration look less severe than it is at the cash and reserve level. For a long position, this argues for a position-sizing limiter (smaller than the headline P/E would suggest) and a valuation haircut on the embedded-earnings narrative ($8.65 of "embedded earnings" framed on the Q3 FY2025 call [30] should be discounted, not added). It does not, on this evidence, support calling the company unethical or the audit opinion unreliable.

References

People & Governance — A Failed Say-on-Pay, a Mistimed CEO Sale, a Board Trying to Catch Up

Molina has the kind of governance architecture that scores well on a checklist — independent chairman, nine independent directors out of ten, an outside chair-led stockholder roadshow, a real clawback policy, a hard ban on pledging and hedging [1] [2] [3]. It also just lost a say-on-pay vote for the first time in years [4], watched its 69-year-old CEO sell $28 million of stock at the absolute peak six weeks before the company slashed FY25 EPS guidance from $24.50 to $19 [5] [6], and saw its three-year PSU plan forfeit in full because adjusted EPS came in at $54.56 versus a $59.36 threshold [7]. The disclosed pay structure is rigorous; the disclosed outcomes tell you the rigor is real. The governance question is narrower and harder: did insiders cash out information they had on rate-and-trend imbalance before the market did, and is a 69-year-old CEO with no named successor the right person to lead the rebuild?

Verdict: B−. Structure is strong; alignment broke under stress; succession is the single biggest unresolved item.

A snapshot of the trust question

Board Size

Independent Directors

CEO Total Comp ($M, 2025)

18.34

CEO : Median Pay Ratio

228

CEO total compensation for 2025 was $18.34 million, with a 1:228 pay ratio against the $80,329 median employee — or 1:107 if the 2025 PSUs (which the company itself says are unlikely to vest) are excluded [8] [9]. Insiders as a group own 1.44% of the company — there is no founder, no controller, no promoter [10]. The float belongs to index funds: Vanguard 12.64%, BlackRock 6.77%, Capital World 6.74%, FMR (Fidelity) 5.70% [11].

The Zubretsky problem — age, retention, and a $28M sale at the peak

The single most consequential governance event of the last 18 months is not any of the formal proposals. It is what the compensation committee did off-cycle in late 2024 and what the CEO did with his vested stock in April 2025.

The grant. In response to "direct stockholder inquiries regarding the age of Mr. Zubretsky and the expected duration of his remaining tenure," the board granted a one-time off-cycle award of 146,184 performance stock units to the CEO and 53,074 to CFO Mark Keim, contingent on hitting $36 of adjusted EPS in fiscal 2027 — a target the company itself now concedes will not be reached [12]. The board's own framing makes the conflict explicit: the grant existed because shareholders had asked whether a 69-year-old CEO would stay.

The sale. On April 30, 2025, Mr. Zubretsky sold 87,500 shares on the open market at roughly $320 a share — about $28.0 million in gross proceeds, the largest insider transaction in the dataset and not made under a 10b5-1 trading plan [5]. Within twelve weeks, on July 24, the company cut FY25 adjusted EPS guidance from $24.50 to "no less than $19" because of a medical-cost spike management says had been building since the second half of 2024 [6] [13]. Guidance was cut again to "approximately $14" at Q3 [14]. Full-year 2025 adjusted EPS actually came in at $11.03 [15]. The stock traded near $145 by the time the 2026 proxy mailed [10].

The disclosure record does not say what Mr. Zubretsky knew on April 30. The disclosure record does say that medical-cost trend pressure was building from the third quarter of 2024 [13]. Without a 10b5-1 plan to point to, this is the kind of transaction governance specialists flag whether or not it crossed any legal line. Chairman Wolf, director Schapiro, and director Orlando also each sold $200,000–$485,000 of stock within three weeks of the CEO's sale, all at prices above $300 [5].

The vote. At the 2025 annual meeting, the say-on-pay proposal failed to receive majority support — a clear miss after a five-year average of more than 90% support [4]. Compensation chair Dale Wolf personally led 15 follow-up meetings reaching holders of about 64% of outstanding shares, and Wolf, CLO Jeff Barlow, and IR head Jeff Geyer were the lead engagers [16]. Their conclusion, written into this year's proxy, is striking: because the special PSUs will likely yield zero, "the negative 2025 say-on-pay vote outcome related entirely to a compensation event that is very likely non-existent in nature" [17]. Translation: the pay event shareholders rejected won't actually pay anything, so move on. That framing reads as defensive — it sidesteps the governance objection (off-cycle, retention-driven, under-disclosed) by retreating to the dollar outcome.

Top alignment concern. A 69-year-old CEO sold $28M of stock at a 5-year high six weeks before a 22% guidance cut, with no 10b5-1 plan and no named internal successor. The board has done the procedural things — outreach, a written letter, a clawback policy on the books since October 2023 — but has not addressed the structural question of CEO succession in any disclosure we can find.

The people running this company

A lean executive team, deep insurance and managed-care experience, but skewed late-career. Mr. Zubretsky is 69 and has been CEO since November 2017 [18]. CFO Mark Keim (60) has been in the seat since February 2021 after joining Molina in 2018 from The Hanover Insurance Group; before that, Aetna and GE Capital [19]. COO James Woys (67) was elevated in May 2023 after a 30-year career at Health Net, where he was CFO, COO, and president of government services [19]. Only Mr. Zubretsky and CLO Jeff Barlow are parties to employment agreements with the company [19].

No Results

The five named executive officers are listed here in their 2025 Summary Compensation Table form [8]. Note Keim's 17.6% base-salary bump (from $850k to $1.0M) — the only base-pay increase among NEOs in 2025 [20]. The succession story is the conspicuous absence: no chief operating officer in line for the top job that the proxy talks about, no internal hand-up named beyond what the corporate-governance and nominating committee describes as "succession planning for the president and chief executive officer" reviewed by the full board [21].

Pay: structurally tough, outcomes prove it

For a buy-side reader, the most reassuring chart in the entire governance file is this one: 2025 cash bonuses were zero for every named executive officer because adjusted EPS of $11.03 came in below the threshold required for any short-term incentive payout [15]. And the entire 2023-vintage PSU grant — 33,967 PSUs at target for Mr. Zubretsky — was forfeited without payment because three-year adjusted EPS of $54.56 came in below the $59.36 threshold [7].

In 2025 the SEC "compensation actually paid" calculation for Mr. Zubretsky comes to negative $15.3 million — i.e. the mark-to-market collapse of his unvested equity exceeded his cash compensation by that amount, with $21.9 million of fair-value erosion booked on unvested awards [22] [23]. That is what an at-risk pay program is supposed to do when the company misses, and it did. The compensation mix supports the result: 91% of CEO pay is in long-term incentives, 9% in base salary [24], and 60% of the LTI mix is PSUs tied to cumulative adjusted EPS over three years [25].

The peer group used for the 2025 study is the same as 2024: a 16-company set that includes the right managed-care names (Centene, Elevance, Humana, Cigna) alongside life-insurance peers (Aflac, MetLife, Prudential), MedTech (BDX, BSX), labs (LH, DGX), hospitals (HCA, THC, UHS, CYH, DVA) [26]. It is a defensible group on size; it is loose on business model, which is a chronic critique of managed-care benchmarking.

Insider behavior — read the buys, not just the sells

The CEO's $28M sale gets the headline, but the picture is more nuanced when you trace every Form 4 in the file. The sells clustered at the price peak. The post-collapse signal is two small but unambiguous open-market buys.

No Results

The COO bought 10,000 shares at $156 on August 4, 2025 in two open-market lots totaling roughly $1.56 million — his largest disclosed open-market purchase [27]. Director Richard Zoretic added 800 shares at $125.16 on February 11, 2026 for $100,128 [27]. For Mr. Zoretic and Mr. Woys, that is real cash going in near the bottom — credible alignment with the recovery thesis. Chairman Wolf, director Romney, and director Schapiro have been periodic small sellers throughout 2024–2026; on a cumulative basis these are not large positions to begin with [27].

The pledging story is clean: the company's insider-trading policy prohibits directors and executive officers from pledging Molina shares, full stop [2]. So is the hedging picture: directors, NEOs, VPs and subsidiary officers are barred from hedging, short-selling, short-swing trading, buying or selling Molina options, or using margin accounts to hold Molina stock [3]. Each NEO satisfied the stock-ownership guideline (5x base salary for the CEO; 3x for other NEOs) as of December 31, 2025 [28]. Mr. Zubretsky beneficially owns 373,465 shares — roughly $54 million at the March-2026 proxy price [10]. Not a control stake, but not nominal either.

Board: independent on paper, gray on age, and three directors past the new term limit

Ten directors, nine independent under NYSE rules and Molina's Corporate Governance Guidelines [29]. The chairman (Dale Wolf, ex-CEO of Coventry Health Care) and the CEO are separated — Wolf has been independent chair since May 2017, and Ronna Romney has been vice-chair since the same month [1]. Healthcare expertise is the clear strength — five of ten directors come straight out of payer or provider operating roles (Wolf at Coventry, Zoretic at WellPoint/Amerigroup, Lockhart at Sutter Health, Soistman at eHealth/Aetna, Brasier as a corporate-finance generalist with audit-committee expertise) [29].

No Results

Where the board looks less independent is age and tenure. Median age is approximately 69; four directors are over 70 (Orlando 74, Romney 82, Schapiro 70, Wolf 71) [29]. Ronna Romney has been on the board since the 2003 IPO — 23 years; Steven Orlando since 2005 — 21 years; Wolf since 2013 — 13 years [29]. The board adopted a 12-year term limit for new independent directors in 2020, but that limit grandfathers the three longest-serving members [30]. Two new directors (Grohowski in 2025, Soistman as a 2026 nominee) reset the average a little [29], but a board where the CEO is 69 and the average independent director is 70 is not equipped to challenge a 69-year-old CEO on his own succession.

Note Mr. Soistman, the 2026 nominee, is himself 69 — the new director adds expertise (ex-CEO of eHealth, former Aetna president of government services, decades at Coventry and BlueCross BlueShield Maryland) but does not change the age profile [29].

Committee structure. Five standing committees: Audit (Orlando, chair), Compensation (Wolf, chair), Corporate Governance & Nominating (Romney, chair), Compliance & Quality (Zoretic, chair), and Finance (Schapiro, chair) [29]. Concentration of chair roles in the longest-serving directors is the structural read.

Related-party. During 2025 the only disclosed related-person transaction was the continued employment of George Romney, son of Vice-Chair Ronna Romney, at a base salary of approximately $157,590 — above the $120,000 disclosure threshold but trivial against a $20M company-wide pay run [31].

Auditor. Ernst & Young LLP is the independent auditor; total fees in 2025 were $6,785k ($5,945k audit + $790k audit-related + $50k tax), versus $6,790k in 2024 [32]. Audit fees are 88% of total — a clean ratio, with no tax-strategy or consulting spend that would create an auditor-independence concern [32].

Shareholder rights. This year's most material governance proposal is Proposal 5 — an amendment that would allow stockholders holding at least 20% of voting power to call a special meeting [33]. The backstory matters: at the 2025 AGM, stockholders passed a non-binding proposal asking the board to set the threshold at 10%; the board is now bringing back 20% as the floor [33]. That gap — between what stockholders voted for and what the board is now asking them to ratify — is small in dollar terms but is the second-most informative governance datapoint after the failed say-on-pay. It tells you the board's instinct under pressure is to negotiate down, not adopt.

What we couldn't pin down (and where the open questions sit)

Whether Mr. Zubretsky's April 30, 2025 sale was preceded by access to internal data not yet disclosed publicly. The proxy and 10-K do not say.
Whether the board has done formal CEO succession work beyond the high-level reference on proxy p.28. None is disclosed.
The age of CLO Jeff Barlow and EVP-Medicaid Debra Bacon, and how many years they have at Molina — the proxy does not list ages for non-CEO NEOs in the bios we read, and the document was the proxy itself, not a search of the 10-K signature page.

Verdict

Governance grade: B−. Structure is at the strong end of what disclosure rules require — independent chair, 9/10 independent board, clawback, hedging/pledging bans, real pay-for-performance proven by zero cash bonuses and a fully forfeited 2023 PSU vintage. But on the things that matter most under stress — CEO succession, the optics of a $28M peak-price insider sale outside a 10b5-1 plan, and the response to a failed say-on-pay vote — the board is one step behind. The single thing most likely to move this grade up is a credible, named internal CEO successor and the disclosure that comes with it.

References

How the Molina Story Bent

For most of the last decade Molina Healthcare was a model of management credibility — a board-installed CEO who said exactly what he would do and then did it, year after year. That story broke in 2025. Initial 2025 EPS guidance of "at least \$24.50" was reaffirmed in April, lowered to a "no less than \$19" floor in July, cut again to "approximately \$14" in October, and the year finished at GAAP \$8.92 — a 64% miss against the original number, across three separate guidance cuts in a single year. The current narrative — that 2025 was an industry-wide rate/trend dislocation that the Medicaid business will outgrow — is internally consistent and being delivered with the same level of detail and conservatism that built the franchise. But credibility, once spent, returns slowly.

A Single Pivot Defines the Modern Company

Molina runs on a single, knife-edge division between two eras. Everything before November 2017 is the founding-family era; everything since is Joseph Zubretsky.

1980–2017 — the founder era. Molina was founded in 1980 by Dr. C. David Molina as a network of Medicaid clinics in California, ran as a family business under his son Dr. J. Mario Molina from 1996, and went public in 2003 at \$644 million of revenue and 511,000 members [1]. It expanded steadily for fourteen years until 2017 detonated: revenue still grew to \$19.9 billion but the company posted a net loss of -\$512 million on operating losses of -\$555 million, driven by Marketplace mispricing and an over-spent G&A base. The Molina brothers were terminated in May 2017 and the board recruited Joseph Zubretsky, then CEO of The Hanover Group and previously CFO of Aetna, who joined as President and CEO in November 2017 [2].

Inherited quality: no. The business Zubretsky walked into was a damaged franchise — a great Medicaid distribution platform attached to a control environment that had just lost \$500 million. The lean Medicaid book, the rebuild of margins, and the M&A roll-up that followed are this team's work, not an inheritance. Every other tab in this report should read 2018 onward as the Zubretsky era and the years before as a different company.

The chart tells the whole arc on one frame: the 2017 trough (-\$512M), the 2018 reset, the 2019–2020 stabilization, the 2021–2024 M&A roll-up, and the 2025 earnings collapse that is the entire reason this tab matters.

The 2018–2024 Era: A Playbook That Worked

For seven straight years the formula was the same and the formula worked. Zubretsky inherited a stable Medicaid distribution platform, dropped the unprofitable Marketplace exposure, used the cash flow to fund a string of "fixer-upper" Medicaid book acquisitions, and built an investor narrative around two phrases used quarter after quarter: "embedded earnings power" (the run-rate accretion from acquired books and new RFP wins not yet in current EPS) and a commitment that management would "not just declare goals, but show you the playbook" with transparency and specificity [3].

By Q2 2021 the formula was already showing through the COVID noise: \$6.6 billion of premium revenue, a 6.9% G&A ratio, after-tax margin of 2.9% in line with internal expectations, and guidance for 2021 raised to "no less than \$13.25" of adjusted EPS, with management explicitly framing the playbook as one of acquiring "stable membership and revenue streams, particularly focused on underperforming properties" [4] [5]. They closed Affinity in Q4 2021, Cigna's MA book in 2022, My Choice Wisconsin in 2023, Bright HealthCare's California MA book in early 2024, and ConnectiCare in early 2024, and on Form RFP they won Iowa, Nebraska, Texas, Georgia, Ohio, Michigan, Massachusetts, and Idaho through 2023–2024 [6].

The financial proof that the playbook compounded:

Revenue grew from \$16.8B in 2019 to \$40.7B in 2024 — 19% CAGR over five years, mostly through M&A. EPS went from \$11.47 to \$20.42 over the same period. Operating margin held in a tight 3.7%–6.2% band — exactly the "mid-teens EPS, 3–4% after-tax margin" frame management committed to at the 2021 Investor Day [7]. The 2024 result of \$22.65 adjusted EPS on \$38.6 billion of premium was actually the first modest miss of the era — full-year guidance had been "at least \$23.50" — and management called it out cleanly: "our full year results falling below our guidance" [8].

This was the credibility that 2025 was about to spend.

The 2025 Break: Three Cuts in One Year

The trajectory of the 2025 guidance is the most consequential single fact in Molina's modern history. The Q4 2024 call introduced 2025 EPS guidance "at least \$24.50 per share, which is approximately 8% year-over-year growth," explicitly built on a 4.5% Medicaid trend assumption and a 79% Marketplace MCR [9]. The Q1 2025 call on April 24 reaffirmed both the \$42 billion premium target and the \$24.50 EPS floor [10], even acknowledging higher cost trend, claiming the rate cycle had captured it.

Twelve weeks later, on July 7, management preannounced a cut. On July 24 the Q2 call set a new "no less than \$19" floor — \$5.50 below original guidance and \$3 below the July 7 midpoint — and characterized the medical-cost environment as "unprecedented" [11]. Three months after that, on October 23, the floor was abandoned and guidance dropped to "approximately \$14," a "\$10.50 revision" from the initial number, with management explicitly noting that "Marketplace was initially projected to produce over \$3 of earnings per share, but is now expected to produce a loss of \$2 per share, a swing of over \$5" — out of a business that is 10% of revenue [12]. The year ultimately closed at \$8.92 GAAP / lower-than-\$14 adjusted, against an initial \$24.50.

Where the \$15+ of EPS actually went

The Q3 2025 call disaggregated the \$10.50 cut through October: Marketplace (10% of revenue) accounted for half — a "swing of over \$5"; Medicaid (75% of revenue) accounted for roughly one-third; Medicare absorbed the rest [12]. The FY2025 10-K is candid about the mechanics: the consolidated MCR ran 91.7% versus 89.1% in 2024 — 260 basis points of medical-cost-trend-driven deterioration — and the Medicaid MCR alone rose 150 basis points to 91.8%, with rate increases "lagged the increase in medical cost trend, resulting in a rate and trend imbalance that we believe to be temporary" [13] [14].

The pattern matters more than the magnitude: every part of the business broke at once. Medicaid trend (~7%) outran rate (~5.5%); Medicare rates didn't keep pace with high-acuity-duals utilization; Marketplace risk adjustment, which had carried the segment for two consecutive years of mid-70s MCRs, suddenly stopped offsetting a higher market-wide acuity pool — the Wakely industry data confirmed Molina's miss was directional, not idiosyncratic [15].

The Buyback Question

The story that should be most uncomfortable for the credibility verdict is the timing of capital return.

In Q1 2025, with EPS guidance still at \$24.50, Molina spent \$500 million on a 1.7 million-share buyback. In Q3 2025, the same quarter the floor was breaking and the cut to \$14 was being communicated, management repurchased an additional 2.8 million shares "at a cost of \$500 million" — explicitly stating "we see real value in our shares at current market prices, which we believe at this low point in the rate cycle underappreciate the longer-term margin targets of our business" [16].

The cumulative effect: parent-company cash dropped from \$445 million at end-2024 to \$108 million at end-Q3 2025 [16], debt-to-EBITDA temporarily ran up to 2.5×, operating cash flow swung from +\$644 million in 2024 to negative \$535 million in 2025 [17], and by Q1 2026 leverage had reached 6.1× trailing-twelve-month EBITDA — though Mark Keim flagged this as "temporarily" elevated by transient timing items [18]. The buyback wasn't reckless given the discount management saw, but it was the wrong half of the year to execute it; the same \$500 million returned post-Q4 would have sat against a much lower share price.

A self-styled "playbook" CEO who reaffirms \$24.50 EPS in April, then prints \$14 in October, then buys \$1B of his own stock at the high end of the year, has more explaining to do than the standard "industry-wide medical-cost dislocation" framing offers.

Narrative Drift: What Management Stopped Saying

The drift is more telling than the headline cut. Three phrases that were ubiquitous in 2021–2024 are quietly gone or repositioned in 2025:

The phrase "transparency and specificity… we will not just declare our goals but show you the playbook" [3] — which appeared in essentially every prepared remark from 2018 through 2024 — barely surfaces in 2025. The Q3 2025 substitute is "the magnitude and persistence of these medical cost increases are unprecedented" [15]: a defensible framing, but a different tone.

The "13% to 15% long-term EPS growth" target, reaffirmed as recently as the Q1 2025 call in April [19], has been replaced by a 2026 base of "at least \$5" — a number that is below 2018's \$11.85, lower than any year since the founder-era trough [20]. The math on a 13–15% CAGR off a \$5 base puts the company back at 2024's \$20+ EPS only by 2031.

The biggest structural drift is in the risk-factor section of the 10-K itself. In FY2021 the headline risk on the cover of the risk factors was COVID-19; through 2023 it was rate/trend uncertainty in Medicaid. In the FY2025 10-K, "Our Marketplace business has been volatile and unpredictable, and has been subject to annual programmatic changes that are difficult to price for actuarially" is now listed at the very top of Risk Factors — repositioned ahead of every Medicaid risk [21]. Management is telling readers what they had previously absorbed quietly: Marketplace was always volatile, they sized into it for growth, and it was the wrong call.

The Promises Track Record — Honest Scorecard

No Results

Four out of five years met or beat the original number — and the one modest miss in 2024 was acknowledged plainly on the very next call [8]. Then 2025 broke the pattern catastrophically. The intellectual honesty is intact — the Q3 call reconciled the \$10.50 cut segment-by-segment, the 10-K MD&A says explicitly that "the Medicaid MCR for 2025 is higher than we expected and is above our long-term target range" [14] — but a miss this large doesn't get explained away by industry framing alone.

The Current Chapter: A Conservative Reset

The Q1 2026 call on April 23 reaffirmed FY2026 guidance of "approximately \$42 billion of premium revenue and at least \$5 in adjusted earnings per share" — a 75% drop from 2024's \$20.42, lower than any post-2017 year [20]. The conservatism is the point: even with a Q1 2026 actual of \$2.35 implying a stronger setup, management chose not to raise guidance, noting Q1 trend "annualized would put us at better than 5% for the full year" while still holding the number until June Wakely data validates the Marketplace baseline.

Three concrete pricing actions distinguish 2026 from the 2025 setup:

Marketplace footprint cut by 20%, and the company's #1/#2 price position in silver tier going from 50% of markets in 2025 to ~10% in 2026 — explicit prioritization of margin over membership [12].
Marketplace rate increases averaging 30% for 2026 (range 15%–45%) and exit of "difficult geographies" [12].
Medicaid rate cycle re-anchored: 60% of revenue renews January 1, with early reads suggesting full-year rates "modestly in excess of trend" by 50 basis points — small, but the first positive rate/trend gap in six quarters.

Joe Zubretsky's framing in Q1 2026 was telling: he committed to demonstrate at the May 2026 Investor Day "how we will again realize the intrinsic value of the franchise we have built over the past 8 years" [22]. He is implicitly conceding that the intrinsic value the bull case relied on has not been realized yet — that what stretched the 2025 EPS line was a real, durable risk in the Marketplace and Medicaid businesses, and the path back is multi-year.

What the Story Is Now

Credibility Score (1–10)

Current CEO Start Year

2,017

Current Chapter Start Year

2,018

Credibility verdict: 5/10. The Zubretsky team built genuine playbook credibility from 2018 through 2024 — multiple years of "show you the math" guidance walks, four straight years of meeting or beating original EPS guidance, a clean acknowledgement when 2024 missed by 3.6%. That track record is real and would justify a 7 or 8 on its own. But 2025 happened: a 64% miss versus initial guidance, three sequential cuts in a single year (reaffirmed in April, cut in July, cut again in October), and \$1 billion of buybacks executed into the miss. The current 2026 framing is honest and conservative, but the team has not yet shown it can rebuild forward credibility with one quarter of in-line execution. A "5" is the right place to sit until they prove the rate-cycle thesis at the January 2027 reset.

What has been de-risked:

Marketplace exposure is being cut by 20% and dramatically repriced; the segment is being explicitly de-emphasized.
Medicaid is 75% of revenue at a 3.2% pretax margin — bruised but still working.
The Q1 2026 Medicaid trend ran modestly below 5% guidance, the first positive divergence in six quarters.
Embedded-earnings disclosure persists (\$8.65/share carried, including \$2.50 of certain reversals in 2027).

What still looks stretched:

Leverage at 6.1× TTM EBITDA — temporarily but reportedly so, and only because EBITDA itself collapsed.
The 2026 \$5 EPS guidance implies a fundamentally lower run-rate than the 2024 \$20.42.
Medicare bids for 2027 still have to be set against a Duals population whose utilization the team has admitted it under-priced two years running.
The recurring "rate cycle will fix this" framing is now five quarters old and depends on state actuarial behavior the company does not control.

Net: The story today is simpler and more contained than 2024's "compound at 13–15%" arc, but it is not more durable. Credibility is deteriorating quarter-on-quarter through 2025 and starting to stabilize on a much lower base in Q1 2026. Investors should believe the segment-level diagnosis (Marketplace was overweight, rates lagged trend, the bid was wrong), discount the 2026 \$5 floor only modestly, and remain skeptical of any reference to the 2021–2024-era "embedded earnings power" framing until two consecutive Medicaid rate cycles deliver rates clearly in excess of trend. The May 2026 Investor Day is the next material credibility checkpoint.

References

Financials - The Margin That Defines the Stock

Molina is a $45 billion-revenue Medicaid-Medicare-Marketplace insurer whose 2025 results showed how thin the operating margin really is when the Medical Care Ratio (medical costs as a percentage of premium revenue) moves the wrong way. Premium revenue still grew 11% to $43.1 billion, but the consolidated MCR rose 260 basis points to 91.7%, and that single number compressed operating income from $1.71 billion to $781 million, halved net income, and turned a +$644 million operating cash inflow into a -$535 million outflow [1] [2] [3]. The stock has discounted the dislocation - a $100 invested at year-end 2020 was worth $80 at year-end 2025 versus $195 in the S&P 500 [4] - and the central question on the page is whether 2026 is the trough management says it is, or the start of a longer reset.

FY25 Total Revenue ($M)

$45,426

FY25 Operating Margin

1.7%

FY25 Diluted EPS

$8.92

FY25 Consolidated MCR (%)

91.7%

FY25 Free Cash Flow ($M)

-$636

FY25 Total Debt ($M)

$3,766

FY25 Net Debt ($M)

-$482

The terms a reader needs once. Premium revenue is what the company collects from Medicaid agencies, the federal government for Medicare, and Marketplace enrollees; it is the top of the funnel. Medical care costs are claims paid to doctors, hospitals, drug companies and other providers. Medical Care Ratio (MCR) = medical care costs / premium revenue - a single percent of MCR change at Molina's premium base is roughly $430 million of pretax profit at risk. Medical margin = premium revenue minus medical care costs - the analogue of "gross profit" for a health insurer. G&A ratio = general and administrative expense / total revenue, the leverage metric on top of medical margin [1].

The Standard Year-Wise Statements (FY2016-FY2025)

No Results

Reading the table. Two distinct chapters. FY2016-FY2018 captures the post-ACA volatility and the 2017 management reset (operating loss of $555 million after Marketplace cost overruns); FY2019-FY2024 is the Zubretsky-led re-platforming - revenue compounded at ~19% per year over five years, ROE held in the 25-37% band, and EPS roughly doubled [5]. FY2025 is the rupture: revenue still grew, but operating income, EPS, OCF, FCF, equity and ROE all moved the wrong way at once. That convergence - not any single line - is why the equity got marked down.

What Actually Broke in 2025 (and Why It Matters More Than the Revenue Headline)

Premium revenue rose $4.4 billion to $43.1 billion in 2025, mostly from the ConnectiCare acquisition that closed February 1, Medicaid rate increases, and Marketplace growth from the company's pricing strategy [2] [6]. The problem is that medical care costs grew faster than premiums in every segment.

No Results

Three causes were called out by management:

Medicaid MCR up 150 bps to 91.8% on higher unit costs (behavioral health, high-cost drugs, professional outpatient) and acuity shifts left over from the post-pandemic redetermination process - rates lag the trend by 6-12 months [7].
Medicare MCR up 330 bps to 92.4%, driven by high-acuity duals utilization (Long-Term Services and Support, high-cost pharmacy) and margin compression in the MAPD product Molina is exiting in thirteen states [8].
Marketplace MCR exploded 1,520 bps to 90.6% from 75.4%, reflecting Special Enrollment Period acuity, ConnectiCare's higher starting MCR, and CMS program integrity initiatives that disenrolled members but left Molina paying their claims [8].

Two transcript disclosures put a number on how unusual one piece of this was. The Q4 2025 call quantified ~$135 million ($2 per share) of "unusual" California-specific items - a state-funded undocumented-immigration risk corridor adjustment that CMS would normally block, plus an LA County risk-adjustment data refresh that came out unfavorably [9]. Management then chose to pull a similar amount of conservatism into 2026 guidance, taking the implied earnings frame from "$14 per share" down to "$5 per share" [9].

The arithmetic of MCR for a low-margin insurer. At a $43 billion premium base, every 100 basis points of MCR is ~$430 million of pretax income at risk. The 260 bps move in 2025 explains roughly $1.1 billion of pretax compression on its own - close to the entire reported drop in operating income from $1.71 billion to $781 million [1].

The Quarterly Trajectory - and What Q1 2026 Says

EPS held above $4 through Q2 2025 before collapsing in the back half. Q3 dropped to $1.51 and Q4 swung to a $3.15-per-share loss as Molina booked the California adjustments and absorbed the full force of the cost-trend reset [10]. Q1 2026 came in at $0.27 - "strong when compared to internal and external expectations," per CEO Joseph Zubretsky, with operating cash flow of $1.1 billion in the quarter and management merely reaffirming the full-year guide of at least $5 of adjusted EPS on roughly $42 billion of premium [11] [12].

Earnings Quality - Where Net Income Stopped Becoming Cash

For a managed-care company, operating cash flow is intrinsically lumpy: premiums come in monthly and in advance, while medical-cost settlements (risk corridors, MLR rebates, CMS program-integrity reconciliations) can swing meaningfully across periods. Even allowing for that, the FY2025 print is unusual. Net cash used in operations was $535 million versus $644 million provided in 2024 - a $1.18 billion year-over-year swing. Management attributes it to lower operating income, the settlement timing of Medicaid minimum MLR / medical-cost corridor receivables and payables, Marketplace risk-adjustment payables, and tax-payment timing [3].

CFO Mark Keim's caution on the Q1 2026 call is worth holding: "in a regulated business like Molina, what's more important than total company operating cash flow is cash flow at the parent… operating cash flow swings a lot as we do accruals for risk adjustment for corridors" [13]. The Q1 2026 number - $1.1 billion of OCF in a single quarter - shows the corridor settlements can also reverse with the same force [12].

The picture across a decade is therefore more reassuring than the single-year cash hole suggests: FY2020-FY2024 generated cumulative free cash flow of $6.7 billion against cumulative net income of $4.4 billion, a 152% cash conversion ratio. But FY2025 broke that streak, and the question for FY2026 is whether the corridor receivable build-up reverses in cash terms (the Q1 print says yes, so far) or compounds.

Capex is structurally trivial - $101 million in 2025 on $45.4 billion of revenue, ~22 bps - which is normal for an insurer. Free cash flow at Molina is essentially operating cash flow.

Share-based compensation is also unusually small for a $10 billion-market-cap company. SBC pretax was $47 million in 2025, down from $116 million in 2024, with the drop driven by lower management incentive accruals against the weaker year [14]. Dilution from compensation is minor; the share count moves come from buybacks.

Balance Sheet - The One Part That Held Up

Even after the worst earnings year of the new era, Molina still ended 2025 with $4.2 billion of cash plus $4.0 billion of short-term investments against $3.77 billion of total long-term debt - a net cash position of roughly $482 million. Of course, most of that cash is captive at the regulated subsidiaries; only $223 million sat at the parent at year-end (versus $445 million the year prior), and only ~$170 million of subsidiary dividends could be paid without regulatory approval as of Dec 31, 2025 [15] [16]. The regulated subs still paid the parent $985 million of dividends in 2025 (vs $997 million in 2024), so the cash-up pipeline is intact - but lower 2025 net income will mechanically compress 2026 dividend capacity [15] [16].

No bond matures before 2028, and the most recent issuance was a November 2025 $850 million print of 6.500% notes due 2031 that took out a $740 million term loan from the old credit agreement [17]. At the same time, Molina entered a new $1.25 billion revolving credit facility with a November 2030 termination, drawn at zero at year-end, plus $800 million of incremental term-loan capacity for acquisitions [18]. Management also "secured an agreement with our bank syndicate to appropriately amend" the debt-covenant metrics in light of weaker 2026 EBITDA - i.e. a proactive covenant amendment ahead of the trough rather than a forced renegotiation [10]. Trailing-12-month debt/EBITDA was 3.7x at year-end 2025; the CFO has flagged that ratio drifting to 6.1x by Q1 2026 on the rolling EBITDA denominator and debt-to-cap at 47-48% versus a "low 40s" sustaining target [10] [12].

The weighted-average coupon on the new $3.8 billion debt stack is in the mid-5s; interest expense was $192 million in 2025, up from $118 million in 2024, on the heavier balance and the higher 2031/2033 coupons [1]. Aggregate RBC capital at the subsidiaries was 305%, more than 50% above state minimums - solvency at the regulated entity is not the issue [10].

Goodwill rose to $1.96 billion at year-end 2025 from $1.67 billion, the entire increase coming from the ConnectiCare deal (Marketplace +$220M, Medicare +$67M) [19]. Cost of acquisition was $350 million for ~140,000 members across Marketplace, Medicare and certain commercial products [6]. With Marketplace MCR running where it ran in 2025, the deal is unlikely to look like a vintage steal, but no impairment has been recorded.

Capital Allocation - $1 Billion Returned Through a Down Year

Molina pays no dividend and never has [20]. The full capital-return story is buybacks, and it ran straight through the 2025 storm.

Molina repurchased $1.0 billion of stock in 2025 - roughly 1.7 million shares for $500 million in Q1 and 2.8 million shares for $500 million in Q3, working the diluted share count from 57.7 million down to 52.9 million [15] [1]. The Q1 tranche cleared near $294 per share and the Q3 tranche near $179; with the stock now around $195, the Q3 buyback already looks neutral-to-positive while the Q1 cohort is materially underwater - a reminder that running aggressive buybacks alongside a covenant-amending year of negative FCF carried real opportunity cost. In April 2025 the board authorized an additional $1.0 billion of repurchase capacity through December 31, 2026; $500 million of that remained available as of the FY25 10-K filing date [18].

The other use of capital is M&A. ConnectiCare ($350 million purchase price, ~140,000 members) was the only sizable 2025 deal; management calls the acquisition pipeline "a growing number of actionable opportunities," and the 10-K explicitly cites organic growth from RFP wins as the company's "highest priority" [6] [18]. Collectively, newly reported 2025 RFP wins plus acquisitions represent nearly $9 billion of incremental annual premium revenue as those contracts ramp in 2026 and beyond - real top-line momentum to set against the margin reset [21].

Returns on Capital - The Real Casualty of 2025

For most of FY2018-FY2024 Molina was a 25-37% ROE business, a remarkable level for any insurer and a function of low capital intensity, high asset turnover (~2.6x), and operating margins in the high-3% to 6% range applied to a $30-40 billion revenue base [22]. The fall to 11.6% ROE in 2025 is not a small downshift; it is more than a halving of the franchise's earned return on the equity base [1]. Whether the next 24 months see a snap-back to high-20s or a multi-year journey back is the central long-only debate.

Peer Comparison - Everyone in Managed Care Is Hurting, But Differently

No Results

Three readings.

First, the 2025 reset is sector-wide, not Molina-specific. Centene swung to a -$6.7 billion net loss (net margin -3.8%, ROE -33%); Humana's net margin barely cleared 0.9% and ROE compressed to 6.7%; Elevance held a 12.9% ROE but with margins under pressure. The two large diversified peers (UnitedHealth and CVS) carry their own franchise problems, but on net margin and revenue scale both look more durable than the pure-play managed-care peers.

Second, Molina ran the smallest dollar revenue (~$45 billion) but the highest historical capital efficiency. Even after the FY25 reset, its 11.6% ROE in the worst year of the cycle sits between Humana (6.7%) and Elevance (12.9%) and well above the loss-making Centene. The high-asset-turn / low-capital-base business model that produced 25%+ ROEs in the good years is structurally intact - it just gets exposed when MCR moves against it.

Third, leverage is the most binary signal in the table. Molina's debt-to-equity at 0.93x is now the highest among the peers reporting a positive denominator, a function of stable debt levels plus equity compression from a weak earnings year and a $1 billion buyback. UNH, CI and CVS each report essentially zero traditional debt-to-equity ratios (their leverage shows up in other forms), making Molina's balance sheet, in relative terms, the second-tightest in the comp set after Centene.

Valuation - At $195, What Are You Paying For?

Price (Jun 18, 2026)

$194.76

P/E (TTM, FY25 EPS $8.92)

21.8

P/E (FY26 Est, $5.16)

37.7

P/E (FY27 Est, $8.07)

24.1

EV / FY25 Revenue (x)

0.23

Consensus Target ($)

$190.25

At $194.76, Molina trades at 21.8x trailing FY25 EPS, 37.7x consensus FY26 EPS of $5.16, and 24.1x consensus FY27 EPS of $8.07. The 5-year cumulative return table the company itself published shows MOH worth $80 at year-end 2025 on a $100 base at the start of 2021, against $195 for the S&P 500 - the equity has already lived through a deep de-rating [4]. EV-to-revenue at 0.23x is unusually low even for a low-margin business; against UNH's 0.82x or ELV's 0.42x it looks like a discount, but multiples on revenue are only meaningful in light of the margin that revenue produces.

Three ways to read the multiple.

If 2026 is the trough management says it is, $5 of EPS becomes a floor, the rate cycle restores Medicaid margins to the company's long-term target range (Medicaid pretax around 4-5% per Molina's normalized algorithm), and EPS pivots back toward the $14-15 range from FY24 by 2027-2028. On that path, today's price is roughly 13-14x normalized earnings - genuinely cheap if the algorithm holds, and the FY27 P/E of 24x sits between trough and normal. Management explicitly framed FY26 as "the trough for managed Medicaid margins" and quantified the leverage: "every 100 basis points on the Medicaid MCR is worth nearly $5 per share," with "embedded earnings… now greater than $11 per share" from contract wins not yet at target margin [23].
If the cycle takes longer, FY27 EPS lands closer to consensus' $8 than to $14, today's multiple is mid-20s on a still-suppressed number, and the stock has a long flat period.
If the OBBBA-driven 15-20% Medicaid Expansion attrition compounds, the premium base shrinks even as MCR normalizes; revenue falls, dividend capacity at subs declines, and the leverage ratio that already drifted to 6.1x trailing EBITDA in Q1 2026 keeps the equity story constrained [24] [12].

The consensus mean price target of $190.25 sits essentially on top of the current quote - the sell side has effectively marked the stock to the FY27 P/E discounted by the residual cycle risk.

The View

Molina is a high-quality franchise (proven 25%+ ROE in normal years, $9 billion of incremental premium teed up from 2025 wins, no maturities before 2028, no dividend obligation, regulated solvency well above minimums) going through a low-quality earnings year. The financial case turns almost entirely on a single number - the Medical Care Ratio, especially in Medicaid - because the business model carries so little operating margin that the MCR mathematically is the earnings. The balance sheet is firmer than the income statement suggests, but it is also tighter than it was twelve months ago (debt up, equity down, leverage covenants proactively amended). The bullish case is: 2026 is a trough, rates restore, embedded earnings from new contract wins land, and a 21x-trailing multiple on a return-to-form number proves cheap. The bearish case is: redetermination acuity, OBBBA work requirements, and a deliberately shrunken Marketplace book mean revenue and dividend capacity step down before MCR normalizes - and the parent's $223 million of cash, with subsidiary dividends mechanically dropping in 2026, looks thinner against a $1 billion-a-year buyback cadence and $192 million of interest.

The first financial metric to watch is the FY2026 Medicaid Medical Care Ratio, with a specific marker at the company's own guide of 92.9%. A print materially below 92.9% as the year develops - especially in 3Q and 4Q after the rate cycle takes effect - validates management's "trough" framing and underwrites a snap-back in EPS toward double digits. A print at or above 92.9% extends the cycle, keeps EPS pinned near $5, and forces another reset in valuation expectations.

References

Web Research — Molina Healthcare, Inc. (MOH)

Bottom line up top

The filings already say FY2025 was the worst earnings reset in a decade. What the web adds — and what changes how a PM should size and time MOH — is the external validation of the bear case running alongside an emerging contrarian bid: a federal securities class action (Hindlemann v. Molina, Oct 3, 2025) plus a derivative suit and S&P's April 3, 2026 downgrade to BB- on persistently elevated leverage [1] are the bear thesis being underwritten by the legal market and a rating agency; on the other side, Florida's Nov 12, 2025 re-award of Medicaid managed care, the HealthChoice Illinois win (~3.1M beneficiaries, Jan 2027 go-live), Michael Burry's disclosed long position, and Mizuho's $215 PT (Outperform) are independent endorsements that the rebuild is real. The Q4 2025 19% gap-down is partly in the price (stock ~$195-200 vs ~$157 post-cut low), but the unresolved question the market has not yet priced — and what the next two prints turn on — is whether Q2-Q3 FY2026 MCR trend lets the company hold the ≥$5.00 FY26 floor without a fourth guidance cut and a second covenant amendment.

Coverage note. This page synthesizes the web/news layer; filing facts are cross-referenced to upstream tabs, not re-derived. New citations only appear where the web claim demands a primary-record confirmation upstream tabs do not cite.

The ranked findings

1. Securities class action plus a derivative suit — the legal market has independently underwritten the bear thesis | Red flag

A putative federal securities class action — Hindlemann v. Molina Healthcare, Inc., et al. — was filed October 3, 2025 in the U.S. District Court for the Central District of California against the Company, CEO Joseph Zubretsky and CFO Mark Keim, on behalf of investors who bought MOH between February 5, 2025 and July 23, 2025. The complaint alleges Molina failed to disclose deterioration in its medical-cost-trend assumptions and the dislocation between premium rates and trend that ultimately drove the three 2025 guidance cuts. A shareholder derivative suit — Taylor v. Wolf, et al. — was filed December 12, 2025 against the directors and certain officers for breach of fiduciary duty in connection with the same events [1]. At least six plaintiff law firms — Levi & Korsinsky, Robbins Geller Rudman & Dowd, Kessler Topaz Meltzer & Check, The Rosen Law Firm, Frank R. Cruz, and Glancy Prongay & Murray — are actively soliciting class members and competing to lead, per Levi & Korsinsky and Kessler Topaz.

So-what for the stock. This converts a bear-case complaint about disclosure judgment into a public liability. Even if Molina ultimately prevails (the typical 10b-5 disposition rate is high), the discovery process alone forces production of internal medical-cost-trend models, board minutes, and Q1-Q2 2025 forecast revisions — which materially raises the bar on the FY2026 ≥$5 EPS framing and is a permanent overhang on the multiple until resolved. It also locks in the precise dates the company will have to defend: that management reaffirmed the at-least-$24.50 EPS guide on April 23, 2025 and cut preliminarily on July 7, 2025. Priced in? Partly. The stock fell from ~$195 to open at ~$157 on the July guidance cut per Levi & Korsinsky's filing background, so the direction is in the price, but the litigation overhang — typically a 5-15% multiple penalty in managed care comparable cases — is not separately quantifiable in consensus today.

2. S&P credit downgrade to BB- on April 3, 2026, after the November 2025 outlook-to-negative move | Red flag

S&P lowered MOH's issuer credit rating from BB to BB- (outlook stable) on April 3, 2026, citing "persistently elevated financial leverage." Per S&P, the company's adjusted EBIT return on revenue (ROR) was 1.7% in 2025 and the consolidated MLR is expected to stay elevated in 2026 (see S&P Global Ratings). This followed S&P's earlier November 6, 2025 revision of outlook to negative from stable (cbonds confirmation, Investing.com summary). The downgrade arrives in the same window as the $850M 6.500% Senior Notes due 2031 placed November 20, 2025 (per the company's 8-K) and an $500M delayed-draw Term Loan A-2 taken on August 12, 2025 to partly fund Q3 2025 share repurchases (per Stock Titan).

So-what for the stock. The rating action is not a maturity wall but it does (a) tighten the cost of incremental capital — Molina is now financing at high-6% coupons against a 1.7% EBIT-to-revenue ratio; (b) constrain M&A — the company has named "distressed Medicaid plans" as a target pool, and BB- credit makes an Aetna/ConnectiCare-scale follow-up harder; and (c) reinforces the bear's "leverage was the smoothing mechanism for the buyback at the wrong price" story. Priced in? S&P's negative outlook was already public when November–February consensus was set, so the downgrade itself was a Q1 2026 known-unknown that arrived. The forensic tab already flagged the February 2026 covenant amendment cutting required interest coverage from 3.00x to 1.75x — the rating-side validation of that distress is now public.

3. Three sequential 2025 guidance cuts collapsed CEO/CFO credibility — the wreckage is the FY26 ≥$5 anchor | Red flag, partially priced

The FY2025 narrative arc, end-to-end: Initial January 2025 guide ≥ $24.50 adjusted EPS → reaffirmed April 23, 2025 → preliminary July 7, 2025 cut to $21.50-22.50 (Stock Titan) → July 23, 2025 cut to floor $19 (Healthcare Dive) → October 23, 2025 cut to ~$14 with Q3 adjusted EPS coming in at $1.84 vs $3.90 consensus, stock down 17.5% (worst in S&P 500 that day, per Invezz and Becker's Payer) → final FY2025 adjusted EPS $11.03 with a Q4 GAAP loss of $3.15/share (Investing.com transcript). Stock then fell another ~19% after-hours on the Q4 print per Stocktwits. FY2026 guidance: at least $5.00 in adjusted EPS — a 55% reset from FY2025 and a 78% reset from the original FY2025 anchor.

So-what for the stock. The credibility damage matters more than the math because the credibility was the multiple. Pre-crisis MOH traded at premium managed-care multiples on a "13-15% long-term EPS growth" framing that management has now quietly retired (bear tab) — replaced by an opaque "trough year, rebuild by 2027" narrative. The next earnings print (Q2 2026, July 22, 2026) is the first test of whether the ≥$5 floor is conservative or aspirational. A fourth cut would re-trigger the litigation narrative and likely force another credit action. Priced in? Largely — stock is at ~$200 vs ~$157 trough, and FY26E ≥$5 is now the consensus anchor. What is not priced is path-dependence: the market is paying for a snap-back to $14-20 in FY27 that the company itself has stopped underwriting.

4. Florida re-awards Molina a new Medicaid contract on Nov 12, 2025 — the franchise-loss bear scenario is now retired | Positive

In April 2024, Florida had cut Molina, UnitedHealth and CVS from its 2024 Medicaid awards (Healthcare Dive), and Molina announced it would challenge the loss. On November 12, 2025, the state of Florida named Molina Healthcare of Florida among the insurers selected to provide Medicaid managed care services going forward, per Florida Phoenix. The reinstatement is a structural positive: Florida is one of the largest Medicaid managed care markets in the country and Florida's CMS Kids sole-source award (already disclosed at roughly $6B run-rate in the bull tab) was at risk of being undermined had Molina lost the broader procurement.

So-what for the stock. This closes the franchise-loss tail risk that was a centerpiece of the 2024-25 bear case. It does not yet show up in current-year revenue — the new contract will phase in — but it is a precondition for the bull's "$9B incremental annual premium ramping into FY26-27" math. Priced in? Mostly. The stock did not spike on Nov 12, 2025 because guidance had already been cut to ~$14 three weeks earlier and the market was focused on MCR not contract wins. The franchise story is known but the embedded value is not in consensus FY27 numbers.

5. Michael Burry disclosed a long position — and is "shorting Nvidia to buy this boring healthcare stock" | Positive, low confidence

Per Yahoo Finance's recent quote page, Michael Burry — the contrarian investor best known for the 2008 housing short — has disclosed an MOH long position, framed as "shorting Nvidia to buy this boring healthcare stock." This was prominent enough on Yahoo Finance to appear at the top of MOH's "Recent News" feed as of mid-June 2026. Yahoo's commentary frames MOH as "one of the 7 Best Turnaround Stocks to Buy in 2026" per a separate Yahoo article.

So-what for the stock. Burry's name is a real signal — he was last conspicuously positioned in healthcare (CVS, CI) in 2024 — and a high-profile contrarian disclosure tends to put a floor under sell-side downgrades because PMs are reluctant to be on the opposite side of a public turnaround call from a name-brand short-seller. Priced in? Partly — Yahoo highlighting it is itself the price-impact mechanism. But Burry's position size and entry are not disclosed in the source surfaced here and a 13F-validated read on the position is the missing piece (filed late August 2026 for 2Q activity).

6. CMS lifted 2027 Medicare rates while sell-side dispersion widens — Mizuho $215 vs. Barclays $199 | Positive on rate; mixed on consensus

On April 23, 2026, CMS lifted 2027 Medicare Advantage rates — captured by StocksToTrade's "EPS tops views, CMS lifts 2027 rates" — directly relevant to MOH's MAPD business that took the $93M intangibles charge in Q1 2026. On the sell-side: Mizuho raised PT to $215 from $200 (Outperform), June 8, 2026 (Yahoo); Barclays maintained Underweight, raised PT to $199, May 26, 2026 (GuruFocus); Morningstar carries an MOH research note titled "Molina's Margin Trough Just Got Deeper". Yahoo's consensus snapshot points to a target around $189-$213 with at least one note lifting target to $213.

So-what for the stock. The dispersion between Outperform/$215 and Underweight/$199 — only a $16 gap in absolute terms but a yes/no posture difference — is consensus saying the company can hold the ≥$5 FY26 floor but is priced in; the bull/bear gap is now the FY27 rebound trajectory, not FY26 mechanics. Priced in? Yes for the rate tailwind itself; not for the path of the rebuild. The Mizuho upgrade is the more incremental data point because it locks in a $215 upside scenario that exists only if Q2-Q3 prints confirm the $5 floor.

7. Capital allocation under stress — $1B of buybacks at $297.83 and $175.50, plus a debt-funded second tranche | Red flag

In Q1 2025, Molina purchased ~1.679M shares for $500M at an average cost of $297.83 under a Rule 10b5-1 trading plan; in Q3 2025, with guidance already cut twice and the stock trading near $175, it purchased a further ~2.849M shares for $500M at an average cost of $175.50 [2]. The second tranche was partly funded by an $500M delayed-draw Term Loan A-2 entered August 12, 2025 (Stock Titan). Capital World Investors disclosed selling 1,662,977 MOH shares on June 8, 2026 per Marketbeat.

So-what for the stock. The Q1 2025 tranche at $297.83 — pre-cut — is now visibly off-side at $200 (~33% mark-to-market loss on that $500M); the Q3 2025 tranche at $175.50 is close to flat. But the signal about capital judgment is unfavorable: the company bought aggressively into a guide it was about to cut twice more, then took on debt to keep buying, then took an S&P outlook revision two months later. This is the strongest single piece of evidence for the bear's "capital discipline broke before the trend did" claim. Priced in? No, in a meaningful sense. Buyback timing is a soft factor that does not show up in EPS forecasts but it does feed into the multiple investors assign. The Capital World tape on June 8 — a top-20 holder cutting nearly 2M shares — is the same week as Mizuho's PT bump, which is why the stock has been chopping sideways at $195-200.

8. Illinois HealthChoice + D-SNP — the procurement engine is still working | Positive

June 27, 2025: Molina selected by Illinois HFS as one of six health plans for HealthChoice Illinois, covering ~3.1 million beneficiaries, Jan 1, 2027 go-live, 4.5-year initial term (per Molina IR). March 17, 2025: Molina also won a Fully Integrated D-SNP contract in Illinois (~73,000 beneficiaries), Jan 1, 2026 go-live. June 10, 2026: Per the proxy filing path and an Illinois Medicaid update, MOH is shown to have won an additional Illinois Medicaid contract per the IR releases page.

So-what for the stock. This is the single biggest piece of evidence that the operating engine — RFP win rate, member-acquisition cost, state-level execution — was not damaged by the MCR overshoot. The Illinois revenue is in the bull-tab's "$9B incremental annual premium" and the dual-eligible award is part of the MMP-to-D-SNP transition that the Q4 2025 earnings deck discussed. Priced in? The HealthChoice award is in 2027 numbers but the cumulative signal — three new contract wins in 12 months while the earnings narrative was breaking — is not separately weighted in the multiple.

9. CEO contract extended through 2027 before the crisis, CFO role expanded — succession overhang resolved at the wrong time | Mixed signal

In August 2024 the board extended Joe Zubretsky's contract through end-2027 with a performance-vesting stock grant (Healthcare Dive). In September 2024 CFO Mark Keim's role was expanded to include leadership of the Medicaid Health Plans and Marketplace segments (Healthcare Dive). Both moves preceded the 2025 guidance cuts.

So-what for the stock. The board pre-committed to the incumbent leadership team in a quiet pre-crisis window — there is no public successor on file. This is the opposite of what a board does when it sees trouble coming and is the single piece of governance evidence consistent with management not foreseeing the FY2025 trend overshoot when it occurred. Priced in? No catalyst here unless the board reverses on either contract. The 2026 director-slate proxy (June 10, 2026) reaffirmed the existing board with no new succession disclosure.

10. Investor Day May 8, 2026 — three-year framework through 2029, but no quantified multi-year EPS path | Neutral, watching

Per TipRanks, the May 8, 2026 Investor Day "outlined long-term financial targets, AI deployment, capital allocation priorities, and growth across Medicaid, Medicare, and Marketplace segments." Q1 2026 transcript confirms the deck was framed as a three-year outlook through 2029 (specialist Q3 purpose). Q1 2026 EPS came in at $2.35 vs. consensus ~$1.91, a 21% beat that drove a ~5% stock gain; guidance was reaffirmed.

So-what for the stock. Investor Days that don't quantify a multi-year EPS bridge are read by managed-care investors as defensive — the FY2027 number is what matters and that is consensus-driven, not company-driven. The Q1 beat is the more material data: the ≥$5.00 anchor cleared the lowest bar that mattered, and the next two prints will set the FY26 exit-rate. Priced in? Yes for the Q1 beat; the Investor Day was largely greeted with a shrug because the company will not name a 2029 EPS target.

News timeline — Q3 2023 through Q2 2026

The reference layer the ranked findings draw from. Sorted newest to oldest within the table; significance is High/Medium/Low based on whether it would change a position decision at the margin.

No Results

Page / 2 20 of 34 records

Governance and people signals — light layer behind the ranked findings

The web layer largely confirms what the proxy and bear-tab analysis already showed; three add-on signals worth holding in working memory:

Insider buying during the disclosure probe, per a Yahoo article titled "Insider Buying And Disclosure Probe Shape Evolving Molina Healthcare Story." Senior executive open-market buys during a shareholder-investigation window cut both ways: legally credible (an executive buying on the same disclosure base the plaintiff bar alleges was deficient is evidence the executive did not believe the disclosure was deficient), but optically a "doubling-down" gesture that hardens both bull and bear positions rather than resolving them.
2026 director slate disclosed June 10, 2026 (Stock Titan proxy filing summary) reaffirms the existing board and references "$9 billion of incremental annual premium revenue" from 2025 RFP wins and acquisitions — same number the bull tab uses, now independently in the proxy.
CEO sale window question. The specialist queries flagged a ~$28M April 30, 2025 CEO sale that the web layer could not source-confirm as a 10b5-1 plan trade; the FY2025 10-K page 135 confirms a 10b5-1 plan was operative for the buyback but not separately for executive sales. This remains the single unresolved governance question that the web record did not settle and the lawsuits will likely probe in discovery.

Specialist questions — coverage of what every specialist asked

This is the reference grid: every specialist query the orchestrator pushed, the one-line web answer the search layer produced, and a confidence note. Findings that change the thesis have been promoted into the ranked list above; the rest sit here as the audit trail.

What the web could not settle — the residual uncertainties a PM should track

Three honest gaps where the web layer was thin and the answer will most likely come from the next earnings print, the next 13F cycle, or the litigation calendar:

The CEO sale window, dollar amount, and whether it was a 10b5-1 plan trade. The bear-case insinuation that the CEO sold near the top of the April 2025 reaffirmed-guide window is unresolved by the public record surfaced here — but it is the single item the class-action discovery will produce first.
Q2 2026 MCR trajectory. A fourth sequential guidance cut would invalidate the recovery narrative, force a second covenant amendment, and likely trigger a second S&P action. The Q2 print (July 22, 2026) is the next binary catalyst.
2026 ACA subsidy extension. Enhanced PTCs expired at end of 2025 and no Congressional renewal has been disclosed in the search layer through mid-June 2026. A clean sunset shrinks the Marketplace premium pool before margins normalize — biggest single political risk to the FY27 rebuild math.

References

Web Watch — Molina Healthcare, Inc. (MOH)

Web Watch in One Page

The report frames a 5-to-10-year underwriting question that pivots on five durable variables: whether the Medicaid rate-versus-trend gap closes, whether the procurement engine retains Texas STAR/CHIP and Washington Apple Health, whether the duals niche delivers a margin premium by fiscal 2027, whether the regulatory-capital architecture stays intact, and whether OBBBA Medicaid Expansion attrition lands at or modestly worse than the 15–20% management baseline. Each watch item below is wired to one of those variables. The set deliberately ignores headline news and quarterly noise — those route through the catalysts tab — and instead tracks the upstream signals (state actuarial bulletins, procurement notices, CMS rulemaking, rating-agency actions, Congressional moves on premium tax credits) that decide which way the durable variables resolve. Together the five monitors cover the long-term thesis's "five things that have to be true" with no overlap.

Active Monitors

Rank	Watch item	Cadence	Why it matters	What would be detected
1	Anchor-state Medicaid capitation rate setting and off-cycle rate updates (CA, TX, WA, NY, OH, FL, MI, IL)	1d	Management has quantified every 100 bps of Medicaid medical care ratio as worth roughly $5 of EPS; off-cycle rate updates are the most mechanical lever between the current 92%+ medical care ratio and the 88–89% long-term target. The Q3 fiscal 2026 print is the first observable resolution and is set up by these state actions.	State actuarial bulletins, fiscal 2027 rate-setting decisions, retroactive rate trues, mid-year rate re-openers, and managed-care-association commentary suggesting the rate side of the rate-vs-trend gap is moving.
2	Texas STAR/CHIP and Washington Apple Health 2028 procurement outcomes	1d	These are the two largest binary outcomes inside the 5-year frame. Texas is roughly 18% of Medicaid premium and Washington roughly 13%; either loss is the Virginia 2024 worked example at 3–5× the dollar magnitude and the cleanest Pillar 1 falsification signal in the report.	Procurement schedules, RFP issuances, awards, scoring rule changes, protests, contract extensions, and any analogous large-state Medicaid procurement that could re-price the franchise from "narrow-moat compounder" toward "regulated yield substitute."
3	CMS dual-eligible (D-SNP) integration rules and the MMP-to-integrated D-SNP transition	1d	The duals niche is the most unproven of the three thesis pillars. The report frames a fiscal 2027 verdict on whether the Medicare-segment medical care ratio drops 200+ bps below the Medicare Advantage Part D competitor average. CMS rulemaking on D-SNP integration, star ratings, and risk adjustment, plus state action on Medicare-Medicaid Plan transitions, determines the segment economics.	CMS proposed and final rules on D-SNP integration, HIDE/FIDE designations, MA star ratings, risk-adjustment factors, plus Humana, UnitedHealth, Elevance, and Centene competitive moves on dual-eligibles.
4	Credit rating actions, covenant amendments, and statutory dividend restrictions	1d	The regulatory-capital architecture is Pillar 2 of the long-term thesis — the protection that survives a cycle reset. The franchise has already absorbed a sub-investment-grade rating action and a covenant cut from 3.00x to 1.75x interest coverage; a second covenant amendment or a regulator-driven subsidiary dividend block would force a slower M&A pipeline, a smaller buyback, and a structurally lower per-share trajectory.	Rating-agency actions from S&P, Moody's, and Fitch on Molina; further amendments to the senior secured credit agreement; state-level statutory capital, risk-based-capital, or dividend-restriction orders against Molina's regulated subsidiaries.
5	OBBBA Medicaid Expansion implementation and enhanced ACA premium tax credit Congressional action	2w	The largest structural shrinkage in the report is the One Big Beautiful Bill Act's 15–20% expected attrition on roughly 1.2 million Medicaid Expansion members; the second-largest is the Marketplace tail risk if the enhanced premium tax credits sunset without replacement. Both are policy-driven failure modes that resolve on regulator and Congressional timelines, not on quarterly prints.	CMS guidance, state work-requirement program adoptions, Expansion redetermination cadences, Congressional bills or CBO scoring on enhanced PTC extension or sunset, and any CMS-NHE updates that re-set the Medicaid TAM trajectory toward 2031.

Why These Five

The set is the long-term thesis written as upstream signals. Monitor 1 is the rate side of "rate versus trend" — the most quantified per-share lever in the report, where one state bulletin can shift the FY2027 EPS distribution. Monitor 2 protects against the single highest-priority failure mode named in the long-term thesis, the procurement loss in either of two anchor states that together account for roughly 31% of Medicaid premium. Monitor 3 tests the most speculative of the three thesis pillars — the duals niche — which is also the strategic option that turns a narrow-moat compounder into a sustained margin premium by fiscal 2027. Monitor 4 watches the capital architecture that lets a small parent balance sheet finance a much larger book; it is the boring, continuous read on whether the cycle reset compounds into something structural. Monitor 5 catches the two policy risks that sit outside the company's control — OBBBA implementation cadence and the enhanced ACA PTC sunset — both of which have material multi-year implications for the size of the Medicaid Expansion and Marketplace pools the franchise serves.

What the set deliberately excludes: the next earnings print (catalysts tab handles July 22), generic peer headline news, near-term short-interest signals (not staged in this run), and the Hindlemann securities class action procedural calendar (a multiple-cap question, not a thesis variable). Adding any of those would be tracking sentiment rather than the durable variables that decide the 5-to-10-year compound.

Variant Perception - Where We Disagree With the Market

The sharpest disagreement is narrow and quantifiable. Consensus FY2027 EPS of $8.07 sits below the company's own mechanical floor of "approximately $7.50 of underlying" FY2026 power, before any Medicaid rate-cycle catch-up — a number CEO Joe Zubretsky disclosed on the Q4 FY2025 call as the building-block walk from the $5 FY2026 floor [1]. The Street has implicitly priced partial execution of two mechanical reversals (the MAPD exit and the Florida CMS Kids implementation drag) and zero contribution from the rate-vs-trend gap closing — even though the same company has quantified each 100 basis points of Medicaid MCR as worth roughly $5 of EPS [1], the FY26 Medicaid MCR is guided 4 points above the long-term target, and Q1 FY2026 already printed Medicaid MCR at 92.0% — favorable to the 92.9% full-year guide [2]. The variant range a PM should leave this page with is FY27 EPS $9.00-10.50, or +12% to +30% above consensus, with one quarter of FY26 Medicaid MCR convergence as the resolving signal.

The disagreement is genuinely narrow. Consensus is correctly priced on three of four issues — the multiple, the credibility discount, the Marketplace de-risk. It is wrong only on whether the mechanical FY2027 bridge survives the rate-vs-trend gap as a binary "trough recovers" call rather than as a quantifiable lever the company itself has sized. That single asymmetry is the entire variant edge.

The variant view in one sentence. Consensus FY27 EPS of $8.07 is paying for partial mechanical recovery; the company's own disclosed math has the floor of underlying FY26 power at ~$7.50 and the upside call option of every 100bps Medicaid MCR catch-up at ~$5/share, both individually quantified by management. The Q3 FY2026 print is the first observable signal that resolves the gap.

What the market actually believes (with the consensus signal that proves it)

Before disagreeing, the consensus position must be stated as a set of testable underwriting assumptions, not as a vibe. The signals below — the sell-side ratings split, the consensus price target sitting essentially on top of spot, S&P's April 2026 downgrade, the disclosed Hindlemann class action, and a top-20 holder selling on June 8 while a marquee contrarian was disclosed long — are all visible in the catalysts and research tabs.

No Results

Two consensus reads are crowded ("watchlist" + "credibility cap"), two are mechanical (FY27 math + Marketplace de-risk), and one is a metric error (consolidated cash-flow read). The variant ledger below targets the two where the evidence and the implied assumption diverge: issue #1 (mechanical FY27 bridge) and issue #4 (cash-flow optic on a regulated subsidiary structure).

Variant scorecard

Variant strength (0-100)

Consensus clarity (0-100)

Evidence strength (0-100)

Months to first resolving print

Variant strength reflects materiality (an FY27 EPS gap of +12-30% to consensus would re-rate the multiple if it prints) discounted by the genuine bear-side counter from the forensic record (prior-cycle EPS was reserve-supported, so the through-cycle ROE anchor used by the bull is too high). Consensus clarity is high: the recommendation distribution and the spot-against-target both leave little ambiguity about what the Street has priced. Evidence strength is moderate: management's quantified building blocks are credible but the same management's FY25 trend forecast missed by 64%. The first resolving print arrives in roughly 4-6 months (Q3 FY2026 in October 2026), with the Q2 FY2026 print on July 22 as the binary on whether the floor holds at all.

The disagreement ledger

There are two genuine variant views, ranked by how much each would change the FY27 underwriting. A third candidate — the bear-leaning "embedded earnings is reserve cushion, not earnings power" — is treated honestly in the red-team section rather than promoted to the ledger; it is the disconfirming evidence, not a separate edge.

No Results

Disagreement #1 — The FY27 EPS bridge is mechanical math, not a rate-cycle bet

Consensus says. FY27 = $8.07 (8 analysts), framed in catalysts and research as the partial mechanical bridge: the $5 FY26 floor holds, the MAPD exit removes ~$1 of segment drag, the Florida CMS Kids implementation-cost burden of ~$1.50 reverses at run-rate margin, and the rate-cycle catch-up is treated as a model-error band rather than as a separable upside lever. The recommendation split (13 of 18 holds) and the $190.25 mean price target on top of spot tell the same story differently: the Street is waiting for evidence, not paying for it.

The evidence disagrees. Management's own walk on the Q4 FY25 call quantified the $5 FY26 guide as producing "approximately $7.50 per share" of underlying earnings after adjusting for the $2.50/share of MAPD product losses and Florida CMS Kids implementation costs that disappear in 2027 [1]. That is the floor before any rate-cycle help — and it is already 7% below the consensus FY27 mean of $8.07 with the upside lever zeroed out. The CFO reaffirmed on the Q1 FY26 call that the $2.50/share burden in FY26 from MAPD and Florida CMS Kids is "certain to be positive impacts to our 2027 performance" [3].

The rate-cycle leg is independent. Zubretsky disclosed on the same Q4 FY25 call that every 100bps of Medicaid MCR is worth nearly $5 per share [1]. The FY26 Medicaid MCR is guided 92.9% against a long-term target of 88-89% — a 300-400bps gap. The Q1 FY26 actual printed 92.0% [2], favorable to the guide and the first positive rate/trend data point after six quarters of imbalance. Even half-closing the gap to 90.9% by FY27 adds ~$5 to EPS pre-tax-effect; quarter-closing to 92.0% (the FY26 Q1 actual) adds ~$2.50. Add either to the $7.50 floor and FY27 lands $9.00-10.50, or 12-30% above the $8.07 mean.

What the market must concede if we are right. That management's two disclosed quantitative anchors — the $7.50 underlying FY26 walk and the $5-per-100bps MCR sensitivity — should each be entered into an FY27 distribution as separate components, not collapsed into a single "trough recovery" probability. The disclosed framework lets a PM size the FY27 distribution mechanically; consensus has chosen to treat the framework as wide model error.

Cleanest disconfirming signal. A Q3 FY26 print (October 2026) showing Medicaid MCR at or above 93.5% — the FY26 guide already drifting up — would invalidate the rate-cycle leg, push consensus toward $7.00-7.50, and reset the variant range to roughly equal to consensus. A second print at that level closes the variant view.

Disagreement #2 — Subsidiary dividend pipeline ($985M intact) is the right cash-quality metric, not consolidated OCF

Consensus says. Consolidated FY25 operating cash flow of negative $535M is what S&P cited when it downgraded to BB- on April 3, 2026 ("persistently elevated financial leverage" and 1.7% EBIT-to-revenue per research tab). It is what screening tools surface as FY25 cash burn alongside the $1B of buybacks executed at average prices materially above the current quote. It feeds the credibility discount that 13 of 18 hold ratings represent.

The evidence disagrees. The forensic tab establishes that the FY20-23 consolidated OCF stream of $1.9B/$2.1B/$0.8B/$1.7B was structurally inflated by COVID-era risk-corridor and minimum-MLR payable accruals that built up but had not been paid; the FY24-25 consolidated OCF of $644M/-$535M is the reverse of the same lever paying down — not earnings deterioration. Management said it on the Q1 FY26 call almost in those exact words: consolidated OCF "swings a lot as we do accruals for risk adjustment for corridors." The Q1 FY26 print itself — operating cash flow of +$1.1B in a single quarter — is the same lever firing in the other direction.

The metric that actually funds debt service, M&A, and buybacks is the subsidiary-to-parent upstream. That number held through the trough: $985M in FY25 vs $997M in FY24 [4] — a 1% decline in the worst earnings year of the post-2017 era. Parent cash dropped from $445M to $223M because the parent was simultaneously buying back $1B of stock and contributing $439M back into subsidiaries for new health-plan funding [4] — both uses of parent cash, not a break in the upstream pipeline.

What the market must concede if we are right. That the BB- rating and the multiple cap that comes with it are partly priced off a metric (consolidated OCF) that the company has publicly stated is the wrong one. As Q2 and Q3 FY26 OCF prints likely normalize on the same corridor-payable timing in the other direction, the cash-flow leg of the bear case should compress — and would expose the multiple to a tactical rerating regardless of the FY27 EPS outcome.

Cleanest disconfirming signal. Two consecutive quarters of normalized OCF still meaningfully negative with the Marketplace risk-adjustment net payable extending beyond the Q1 FY26 level of $518M — that combination would force the variant to be revisited because the timing read would fail.

The evidence audit — what each item moves, and where it could be fragile

The table below lists the items that actually move the probability of the variant view, the consensus read of each, and what could make the evidence misleading.

No Results

Three items in the audit are decisive in isolation — the disclosed $7.50 underlying floor, the 100bps = $5/share sensitivity, and the Q1 FY26 Medicaid MCR print of 92.0%. The other items strengthen the case but are not load-bearing on their own. The fragility column is non-negotiable: each piece of evidence has a specific way it could be misleading, and the resolution signals below are designed against those failure modes.

Resolution signals — what to put on the watchlist today

Each row below is observable on a filing, a transcript, a state-agency disclosure, or a rating-agency action. None requires "better execution" or "time will tell" — those are not signals. Cathy printable dates are intentionally absolute, not relative.

No Results

Signals #1 and #2 are decisive — they resolve the FY27 EPS gap directly. Signals #3 and #4 are corroborative — they update the leading indicators and the cash-flow leg. Signals #5 and #6 are multiple-cap signals — they do not move EPS but they compress or extend the credibility discount that 13 of 18 holds and a BB- rating represent.

Variant view classification — which of the eight buckets each disagreement fits

No Results

Neither variant view falls into the banned weak forms ("high quality but undervalued," "market too pessimistic," "valuation attractive if estimates go up"). Both are gaps between specific evidence and a specific market-implied assumption, each with an observable signal that resolves it on a calendar window inside 9 months.

Red team — what would prove the variant wrong

This is the section to take seriously. The variant view is genuinely close to falsification, and the forensic record contains material evidence that the upstream tabs have already documented honestly. The order below is by probability that the evidence is right against the variant.

1. Embedded earnings was reserve-cushion, not durable EPS power. The forensic tab established that prior-year reserve development collapsed from $675M in FY24 to $98M in FY25 — the equivalent of 57% of FY24 net income vanishing as a cushion — and that the FY25 disclosure explicitly notes "the impact of prior year reserve development in 2025 was partially absorbed by minimum MLRs and medical cost corridors and was ultimately not material to our consolidated MCR." If the FY18-24 EPS stream that anchors the through-cycle ROE math was structurally reserve-supported rather than pure underwriting earnings, then the $11+ of disclosed embedded earnings should be discounted significantly, and the "normalized EPS" the bridge is reaching for is closer to $12-14 than to $15-19. Materially, this could compress the FY27 variant range from $9-10 toward $8-9 — closer to consensus, narrower edge.

2. The Q1 FY26 Medicaid MCR of 92.0% is Q1 seasonality, not a trend. Q1 is structurally favorable in managed care because the deductible-reset cycle has not yet exposed the back-loaded utilization. A 92.0% Q1 paired with a 93.5%+ Q3-Q4 would print a full-year close to or above the 92.9% guide and the rate-cycle leg of the variant evaporates. The CFO has already cautioned that Q1 FY26 OCF of +$1.1B is partly "timing" and the same caution applies to Q1 Medicaid MCR. A single favorable quarter is not a trend; the variant view needs two.

3. OBBBA implementation comes in worse than the 15-20% Medicaid Expansion attrition expectation. Management's baseline is a 15-20% reduction on 1.2 million Medicaid Expansion members by 2029, but state implementations of work requirements and redetermination cadences are still being designed. A 25-30% attrition rate compresses the premium base by another 2-3% before margin restoration, and the $50B FY27 premium target gets pushed to FY28-29. EPS does not deteriorate dollar-for-dollar, but the FY27 starting volume is lower than the bridge math implies.

4. A Texas STAR/CHIP or Washington Apple Health 2028 procurement loss. Texas (18% of Medicaid premium) and Washington (13%) are inside the 5-year window per the FY25 10-K [5]. A loss in either would re-rate the franchise from "narrow-moat compounder" to "regulated yield substitute" regardless of the FY27 EPS outcome — the multiple compression would swamp the EPS upside.

5. A fourth FY26 guidance cut, or a second covenant amendment. Either is a -25% event per the catalysts tab. The credit agreement was already amended from 3.00x to 1.75x interest coverage in February 2026, and S&P has already downgraded to BB-. A second amendment closes the loop on the credibility narrative and re-engages the Hindlemann class action's central allegation. The variant view is structurally incompatible with another disclosure misstep.

Items #1 and #2 are the most fragile parts of the variant evidence and deserve continuous monitoring; items #3-5 are tail risks that should be priced into position sizing rather than into the central case.

The honest counter-case. The most serious red-team item is #1 - if the prior-cycle EPS that anchors the through-cycle ROE math was reserve-cushioned, the variant range compresses materially and the edge narrows from "+12-30% above consensus" to "+5-10% above consensus." That alone would not invalidate the variant, but it would soften the conviction. A PM should not size on this view above the level where the forensic-cushion-exhausted scenario is acceptable.

The single signal to watch

Watch the Q3 FY2026 Medicaid MCR print (October 22-23, 2026), specifically against the 92.9% full-year guide and the company's own 88-89% long-term target. It is the single most decisive update to the variant view inside the 6-month window. The Q2 print (July 22) sets the slope; the Q3 print updates the FY26 floor and is the first quarter in which management has pre-committed to revisit guidance ("after 2 full quarters of information," per CEO Q1 FY26 call). A Q3 Medicaid MCR at or below 91.5% with neutral-to-favorable PYD plus off-cycle rate-update disclosures from three or more states moves the variant from "open" to "validated"; a print at or above 93.5% closes the variant view and concedes the consensus FY27 of $8.07 is correctly priced. Everything else in the resolution table is corroborative around that single number.

References

Liquidity and Technical

The price record staged for this run covers only the 66 trading days from 2026‑03‑18 through 2026‑06‑18 — too short to compute a 200‑day moving average, a 52‑week range, golden/death‑cross dates, or a multi-year relative-strength series. The page leans on what is in the data (a 66‑day OHLCV record that brackets the April 22 guidance shock and the eight‑week recovery) and pulls capital-structure context from the FY2025 10‑K and Q1 FY2026 transcript. Where the playbook expects a 200‑day or 52‑week answer, the page says so rather than fabricating one.

Liquidity is not the bottleneck — MOH is a roughly $10B mid‑cap with about $189M of value‑weighted 20‑day ADV and a clean single-class capital structure with no promoter or government block. The technical setup is neutral with an upside bias — the post‑shock rebound has reclaimed pre‑disappointment levels, a clear ceiling has built at $204‑205, and the multi-year relative-strength baseline is poor. Implementation read: build into and below the $172 line where the buyback has been active, don't chase $200.

Headline read

Last close (2026-06-18, $)

$194.76

vs 50‑day SMA

11.3%

RSI(14)

55.8

Mkt cap ($M)

$10,030

ADV 20d (shares)

968,016

ADV 20d ($)

$188,502,270

Off 4/22 low

45.4%

Realized vol 30d (ann.)

34.7%

Market cap above uses the 51.5 million shares of Common Stock outstanding as of February 6, 2026 [1] disclosed on the cover of the FY2025 10‑K, multiplied by the latest staged close. The 51.5M figure is the foundation for every per‑share, capacity and float number on this page.

Implementation verdict — liquidity is deep, structurally clean

liquidity.json was stamped no_public_market because the upstream pipeline gates the precomputed capacity numbers on a multi-year window MOH's staged file does not have. That gate is a data-pipeline rule, not a market reality: MOH trades on NYSE under the symbol "MOH" [2], is a large accelerated filer [1], and was an S&P 500 constituent benchmark name in the FY2025 stock-performance comparison [2]. Recomputing capacity from the staged OHLCV against the disclosed share count gives the answers below.

No Results

At a 20% participation rate over five trading days, a fund can move roughly $189M, or about 968k shares. That clears a 5% position for a fund up to ~$3.8B AUM, a 2% position up to ~$9.4B AUM, and a 10% position up to ~$1.9B AUM. Exiting a 1%‑of‑market‑cap holding (~515k shares) at the same 20%/5d participation takes about 2.7 trading days — the name is institutionally tradable, but a sub‑$4B AUM fund is the comfortable size for an overweight; mega-cap funds will be size‑constrained and have to step their builds.

Execution friction is elevated: the median daily high‑low range over the 66 days is 3.7%, materially wider than the sub‑2% regime a managed-care name normally trades in. Most of that wide range is concentrated around the April shock, but the recovery legs themselves carry 2‑3% daily ranges. The practical read: paper any limit order with care, and assume single‑day impact cost is not the bottleneck — the bottleneck is the regime of vol you are entering, not the size of the line you want to build.

Float quality reinforces, rather than undercuts, the raw‑ADV verdict. MOH has a single class of common stock, par value $0.001 per share [1], no promoter, family or government block, and pays no dividend [2]. The aggregate market value of common stock held by non‑affiliates on the last business day of Q2 2025 was approximately $16.0 billion [1] — the public float is essentially the share count. 13G filers concentrate the register (BlackRock approximately 11.7%, Capital World about 6.8%, Fidelity about 5.8%, AQR about 5.5%, Vanguard family low‑5%, collectively about a third of shares) [9], but these are passive and quant rather than control holders, and they sit in the same flows that make the tape liquid.

The structural buyback is the other liquidity backstop. The board authorized up to $1 billion of common-stock purchases in April 2025, running through December 31, 2026 [3]. As of February 10, 2026, $500 million of the authorization remained [3]. The company has prosecuted these programs in size: it bought approximately 1,679,000 shares for $500 million in Q1 2025 at $297.83, and approximately 2,849,000 shares for $500 million in Q3 2025 at $175.50 [4] — a meaningful indicator of management's willingness to step into weakness. The $500M still on the shelf is roughly 2.5M shares at current levels — about 5% of the float and about 13 days of 20%‑participation ADV — a structurally meaningful bid that will lean against any retest of the lower band.

Liquidity verdict: institutionally tradable, size-aware. ~$189M ADV against a ~$10B mid-cap gives a clean 5% line for funds up to ~$3.8B AUM at 20% participation over five days. A $500M live buyback authorization (about 13 days of ADV) is a structural bid below current levels.

The April 22 shock is the central feature of the tape

The defining event in the staged record is 2026‑04‑22: the Q1 FY2026 earnings release, in which management reaffirmed — rather than raised — full‑year 2026 guidance of approximately $42 billion of premium revenue and at least $5 of adjusted EPS [5] despite Q1 adjusted EPS of $2.35 on $10.2B of premium revenue, with management explicitly framing the choice as "merely reaffirming our prior full year guidance is a prudent approach at this early point in the year" [6]. The 8‑K filed the same day formally reaffirmed "the Company's full-year 2026 premium revenue and adjusted earnings guidance" [7]. The stock had closed at $171.95 the prior session, opened at $121.06, traded to $137.96 intraday and closed at $133.94 — a one-day decline of 22.1% from prior close, an opening gap of -29.6%, and an intraday range of 14.0%, on volume of 11.18 million shares — approximately 7.9× the average of the rest of the staged record.

What followed the gap is the rest of the story: the stock probed a low of $129.41 on April 27, found a base, then rebuilt for eight weeks back to $194.76, a 45.4% gain from the 4/22 close and a recovery to within 4.6% of the pre-shock period peak. The recovery has the shape of a normal post‑shock V — heavy volume in the first ten sessions (multiple 2.0‑3.1M share days), then declining volume into the climb back to $200. The unfinished business sits at $204‑205: prints of $204.95 on 6/9, $204.45 on 6/10, $204.66 on 6/16 have each been rejected, defining the ceiling.

The April 22 event sits inside a broader narrative the corpus already names. A putative securities class action, Hindlemann v. Molina Healthcare, Inc. et al., was filed on October 3, 2025 in the U.S. District Court for the Central District of California, on behalf of a class who allegedly acquired MOH securities between February 5, 2025 and July 23, 2025 and asserting violations of federal securities laws relating to the Company's disclosures, "including those involving earnings guidance" [8]. A related shareholder derivative action, Taylor v. Wolf, et al., was filed December 12, 2025 [8]. The litigation overhang and a second consecutive guidance disappointment in April 2026 explain why the recovery is unfinished and why the $204‑205 ceiling is so well defended — the market is rationally pricing the option that "at least $5" is still soft.

Trend, regime and momentum

The 200‑day SMA and 52‑week levels are unavailable — the 66‑day window does not span enough history. The short‑MA picture is usable:

20-day SMA ($)

$194.81

50-day SMA ($)

$175.06

Period total return (3/18 → 6/18)

5.6%

The current close of $194.76 sits essentially on the 20‑day SMA ($194.81) and ~11.3% above the 50‑day SMA ($175.06). SMA20 above SMA50, and the gap widening over the past three weeks, is the textbook signature of a recovering uptrend. Without a 200‑day reference, the trend classification stops there: uptrend on the visible window, regime unknown beyond it. The corpus, however, is unambiguous about the longer-period regime: the five‑year cumulative total‑return graph in the FY2025 10‑K shows $100 invested in MOH on December 31, 2020 ended December 31, 2025 worth $80, while the same investment in the S&P 500 ended at $195 and the peer group at $160 [2]. The visible 2026 rebound is happening from a multi‑year relative low, not a multi-year high — which is what makes the technical and the fundamental tabs disagreeable rather than redundant.

RSI(14) closed at 55.8 — the textbook neutral zone. There is no overbought signal that warrants trimming a fresh entry, and no oversold tell that argues for an aggressive add. MACD on a 66‑day window is computable but the histogram is dominated by the gap-day discontinuity and is not informative — skip it on this data.

No Results

The action since June 8 has repeatedly tested and failed at $204‑205 — the same prints that capped the pre-shock March 31 peak. A close above $205 reopens the path; a close below the 50‑day at $175 forfeits the recovery's slope; a close below the $172 pre‑shock support says the recovery has failed.

Volume, volatility, sponsorship

Volume confirms the event, less so the recovery's last leg. Of the top five volume days in the 66‑day window, all five fall in the 4/22 → 5/01 window — the panic and the immediate flush. Volume on the climb from $170 to $200 over the last three weeks is conspicuously modest: many sub‑1M share days (964k on 6/1, 867k on 6/2, 724k on 6/3, 884k on 6/4, 665k on 6/5, 879k on 6/15, 711k on 6/16, 867k on 6/17, 300k on 6/18). Below‑average volume on the up‑move is not a refutation of the trend, but it is not the kind of confirming sponsorship a clean breakout would carry — which is consistent with the repeated rejections at $205.

No Results

Realized volatility is 34.7% annualized on a 30‑day window — elevated for a managed-care name (typical 20‑30%). On a 60‑day basis it lifts to ~67% because the 4/22 single‑day return mathematically dominates the window; that number will normalize as the gap day rolls off. The honest takeaway: vol regime is elevated and normalizing, not low — risk-budget the position accordingly.

Volume around the structural buyback matters: the $500M still on the shelf through Dec 31, 2026 [3] is about 13 days of 20%‑participation ADV — the program can be a meaningful bid into weakness without straining the tape, and the precedent of executing $500M tranches inside a single quarter (Q1 2025 and Q3 2025, the latter at $175.50 average cost — essentially today's 50‑day SMA) [4] suggests management is willing to step in around this level.

Cross‑reference with the fundamental story

The companion Financials/Quant tab is not yet present in this run, so the cross‑read is one‑directional: the tape and the disclosures broadly agree that the 2025 sell‑off was deserved (a $80/$195 endpoint on the five‑year cumulative chart is not a chart that gets there by accident), and the tape has begun to disagree with the disclosures as it claws back through the post‑shock recovery — pricing some optionality that "at least $5" is conservative even after April 22. The unresolved litigation over the Feb 5 → July 23, 2025 disclosure window [8] is the reason this disagreement does not yet read as conviction.

Technical scorecard

The standard six dimensions, scored against the visible window. Where the playbook expects a 52‑week or 200‑day reference, the score is 0 by force of missing data, not because the picture is neutral.

No Results

Scorecard total (max +3 / min −3)

-1

Sum is −1: the active recovery (Trend +1) is offset by elevated vol and the multi-year relative-strength baseline. Note the multi-year leg of the scorecard is sourced from the 10‑K's own five‑year cumulative-return disclosure [2] — the staged price file alone could not support it.

Stance — 3-to-6 month horizon

Neutral with upside bias. The recovery is real and the structural buyback gives the long side a measurable backstop, but the $204‑205 ceiling has held four times in two weeks, the multi-year relative baseline is dismal, and the second guidance disappointment in twelve months keeps the litigation overhang [8] live. The implementation answer is act, but earn the position: liquidity is not the constraint — a clean 5% position is implementable for funds up to ~$3B AUM at 20%/5d participation. Build a half‑weight into and below the 50‑day at $175 (where the company itself has shown a willingness to repurchase), and let one of the two named levels below decide the rest.

No Results

Hard rules. A daily close above $205 confirms the breakout; a daily close below $172 invalidates the recovery thesis. Between those two lines, the live $500M buyback authorization (cited above) is the dominant marginal bid and the principal reason to stay engaged rather than wait for resolution.

Caveats and what the data does not say

The staged window cannot answer three questions a normal technical page would:

52‑week levels and 200‑day MA — both require ≥252 trading days; the staged record has 66.

Golden‑ or death‑cross dates — both require continuous SMA50 and SMA200 series across a year or more; not computable here.

Multi-year relative strength vs S&P 500 / XLV / peer basket — the staged relative_performance.json is unavailable. The five‑year cumulative‑return numbers used above ($80 / $195 / $160) come from the FY2025 10‑K's stock-performance graph [2] and are anchored to year-end prints, not daily series.

Anything the page does not name above is either uncited because it is a computed price metric from the 66-day staged file, or absent because the data does not support the claim.

References

Short Interest and Thesis — Molina Healthcare (MOH)

Reported short-interest, short-sale-volume, borrow, and peer-context data were all unavailable for this run, so positioning, crowding, and squeeze risk cannot be quantified here. The decision-useful short thesis instead comes from the primary record: a filed securities class action and a derivative suit alleging Molina failed to disclose deterioration in its medical cost trend assumptions during 1H 2025, set against a documented 2025 guidance arc that was cut from at-least-$24.50 of adjusted EPS to a $19 floor and then to roughly $14, with the Marketplace MCR rising from 75.4% to 90.6% year-on-year. The contested issues — Medicaid rate-versus-trend imbalance and Marketplace pricing volatility — were both standing risk-factor disclosures, so the unresolved question is one of timing and quantification of internal information, not whether the issues themselves were unknown.

Evidence Quality. Official reported short interest, FINRA short-sale volume, public net-short disclosures, borrow indicators, and peer short-interest context are all empty in this run's structured data. Conclusions below are confined to: (i) the disclosed short-thesis substance in the FY2025 10-K and 2025 transcripts, and (ii) liquidity/capital-structure context drawn from the same filings.

Reported short-interest data — unavailable

No Results

Source class summary drawn from the run's data/short_interest/manifest.json and latest.json — not from a corpus PDF. No reported-short-interest conclusion can be drawn from this run's data; do not substitute short-sale volume or anecdote for the missing position-level series.

Liquidity and float context (for a future positioning read)

Float and capital-structure context are sourced from the FY2025 10-K so the reader can size the implication if reported short interest becomes available later. Approximately 51.5 million shares of common stock were outstanding as of February 6, 2026 [1], and the board's April 2025 buyback authorization had $500 million remaining as of February 10, 2026, scheduled to run through year-end 2026 [2]. Share count has compressed materially over five years — from roughly 58.6M at FY2021 to 52.9M at FY2025 — indicating an active buyback program that shrinks the absorbable float for any short cover.

Figures in the chart are calendar-year period-end share counts from the staged income-statement data; the FY2025 February-6 share count cited above is the more current authoritative snapshot.

The disclosed public short thesis

There is one public, source-anchored short thesis to engage with. On October 3, 2025 a putative securities class action — Hindlemann v. Molina Healthcare, Inc., et al. — was filed in the U.S. District Court for the Central District of California against Molina, its CEO and its CFO, on behalf of holders who acquired the stock between February 5, 2025 and July 23, 2025, alleging violations of federal securities laws related to the Company's disclosures, including those involving earnings guidance [3]. A shareholder derivative action — Taylor v. Wolf, et al. — followed on December 12, 2025 against the directors and certain officers, asserting breach of fiduciary duty and securities-law violations in connection with the same statements and events; Molina states it intends to vigorously contest each lawsuit and that it cannot predict an outcome or reasonable estimate of loss [3].

The substantive allegation tracks the sequence of guidance revisions and MCR moves visible in management's own disclosures. The class period opens at the February 5, 2025 release in which Molina guided to adjusted EPS of at least $24.50, "8% growth over the full year 2024" (initial guide referenced in the plaintiff complaint summarized in the staged research). At the Q2 FY2025 print on July 23, 2025 the adjusted EPS floor was cut by $5.50 to "no less than $19," with management citing a "very challenging medical cost trend environment for each of our segments" [4]. At the Q3 FY2025 print on October 23, 2025 the guide was cut again, by a further ~$5 to approximately $14, with management acknowledging that "half of this revision emerges from the unprecedented utilization trend in Marketplace, which represents nearly 10% of our business" and "only one-third emerges from the rate and trend imbalance in Medicaid, which is 75% of our business" [5]. FY2025 then printed a consolidated MCR of 91.7% versus 89.1% in 2024, "reflecting a challenging medical cost trend environment in all our segments" [6]; the segment split showed Marketplace MCR moving from 75.4% to 90.6% [7] and Medicaid MCR moving from 90.3% to 91.8%, characterized as a "rate and trend imbalance" management believes is temporary [8].

Short-thesis ledger — allegation, evidence, company response, unresolved risk

No Results

Both topics the plaintiffs lean on were disclosed risk factors before the class period. The FY2024 10-K already characterized the Marketplace business as "volatile and unpredictable" [9], and the FY2025 10-K's risk-factor section explicitly walks through the financial sensitivity — a one-percentage-point move in the consolidated MCR (91.7% → 92.7%) would have reduced FY2025 diluted EPS from $8.92 to roughly $2.72, a $6.20 swing [10]. The Critical Audit Matter in the FY2025 audit report singles out IBNP claims reserves as a complex, judgmental estimate but does not identify a material weakness or restatement [11]. That combination — pre-existing risk-factor disclosure plus auditor judgment-but-no-defect — is the central defensive evidence the company would lean on; the live legal question is the timing of management's knowledge of the magnitude of the cost-trend deterioration during 1H 2025.

Management framing — what the call transcripts actually say

The qualitative case for and against a forward short on MOH rests heavily on whether management's "temporary, rate-cycle" framing of 2025 is credible. The Q3 FY2025 call carried management's most explicit rebuttal: CEO Joe Zubretsky characterized the operating environment as "inclement weather rather than climate change, metaphorically meaning temporary rather than permanent" and argued Medicaid is expected to "recalibrate to target margins" as rates catch up [12]. On the Q2 call he described 2025 as a year in which "we power through short-term industry-wide challenges and strive to deliver superior sector performance" [13]. On Q3, management quantified the EPS arithmetic: the original $24.50 guide was cut by $10.50 in total, with half of the cut from Marketplace and only one-third from Medicaid — a meaningful tell because Medicaid is 75% of revenue but only one-third of the miss, supporting the "rate-cycle catch-up" thesis [5].

This is the variant-perception axis a short would attack: if 2026 Medicaid rates do not close the gap, the "temporary" framing weakens and the live litigation becomes more damaging; if rates do catch up and Marketplace is meaningfully de-risked (the company has already narrowed Marketplace participation for 2026), the short thesis decays.

Borrow, locate, public net-short

No borrow-fee, utilization, lendable-supply, hard-to-borrow, locate-friction, or public net-short threshold-disclosure rows were staged for MOH in this run, and the latter regime does not apply to a US-listed name. There is no source-backed evidence here of borrow pressure or hard-to-borrow status; absence of evidence is the only honest conclusion.

Peer context

No peer short-interest rows were staged, so cross-name positioning relative to managed-care peers (UNH, ELV, CNC, HUM, CVS) cannot be assessed in this tab. Any peer-relative crowding claim would need to be sourced before being made.

Market setup — what the tape says, what it does not

The staged price series covers only March 18, 2026 → June 18, 2026 (66 trading days), opening at $184.50 and closing at $194.76 on the last bar — a calm, low-volume window that does not span either of the 2025 guidance cuts. The major tape event in the contested period is the $38.08 single-day drop on July 24, 2025 reported by plaintiff counsel after the Q2 guidance cut; that figure is sourced from third-party press releases rather than from a primary-record page, and the corpus does not contain a same-day intraday print to cite. Without intraday volume around the catalysts and without reported short-interest snapshots before and after each cut, the market-setup module collapses to a directional observation: the catalysts that the litigation hinges on are behind the company, the cost-trend and rate-cycle catalysts a short would lean on (2026 Medicaid rate updates, Marketplace pricing reset, OBBBA implementation) are still ahead [14].

Evidence limitations

No Results

Bottom line for sizing and risk

For positioning: no actionable read — reported short interest is missing, so this tab cannot tell a PM whether positioning is crowded, light, rising, or falling. Build the position thesis on the underlying fundamentals, not on assumed crowding.

For thesis risk: a real, documented short thesis exists, with a securities class action and a derivative suit pending, both anchored to disclosure timing around 2025 guidance cuts and the Marketplace MCR jump from 75.4% to 90.6% — not to fraud, accounting restatement, or going-concern doubt. The defensive disclosures (Marketplace volatility as a standing risk factor, IBNP as a CAM rather than a material weakness, a still-running buyback program with $500M of authorization remaining) are credible but do not resolve the litigation. Treat litigation outcome and 2026 Medicaid rate-vs-trend reset as the live binary catalysts, and re-run this analysis once reported short-interest data is available to confirm whether short positioning has actually built up around them.

References

Generated Jun 19, 2026 10:03 UTC